0001360214 2023-01-01 2023-12-31 0001360214 HROW:CommonStock0.001ParValuePerShareMember 2023-01-01 2023-12-31 0001360214 HROW:Sec8.625SeniorNotesDue2026Member 2023-01-01 2023-12-31 0001360214 HROW:Sec11.875SeniorNotesDue2027Member 2023-01-01 2023-12-31 0001360214 2023-06-30 0001360214 2024-03-18 0001360214 2023-12-31 0001360214 2022-12-31 0001360214 2022-01-01 2022-12-31 0001360214 HROW:ProductSalesNetMember 2023-01-01 2023-12-31 0001360214 HROW:ProductSalesNetMember 2022-01-01 2022-12-31 0001360214 HROW:OtherRevenuesMember 2023-01-01 2023-12-31 0001360214 HROW:OtherRevenuesMember 2022-01-01 2022-12-31 0001360214 us-gaap:CommonStockMember 2021-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001360214 us-gaap:RetainedEarningsMember 2021-12-31 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2021-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2021-12-31 0001360214 2021-12-31 0001360214 us-gaap:CommonStockMember 2022-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001360214 us-gaap:RetainedEarningsMember 2022-12-31 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2022-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2022-12-31 0001360214 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001360214 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2022-01-01 2022-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001360214 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001360214 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2023-01-01 2023-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001360214 us-gaap:CommonStockMember 2023-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001360214 us-gaap:RetainedEarningsMember 2023-12-31 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2023-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2023-12-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2023-01-01 2023-12-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2022-01-01 2022-12-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2023-12-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2022-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember us-gaap:CommonStockMember 2023-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember us-gaap:PreferredStockMember 2023-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2023-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2021-01-01 2021-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2022-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2023-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2022-12-31 0001360214 HROW:SurfaceOphthalmicsIncMember 2023-12-31 0001360214 HROW:SurfaceOphthalmicsIncMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001360214 srt:MinimumMember 2023-12-31 0001360214 srt:MaximumMember 2023-12-31 0001360214 srt:MinimumMember HROW:NewDrugApplicationsMember 2023-12-31 0001360214 srt:MaximumMember HROW:NewDrugApplicationsMember 2023-12-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2023-12-31 0001360214 HROW:EtonPharmaceuticalsIncMember 2022-12-31 0001360214 HROW:StockOptionsUnvestedRSUsAndUnvestedPSUsMember 2023-01-01 2023-12-31 0001360214 HROW:StockOptionsUnvestedRSUsAndUnvestedPSUsMember 2022-01-01 2022-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2023-01-01 2023-12-31 0001360214 HROW:SurfaceOphthalmicsIncMember 2023-01-01 2023-12-31 0001360214 us-gaap:CommonStockMember HROW:MeltPharmaceuticalsIncMember 2023-12-31 0001360214 us-gaap:PreferredStockMember HROW:MeltPharmaceuticalsIncMember 2023-12-31 0001360214 us-gaap:CommonStockMember HROW:MeltPharmaceuticalsIncMember 2022-12-31 0001360214 us-gaap:CommonStockMember HROW:MeltPharmaceuticalsIncMember 2022-01-01 2022-12-31 0001360214 HROW:LoanMember HROW:MeltPharmaceuticalsIncMember 2022-12-31 0001360214 HROW:LoanMember HROW:MeltPharmaceuticalsIncMember 2022-01-01 2022-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2022-01-01 2022-12-31 0001360214 us-gaap:CommonStockMember HROW:SurfaceOphthalmicsIncMember 2023-12-31 0001360214 us-gaap:CommonStockMember HROW:SurfaceOphthalmicsIncMember 2022-12-31 0001360214 HROW:TwoThousandAndTwentySixNotesMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001360214 HROW:TwoThousandAndTwentySixNotesMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001360214 HROW:TwoThousandAndTwentySevenNotesMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001360214 HROW:TwoThousandAndTwentySevenNotesMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001360214 HROW:OaktreeLoanMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001360214 HROW:OaktreeLoanMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001360214 HROW:CommissionsMember 2023-01-01 2023-12-31 0001360214 HROW:CommissionsMember 2022-01-01 2022-12-31 0001360214 HROW:TransferOfAcquiredProductSalesProfitsMember 2023-01-01 2023-12-31 0001360214 HROW:TransferOfAcquiredProductSalesProfitsMember 2022-01-01 2022-12-31 0001360214 HROW:VEVYEMember 2023-07-31 0001360214 HROW:VEVYEMember 2023-07-01 2023-07-31 0001360214 HROW:VEVYEMember 2023-12-31 0001360214 HROW:SantenProductsAcquisitionMember 2023-07-01 2023-07-31 0001360214 HROW:SantenProductsAcquisitionMember 2023-12-31 0001360214 HROW:SantenProductsAcquisitionMember 2023-01-01 2023-12-31 0001360214 HROW:OneTimePaymentMember 2023-01-01 2023-01-31 0001360214 srt:MaximumMember HROW:OneTimePaymentMember 2023-01-01 2023-01-31 0001360214 HROW:OneTimePaymentMember 2023-01-01 2023-12-31 0001360214 HROW:OneTimePaymentMember us-gaap:SubsequentEventMember 2024-01-01 2024-01-20 0001360214 HROW:OneTimePaymentMember 2023-01-31 0001360214 HROW:AssetPurchaseAgreementMember 2022-10-01 2022-10-30 0001360214 HROW:AssetPurchaseAgreementMember 2022-10-30 0001360214 HROW:RPCAgreementMember 2023-12-31 0001360214 HROW:RPCAgreementMember 2023-01-01 2023-12-31 0001360214 srt:MaximumMember HROW:OneTimePaymentMember HROW:SinteticaAgreementMember 2021-06-01 2021-06-30 0001360214 HROW:UpfrontPaymentMember HROW:SinteticaAgreementMember 2021-06-01 2021-06-30 0001360214 us-gaap:ResearchAndDevelopmentExpenseMember HROW:SinteticaAgreementMember 2021-01-01 2021-12-31 0001360214 HROW:SinteticaAgreementMember 2022-01-01 2022-12-31 0001360214 HROW:SinteticaAgreementMember 2023-08-01 2023-08-31 0001360214 HROW:SinteticaAgreementMember 2023-01-01 2023-12-31 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2019-02-01 2019-02-28 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2023-01-01 2023-12-31 0001360214 us-gaap:SeriesBPreferredStockMember HROW:MeltPharmaceuticalsIncMember 2023-01-01 2023-12-31 0001360214 HROW:MeltLoanAgreementMember 2021-09-01 0001360214 HROW:ThirdPartyInvestorMember HROW:MeltLoanAgreementMember 2022-04-30 0001360214 HROW:MeltLoanAgreementMember 2023-12-28 0001360214 HROW:SeriesBOnePreferredStockMember HROW:MeltLoanAgreementMember 2023-12-28 0001360214 us-gaap:SeriesBPreferredStockMember HROW:MeltLoanAgreementMember 2023-12-28 0001360214 HROW:SurfaceOphthalmicsIncMember 2023-12-31 0001360214 HROW:SurfaceOphthalmicsIncMember 2021-01-01 2021-12-31 0001360214 HROW:CapitalizedInternalUseSoftwareMember 2023-12-31 0001360214 HROW:CapitalizedInternalUseSoftwareMember 2022-12-31 0001360214 HROW:ThirdPartySoftwareLicenseMember 2023-12-31 0001360214 HROW:ThirdPartySoftwareLicenseMember 2022-12-31 0001360214 HROW:CapitalizedSoftwareDevelopmentCostsMember 2023-01-01 2023-12-31 0001360214 HROW:CapitalizedSoftwareDevelopmentCostsMember 2022-01-01 2022-12-31 0001360214 srt:MinimumMember us-gaap:PatentsMember 2023-12-31 0001360214 srt:MaximumMember us-gaap:PatentsMember 2023-12-31 0001360214 us-gaap:PatentsMember 2023-12-31 0001360214 srt:MinimumMember HROW:LicensesMember 2023-12-31 0001360214 srt:MaximumMember HROW:LicensesMember 2023-12-31 0001360214 HROW:LicensesMember 2023-12-31 0001360214 us-gaap:TrademarksMember 2023-01-01 2023-12-31 0001360214 us-gaap:TrademarksMember 2023-12-31 0001360214 HROW:NewDrugApplicationsMember 2023-12-31 0001360214 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2023-12-31 0001360214 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2023-12-31 0001360214 us-gaap:CustomerRelationshipsMember 2023-12-31 0001360214 us-gaap:TradeNamesMember 2023-12-31 0001360214 srt:MinimumMember HROW:NonCompetitionClauseMember 2023-12-31 0001360214 srt:MaximumMember HROW:NonCompetitionClauseMember 2023-12-31 0001360214 HROW:NonCompetitionClauseMember 2023-12-31 0001360214 HROW:StatePharmacyLicensesMember 2023-12-31 0001360214 srt:MinimumMember us-gaap:PatentsMember 2022-12-31 0001360214 srt:MaximumMember us-gaap:PatentsMember 2022-12-31 0001360214 us-gaap:PatentsMember 2022-12-31 0001360214 HROW:LicensesMember 2022-12-31 0001360214 us-gaap:TrademarksMember 2022-01-01 2022-12-31 0001360214 us-gaap:TrademarksMember 2022-12-31 0001360214 HROW:NewDrugApplicationsMember 2022-12-31 0001360214 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2022-12-31 0001360214 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2022-12-31 0001360214 us-gaap:CustomerRelationshipsMember 2022-12-31 0001360214 us-gaap:TradeNamesMember 2022-12-31 0001360214 srt:MinimumMember HROW:NonCompetitionClauseMember 2022-12-31 0001360214 srt:MaximumMember HROW:NonCompetitionClauseMember 2022-12-31 0001360214 HROW:NonCompetitionClauseMember 2022-12-31 0001360214 HROW:StatePharmacyLicensesMember 2022-12-31 0001360214 us-gaap:PatentsMember 2023-01-01 2023-12-31 0001360214 us-gaap:PatentsMember 2022-01-01 2022-12-31 0001360214 HROW:LicensesMember 2023-01-01 2023-12-31 0001360214 HROW:LicensesMember 2022-01-01 2022-12-31 0001360214 HROW:AcquiredNewDrugApplicationsMember 2023-01-01 2023-12-31 0001360214 HROW:AcquiredNewDrugApplicationsMember 2022-01-01 2022-12-31 0001360214 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0001360214 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-12-31 0001360214 HROW:FinancingAgreementMember 2022-08-17 2023-08-16 0001360214 srt:ScenarioForecastMember HROW:FinancingAgreementMember 2023-08-17 2024-08-16 0001360214 srt:MaximumMember HROW:SeniorSecuredTermLoanMember HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2023-03-31 0001360214 HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2023-03-31 0001360214 srt:MaximumMember HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2023-03-01 2023-03-31 0001360214 HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2023-03-01 2023-03-31 0001360214 HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2023-03-03 0001360214 HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2023-01-01 2023-12-31 0001360214 HROW:OaktreeLoanMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember HROW:OaktreeFundAdministrationLLCMember 2023-01-01 2023-12-31 0001360214 HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2023-12-31 0001360214 srt:MinimumMember HROW:OaktreeCreditAgreementAmendmentMember 2023-07-01 2023-07-31 0001360214 srt:MaximumMember HROW:OaktreeCreditAgreementAmendmentMember 2023-07-01 2023-07-31 0001360214 HROW:OaktreeCreditAgreementAmendmentMember 2023-07-31 0001360214 HROW:SantenProductsAcquisitionMember HROW:OaktreeLoanMember HROW:OaktreeCreditAgreementAmendmentMember 2023-07-31 0001360214 srt:MaximumMember HROW:OaktreeCreditAgreementAmendmentMember 2023-12-31 0001360214 us-gaap:CommonStockMember HROW:OaktreeLoanMember HROW:OaktreeFundAdministrationLLCMember 2023-12-31 0001360214 HROW:OaktreeLoanMember 2023-01-01 2023-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2022-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2023-01-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2022-12-01 2022-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2023-01-01 2023-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2022-01-01 2022-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2023-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-04-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-05-01 2021-05-31 0001360214 us-gaap:InvestorMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-04-30 0001360214 us-gaap:InvestorMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-04-01 2021-04-30 0001360214 us-gaap:InvestorMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-09-01 2021-09-30 0001360214 us-gaap:InvestorMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-09-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-09-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-04-01 2021-04-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2023-01-01 2023-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2022-01-01 2022-12-31 0001360214 HROW:BRLoanMember HROW:LoanAndSecurityAgreementMember 2022-12-14 0001360214 HROW:BRLoanMember HROW:LoanAndSecurityAgreementMember 2022-12-13 2022-12-14 0001360214 HROW:BRLoanMember HROW:LoanAndSecurityAgreementMember 2023-01-31 0001360214 HROW:BRLoanMember HROW:LoanAndSecurityAgreementMember 2023-01-01 2023-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2023-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2022-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2023-12-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySevenMember 2022-12-31 0001360214 HROW:OaktreeLoanMember 2023-12-31 0001360214 HROW:OaktreeLoanMember 2022-12-31 0001360214 srt:MinimumMember HROW:OfficeAndLaboratorySpaceMember 2023-12-31 0001360214 srt:MaximumMember HROW:OfficeAndLaboratorySpaceMember 2023-12-31 0001360214 HROW:CarlsbadMember 2023-12-31 0001360214 HROW:CarlsbadMember 2023-01-01 2023-12-31 0001360214 HROW:LedgewoodMember 2023-12-31 0001360214 HROW:LedgewoodMember 2023-01-01 2023-12-31 0001360214 HROW:LedgewoodMember HROW:LeaseAmendmentMember 2023-01-01 2023-12-31 0001360214 HROW:LedgewoodMember HROW:LeaseAmendmentMember 2023-12-31 0001360214 HROW:NashvilleMember 2023-12-31 0001360214 HROW:NashvilleMember 2023-01-01 2023-12-31 0001360214 HROW:Nashville1Member 2023-12-31 0001360214 HROW:Nashville1Member 2023-01-01 2023-12-31 0001360214 HROW:CommonStockOfferingMember 2023-12-31 0001360214 HROW:CommonStockOfferingMember 2023-01-01 2023-12-31 0001360214 HROW:PerformanceStockUnitsMember 2023-12-31 0001360214 srt:MinimumMember HROW:PerformanceStockUnitsMember 2023-12-31 0001360214 srt:MaximumMember HROW:PerformanceStockUnitsMember 2023-12-31 0001360214 HROW:PerformanceStockUnitsMember 2023-01-01 2023-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember srt:DirectorMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 us-gaap:EmployeeStockOptionMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 HROW:MarkLBaumMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 HROW:MarkLBaumMember us-gaap:CommonStockMember 2023-12-31 0001360214 HROW:AndrewRBollMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 HROW:AndrewRBollMember us-gaap:CommonStockMember 2023-12-31 0001360214 HROW:JohnSaharekMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 HROW:JohnSaharekMember us-gaap:CommonStockMember 2023-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember HROW:AndrewRBollMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember HROW:MarkLBaumMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360214 HROW:MarkLBaumMember 2022-01-01 2022-12-31 0001360214 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001360214 us-gaap:WarrantMember 2022-12-31 0001360214 HROW:ConsultantMember 2022-01-01 2022-12-31 0001360214 HROW:ConsultantOneMember 2022-01-01 2022-12-31 0001360214 HROW:ConsultantTwoMember 2022-01-01 2022-12-31 0001360214 srt:MinimumMember HROW:ConsultantTwoMember 2022-01-01 2022-12-31 0001360214 srt:MaximumMember HROW:ConsultantTwoMember 2022-01-01 2022-12-31 0001360214 HROW:EmployeesMember 2022-01-01 2022-12-31 0001360214 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001360214 srt:MaximumMember HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember 2023-12-31 0001360214 HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember 2023-12-31 0001360214 HROW:StockOptionPlanMember 2023-12-31 0001360214 HROW:StockOptionPlanMember 2022-12-31 0001360214 HROW:EmployeesAndConsultantMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001360214 HROW:EmployeesAndDirectorsMember 2023-01-01 2023-12-31 0001360214 us-gaap:EmployeeStockOptionMember 2023-12-31 0001360214 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001360214 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001360214 HROW:PerformanceStockUnitsPSUMember 2023-04-01 2023-04-30 0001360214 srt:MinimumMember HROW:PerformanceStockUnitsPSUMember us-gaap:CommonStockMember 2023-04-30 0001360214 srt:MaximumMember HROW:PerformanceStockUnitsPSUMember us-gaap:CommonStockMember 2023-04-30 0001360214 HROW:PerformanceStockUnitsPSUMember 2023-01-01 2023-12-31 0001360214 HROW:UnvestedPSUMember 2023-12-31 0001360214 HROW:UnvestedPSUMember 2023-01-01 2023-12-31 0001360214 HROW:UnvestedPSUMember 2022-01-01 2022-12-31 0001360214 HROW:DirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001360214 HROW:EmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001360214 HROW:UnvestedRSUMember 2023-12-31 0001360214 HROW:UnvestedRSUAndPSUMember 2023-01-01 2023-12-31 0001360214 HROW:UnvestedRSUMember 2023-01-01 2023-12-31 0001360214 HROW:UnvestedRSUMember 2022-01-01 2022-12-31 0001360214 HROW:StockOptionPlanOneMember 2022-12-31 0001360214 HROW:StockOptionPlanOneMember 2023-01-01 2023-12-31 0001360214 HROW:StockOptionPlanOneMember 2023-12-31 0001360214 HROW:StockOptionPlanOneMember 2021-12-31 0001360214 HROW:StockOptionPlanOneMember 2022-01-01 2022-12-31 0001360214 HROW:RangeOneMember 2023-01-01 2023-12-31 0001360214 HROW:RangeOneMember 2023-12-31 0001360214 HROW:RangeTwoMember 2023-01-01 2023-12-31 0001360214 HROW:RangeTwoMember 2023-12-31 0001360214 HROW:RangeThreeMember 2023-01-01 2023-12-31 0001360214 HROW:RangeThreeMember 2023-12-31 0001360214 HROW:RangeFourMember 2023-01-01 2023-12-31 0001360214 HROW:RangeFourMember 2023-12-31 0001360214 HROW:RangeFiveMember 2023-01-01 2023-12-31 0001360214 HROW:RangeFiveMember 2023-12-31 0001360214 HROW:RangeSixMember 2023-01-01 2023-12-31 0001360214 HROW:RangeSixMember 2023-12-31 0001360214 HROW:RangeSevenMember 2023-01-01 2023-12-31 0001360214 HROW:RangeSevenMember 2023-12-31 0001360214 HROW:RangeEightMember 2023-01-01 2023-12-31 0001360214 HROW:RangeEightMember 2023-12-31 0001360214 HROW:RangeNineMember 2023-01-01 2023-12-31 0001360214 HROW:RangeNineMember 2023-12-31 0001360214 HROW:RangeTenMember 2023-01-01 2023-12-31 0001360214 HROW:RangeTenMember 2023-12-31 0001360214 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-12-31 0001360214 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-12-31 0001360214 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-12-31 0001360214 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-12-31 0001360214 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-01-01 2023-12-31 0001360214 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-12-31 0001360214 HROW:ShareBasedCompensationAwardTrancheFourMember 2023-01-01 2023-12-31 0001360214 HROW:ShareBasedCompensationAwardTrancheFourMember 2023-12-31 0001360214 HROW:PerformanceStockUnitsPSUMember 2022-12-31 0001360214 HROW:PerformanceStockUnitsPSUMember 2023-12-31 0001360214 HROW:PerformanceStockUnitsPSUMember 2021-12-31 0001360214 HROW:PerformanceStockUnitsPSUMember 2022-01-01 2022-12-31 0001360214 HROW:EmployeesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001360214 HROW:EmployeesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0001360214 HROW:EmployeesMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001360214 HROW:EmployeesMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001360214 srt:DirectorMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001360214 srt:DirectorMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0001360214 HROW:ConsultantMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001360214 HROW:ConsultantMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0001360214 us-gaap:DomesticCountryMember 2023-01-01 2023-12-31 0001360214 us-gaap:StateAndLocalJurisdictionMember 2023-01-01 2023-12-31 0001360214 HROW:ReasearchAndDevelopmentMember 2023-01-01 2023-12-31 0001360214 us-gaap:InternalRevenueServiceIRSMember 2023-12-31 0001360214 HROW:SalesAndMarketingAgreementsMember 2023-01-01 2023-12-31 0001360214 srt:MinimumMember HROW:SalesAndMarketingAgreementsMember 2023-01-01 2023-12-31 0001360214 srt:MaximumMember HROW:SalesAndMarketingAgreementsMember 2023-01-01 2023-12-31 0001360214 HROW:SalesAndMarketingAgreementsMember 2022-01-01 2022-12-31 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2023-12-31 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2022-12-31 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2023-01-01 2023-12-31 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2022-01-01 2022-12-31 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:RichardLLindstromMDMember HROW:InitialPaymentMember HROW:KlarityLicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:RichardLLindstromMDMember HROW:SecondPaymentMember HROW:KlarityLicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:RichardLLindstromMDMember HROW:FinalPaymentMember HROW:KlarityLicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:KlarityLicenseAgreementMember 2023-01-01 2023-12-31 0001360214 HROW:KlarityLicenseAgreementMember 2022-01-01 2022-12-31 0001360214 HROW:KlarityLicenseAgreementMember 2023-12-31 0001360214 HROW:KlarityLicenseAgreementMember 2022-12-31 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2019-12-01 2019-12-31 0001360214 HROW:InjectableAssetPurchaseAgreementMember 2023-01-01 2023-12-31 0001360214 HROW:InjectableAssetPurchaseAgreementMember 2022-01-01 2022-12-31 0001360214 HROW:LindstromAgreementMember 2023-01-01 2023-12-31 0001360214 HROW:LindstromAgreementMember 2022-01-01 2022-12-31 0001360214 HROW:RichardLLindstromMDMember HROW:PresbyopiaAssetPurchaseAgreementMember 2019-12-01 2019-12-31 0001360214 HROW:PresbyopiaAssetPurchaseAgreementMember 2023-01-01 2023-12-31 0001360214 HROW:PresbyopiaAssetPurchaseAgreementMember 2022-01-01 2022-12-31 0001360214 HROW:PresbyopiaAssetPurchaseAgreementMember 2023-12-31 0001360214 HROW:PresbyopiaAssetPurchaseAgreementMember 2022-12-31 0001360214 HROW:DexycuAgreementMember 2023-01-01 2023-12-31 0001360214 HROW:DexycuAgreementMember 2022-01-01 2022-12-31 0001360214 HROW:TwoProductConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0001360214 HROW:TwoProductConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0001360214 HROW:SingleCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001360214 HROW:SingleCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001360214 HROW:SingleCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001360214 HROW:SingleCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001360214 HROW:ThreeSuppliersMember us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember 2023-01-01 2023-12-31 0001360214 HROW:ThreeSuppliersMember us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-12-31 0001360214 HROW:AndrewRBollMember us-gaap:SubsequentEventMember 2024-02-01 2024-02-29 0001360214 HROW:MarkLBaumMember us-gaap:SubsequentEventMember 2024-02-01 2024-02-29 0001360214 HROW:JohnSaharekMember us-gaap:SubsequentEventMember 2024-02-01 2024-02-29 0001360214 HROW:EmployeesMember us-gaap:SubsequentEventMember 2024-02-01 2024-02-29 0001360214 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-02-01 2024-02-29 0001360214 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-01 2024-03-31 0001360214 srt:MinimumMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-02-29 0001360214 srt:MinimumMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-31 0001360214 srt:MaximumMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-02-29 0001360214 srt:MaximumMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-31 iso4217:USD shares iso4217:USD shares HROW:Segment utr:sqft pure false FY 0001360214

P3Y

P2Y

P1Y

10-K true 2023-12-31 --12-31 2023 false 001-35814 HARROW, INC. DE 45-0567010 102 Woodmont Blvd. Suite 610 Nashville TN 37205 (615) 733-4730 Common Stock, $0.001 par value per share HROW NASDAQ 8.625% Senior Notes due 2026 HROWL NASDAQ 11.875% Senior Notes due 2027 HROWM NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 464000000 35362642 Portions of the registrant’s definitive Proxy Statement for its 2024 Annual Meeting of Stockholders to be held on June 13, 2024 are incorporated by reference in Part III of this Annual Report on Form 10-K, to the extent stated herein. 170 KMJ Corbin & Company LLP Irvine, California

74085000

96270000

8681000

5589000

36261000

6249000

10867000

6541000

9588000

3611000

139482000

118260000

3521000

3486000

2138000

2112000

1950000

6785000

7513000

159906000

23725000

332000

312164000

157378000

24581000

13771000

18432000

5450000

4025000

75000

113000

806000

723000

49344000

18632000

6524000

7332000

2713000

183172000

104174000

241753000

130138000

0.001

50000000

35168260

29901530

35000

30000

204635000

137058000

-133904000

-109493000

70766000

27595000

-355000

70411000

27240000

312164000

157378000

117447000

83524000

12746000

5071000

130193000

88595000

39640000

25383000

90553000

63212000

83090000

58243000

6652000

3050000

380000

90122000

61293000

431000

1919000

21324000

7244000

11133000

3092000

-2914000

-5465000

5259000

-444000

102000

-24141000

-15930000

-23710000

-14011000

701000

75000

-24411000

-14086000

-0.75

-0.51

32616777

27460968

26902763

27000

106666000

-95407000

11286000

-355000

10931000

19679

55000

221086

1000

586000

587000

306347

185000

1000

-1000

109771

-1000

-875000

-876000

2376426 2000 22653000 22655000 22655000

7974000

-14086000

29901530

30000

137058000

-109493000

27595000

-355000

27240000

29901530

30000

137058000

-109493000

27595000

-355000

27240000

3887324

4000

64516000

64520000

10000

85000

235975

294000

1847876

2000

-2000

714445

-1000

-13012000

-13013000

15696000

-24411000

35168260

35000

204635000

-133904000

70766000

-355000

70411000

35168260

35000

204635000

-133904000

70766000

-355000

70411000

-24411000

-14086000

1530000

1477000

10082000

1578000

728000

610000

332000

81000

4097000

782000

3092000

-2914000

11133000 168000 69000

380000

-5465000

15696000

7974000

5259000

30344000

1860000

4326000

2324000

5647000

3350000

31795000

933000

1425000

936000

-38000

97000

3840000

1705000

6000000

18000

176000

30000

-151075000 -5000000

1460000

2597000

-152553000

-1743000

4961000 31738000

73552000

13013000 876000

379000

642000

55879000

59750000

64520000

22655000

18000

126528000

54141000

-22185000

54103000

96270000

42167000

74085000

96270000

75000

18887000

6480000

1950000 2713000 873000 906000 5000000 299000 123000

2188000

<p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z918qQkGzjqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in">NOTE 1. ORGANIZATION Harrow, Inc. (together with its consolidated subsidiaries, unless the context indicates or otherwise requires, the “Company” or “Harrow”) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year. The Company owns commercial rights to one of the largest portfolios of branded ophthalmic pharmaceutical products in the U.S. that are marketed under its Harrow name. The Company also owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical-compounding businesses. The Company owns non-controlling equity interests in Surface Ophthalmics, Inc. (“Surface”) and Melt Pharmaceuticals, Inc. (“Melt”), both companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt. Effective September 29, 2023, the Company changed its corporate name from Harrow Health, Inc. to Harrow, Inc. pursuant to a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation Harrow has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries. Harrow consolidates entities in which it has a controlling financial interest. The Company assesses control under the variable interest entity (“VIE”) model to determine whether the Company is the primary beneficiary of that entity. The Company consolidates (i) entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights, and (ii) VIEs for which the Company is deemed to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among others, allowance for credit losses, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, renewal periods and discount rates for leases, realizability of inventories, recoverability of investments, realizability of deferred tax assets, recoverability of long-lived assets and goodwill, valuations and purchase price allocations related to business combinations and asset acquisitions, fair value of loans payable, and valuation of stock-based transactions with employees and non-employees. Actual results could differ from those estimates. Risks, Uncertainties and Liquidity The Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, this may have a material impact on the Company’s financial condition, liquidity and results of operations. Credit Losses The Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables. Management considers historical collection rates, the current financial status of the Company’s customers, macroeconomic factors, and other industry-specific factors when evaluating current expected credit losses. Forward-looking information is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of accounts receivable, management believes that the carrying value, net of expected losses, approximates fair value and therefore, relies more on historical and current analysis of such financial instruments, including its trade receivables. To determine the provision for credit losses for accounts receivable, the Company has disaggregated its accounts receivable by class of customer at the business component level, as management determined that risk profile of the Company’s customers is consistent based on the type and industry in which they operate, mainly in the pharmaceuticals industry. Each business component is analyzed for estimated credit losses individually. In doing so, the Company establishes a historical loss matrix, based on the previous collections of accounts receivable by the age of such receivables, and evaluates the current and forecasted financial position of its customers, as available. Further, the Company considers macroeconomic factors and the status of the pharmaceuticals industry to estimate if there are current expected credit losses within its trade receivables based on the trends of the Company’s expectation of the future status of such economic and industry-specific factors. Also, specific allowance amounts are established based on review of outstanding invoices to record the appropriate provision for customers that have a higher probability of default. Accounts receivable at December 31, 2023 and 2022 are net of allowances for credit losses of $371,000 and $73,000, respectively. The following table provides a roll-forward of the allowance for credit losses that is deducted from the amortized cost basis of accounts receivable to present the net amount expected to be collected at December 31, 2023 and 2022: SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Balance at January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20230101__20231231_zmB0Uwtp9ove" style="width: 20%; text-align: right" title="Beginning balance">73,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Change in expected credit losses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_c20230101__20231231_zVIX0jQ7Y8Df" style="text-align: right" title="Change in expected credit losses">332,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Write-offs, net of recoveries</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230101__20231231_zRNV98RFWQug" style="border-bottom: Black 1.5pt solid; text-align: right" title="Write-offs, net of recoveries">(34,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20230101__20231231_zBZGYcX40h6" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">371,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Business Combinations and Asset Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether the Company has acquired inputs, process, and output, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). ASC 805, Business Combinations, requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including any contingent assets and liabilities, and any non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. The Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligation for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, would be recognized as a gain or loss and recorded in the consolidated statement of operations. If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, Business Combinations – Related Issues, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity or a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s financial statements. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired, and liabilities assumed, whichever is more clearly evident and more reliably measurable. The obligation for contingent consideration payments is recorded when probable and reasonably estimable. Contingent consideration recognized is included in the initial cost of the assets acquired and any subsequent changes in the recorded amount of contingent consideration are recognized as an adjustment to the cost basis of the acquired assets and allocated to the acquired assets based on the relative fair value at the date of acquisition. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Noncontrolling Interests The Company recognizes any noncontrolling interest as a separate line item in equity in the consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors that are considered as well, such as decision-making rights. When applicable, and in prior periods, the Company includes the amount of net loss attributable to noncontrolling interests in consolidated net loss on the face of the consolidated statements of operations. The Company provides in the consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interests that separately discloses: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">net income or loss;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">2.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">3.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">each component of other income or loss.</td></tr> </table> The noncontrolling interests in the consolidated balance sheets as of December 31, 2023 and 2022, relate to consolidated subsidiaries that the Company owns a controlling interest in, but not 100% of the equity interests, and that no longer have active operations, assets and related financial activity. Revenue Recognition and Deferred Revenue The Company recognizes revenue at the time of transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services (see Note 3). Cost of Sales Cost of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, depreciation and amortization of certain intangible assets and the write-off of obsolete inventory. Research and Development Research and development (“R&D”) expenses consist of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses, and costs related to clinical trials, contract services and outsourced contracts. We expense all costs related to R&D as they are incurred. Upfront and milestone payments related to the acquisition and licensing of technology for drug and product candidates that are not yet approved by the FDA are considered acquisition of in process R&D and expensed as R&D in the period in which the expense occurs. Debt Issuance Costs and Debt Discount Debt issuance costs and the debt discount are recorded net of notes payable in the consolidated balance sheets. Amortization of debt issuance costs and the debt discount is calculated using the effective interest method over the term of the related debt and is recorded in interest expense in the accompanying consolidated statements of operations. At December 31, 2022, the Company recorded deferred financing costs of $1,950,000 related to the B. Riley Loan and Security Agreement (the “BR Loan”), which was recorded as a debt issuance cost and net of the related BR Loan when it funded in January 2023 (see Note 13). Intellectual Property The costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where we have identified an alternative future use for the acquired rights. Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain (see “Goodwill and Intangible Assets” below). If costs are not capitalized they are expensed as incurred. Income Taxes As part of the process of preparing the Company’s consolidated financial statements, the Company must estimate the actual current tax assets and liabilities and assess permanent and temporary differences that result from differing treatment of items for tax and accounting purposes. The temporary differences result in deferred tax assets and liabilities, which are included within the consolidated balance sheets. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not more likely than not, a valuation allowance must be established which reduces the amount of deferred tax assets recorded on the consolidated balance sheets. To the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be included in income tax expense in the consolidated statements of operations. The Company accounts for income taxes under the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes. As of December 31, 2023 and 2022, there was $2,853,000 and $0, respectively, of unrecognized tax benefits included in the consolidated balance sheets that would, if recognized, affect the effective tax rate. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties in its consolidated balance sheets at December 31, 2023 and 2022, and has not recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2023 and 2022. The Company is subject to taxation in the United States, California, New Jersey, Tennessee, and various other states. The Company’s tax years since 2000 may be subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses. Cash and Cash Equivalents Cash equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition. Concentrations of Credit Risk The Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (“FDIC”) provides basic deposit coverage with limits up to $250,000 per owner. The Company believes the majority of its cash deposits are covered under FDIC limits, however there are various accounts in which the Company has deposits in excess of FDIC limits. Investment in Eton Pharmaceuticals, Inc. The Company’s investment in Eton Pharmaceuticals, Inc. (“Eton”) consists of common stock with a readily determinable fair value which is carried at fair value with changes in fair value recognized in earnings. In accordance with ASC 321, Investments — Equity Securities, the Company recorded an unrealized holding gain/(loss) from its Eton common stock position of $<span id="xdx_903_eus-gaap--UnrealizedGainLossOnInvestments_c20230101__20231231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zxsNC0QJBJFl" title="Investments related to change in fair market value of its investment">3,092,000 and $<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_c20220101__20221231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zueVmQMO1bQg" title="Investments related to change in fair market value of its investment">(2,914,000), during the years ended December 31, 2023 and 2022, respectively, related to the change in fair market value of its investment in Eton during the measurement period. As of December 31, 2023 and 2022, the Company owned <span id="xdx_907_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_z1rYcL6BzjRa" title="Number of shares owned"><span id="xdx_90A_eus-gaap--InvestmentOwnedBalanceShares_iI_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zppVXmbmc40j" title="Number of shares owned">1,982,000 shares of Eton common stock, which represents less than <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zUqP0mXhjM68" title="Equity method investment ownership, percentage"><span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zAcq5zeJPIwh" title="Equity method investment ownership, percentage">10% of the equity interests of Eton. At December 31, 2023 and 2022, the fair market value of Eton’s common stock was $4.38 and $2.82 per share, respectively. As of December 31, 2023 and 2022, the fair market value of the Company’s investment in Eton was $<span id="xdx_90C_eus-gaap--InvestmentOwnedAtFairValue_iI_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zlyzXAt4SQDk" title="Investment owned, at fair value">8,681,000 and $<span id="xdx_902_eus-gaap--InvestmentOwnedAtFairValue_iI_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zO0VpcVCky1e" title="Investment owned, at fair value">5,589,000, respectively. Accounts Receivable Accounts receivable are stated net of allowances for credit losses and contractual adjustments. The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. Our gross product revenues are subject to a variety of contractual deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Accounts receivable at December 31, 2023 are presented net of allowances for credit losses of $371,000 and $14,875,000 for contractual adjustments (in aggregate $15,146,000) and at December 31, 2022, net of allowances for credit losses of $73,000 and $706,000 for contractual adjustments (in aggregate $779,000). Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories. The Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses. Investment in Melt Pharmaceuticals, Inc. – Related Party The Company owns <span id="xdx_905_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember_zunl5JfTU7Fc" title="Investment owned balance shares">3,500,000 shares of common stock and <span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember_zhaa2M67tWAj" title="Investment owned balance shares">2,334,256 shares of preferred stock of Melt (representing in aggregate approximately <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zR8OWuXjFLO4" title="Ownership percentage">47% of the equity interests as of December 31, 2023). The Company analyzes its investment in Melt and related agreements on a regular basis to evaluate its position of variable interests in Melt. The Company has determined that it does not have the ability to control Melt, however it has the ability to exercise significant influence over the operating and financial decisions of Melt and uses the equity method of accounting for this investment. Under this method, the Company recognizes earnings and losses in Melt in its consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company reduced the carrying value of its investment in Melt to $<span id="xdx_90D_ecustom--ReductionInInvestment_c20210101__20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_z0TKBjSFLBc7" title="Reduction in investment">0 as a result of the Company recording its share of equity losses in Melt since its deconsolidation in 2019. As of December 31, 2022, and at the time of entering into the Melt Loan Agreement (see Note 5), the Company owned <span id="xdx_90F_eus-gaap--InvestmentInterestRate_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zY6SwdTJJjM5" title="Investment interest rate">100% of Melt’s indebtedness. Following the reduction of the carrying value of the Company’s common stock investment in Melt to $<span id="xdx_901_ecustom--ReductionInInvestment_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember_zqoTnjw15csj" title="Reduction in investment">0, the Company began recording <span id="xdx_903_eus-gaap--InvestmentInterestRate_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zilUi1O4lha2" title="Investment interest rate">100% of the equity method losses of Melt, based on its ownership of Melt’s total indebtedness. In addition, the Company treated interest paid in kind on the Melt Loan Agreement as an in-substance capital contribution and reduced its investment in Melt accordingly, rather than recording interest income. On a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company’s equity method investments may be other than temporarily impaired. Indicators include financial condition, operating performance, and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity method investments. During the year ended December 31, 2023, the Melt Loan Agreement (as defined in Note 5) was settled in exchange for Melt preferred stock (see Note 5 for loan settlement disclosure). The Company reduced the Melt Loan Agreement and subsequent preferred stock investment in Melt to $<span id="xdx_909_ecustom--ReductionInInvestment_c20230101__20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember_zRLbF5IfKPlf" title="Reduction in investment">0 as a result of the Company recording its share of equity losses of Melt. The Company has no other investments in Melt and no other requirements to advance funds to Melt. <p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zmEbTE94Pfte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the Company’s investments in Melt as of December 31, 2023: SCHEDULE OF INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Share of Equity Method Losses</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify">Common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z9I1fpZhHhWa" style="width: 14%; text-align: right" title="Cost basis">5,810,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zQE3WgDyFCt5" style="width: 14%; text-align: right" title="Share of Equity Method Losses">(5,810,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zf7vl3OounWj" style="width: 14%; text-align: right" title="Net Carrying Value"> -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zRUXdl7j8Yd2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost basis">18,397,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJeMn2AeVVg7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share of Equity Method Losses">(18,397,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z7gw0phnX3gf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Value">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z9HYs707p8v1" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost basis">24,207,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z2hXoFn2S8k2" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses">(24,207,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--Investments_iI_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zLDOFCzO9Te9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the Company’s investments in Melt as of December 31, 2022: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Share of Equity Method Losses</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Paid-in-Kind Interest</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">In-substance Capital Contributions</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify">Common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSGupMWvo1t1" style="width: 11%; text-align: right" title="Cost basis">5,810,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zrfcDREyXKl9" style="width: 11%; text-align: right" title="Share of Equity Method Losses">(5,810,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--InvestmentPaidInKindInterest_iI_pp0p0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zDlg9sSm6lDc" style="width: 11%; text-align: right" title="Paid in Kind Interest">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSXrv6iAkYT3" style="width: 11%; text-align: right" title="In Substance Capital Contributions">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iI_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zfp75lrKQFsh" style="width: 11%; text-align: right" title="Net Carrying Value">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zGuT3xldFvQ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost basis">13,500,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSIzisTS5Rpa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share of Equity Method Losses">(13,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--InvestmentPaidInKindInterest_iI_c20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zn9KWKSGNwB6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Paid in Kind Interest">2,484,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zMyy8nDrJqu4" style="border-bottom: Black 1.5pt solid; text-align: right" title="In Substance Capital Contributions">(2,484,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--Investments_iI_c20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zaLSMp1tfC27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Value">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_ztk6deM36LB4" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost Basis">19,310,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKje2z9tjes" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses">(19,310,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--InvestmentPaidInKindInterest_iI_c20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zuccmpqFMszi" style="border-bottom: Black 2.5pt double; text-align: right" title="Paid in Kind Interest">2,484,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zLgp7W1PNgJa" style="border-bottom: Black 2.5pt double; text-align: right" title="In Substance Capital Contributions">(2,484,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--Investments_iI_c20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zVWkYNS3dKLa" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> At December 31, 2023 and 2022, the Company recorded $89,000 and $139,000, respectively, due from Melt for reimbursable expenses and amounts due under a Management Services Agreement between the Company and Melt (the “Melt MSA”), which are included in prepaid expenses and other current assets in the accompanying consolidated balance sheets. See Note 5 for more information and related party disclosure regarding Melt. Investment in Surface Ophthalmics, Inc. – Related Party The Company owns <span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_zx4vMyD0r83g" title="Investment owned balance shares">3,500,000 common shares of Surface (representing approximately <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_z7AvRdYE6bB2" title="Ownership percentage">20% of Surface’s equity interests following the closing of a round of financing completed by Surface in July 2021) and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company reduced its common stock investment in Surface to $<span id="xdx_90E_ecustom--ReductionInInvestment_c20210101__20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember_zMeHO6aHLgK9" title="Reduction in investment">0 as a result of the Company recording its share of equity losses of Surface. The Company has no other investments in Surface and no other requirements to advance funds to Surface. <p id="xdx_893_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_znk9Pe1rMJBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the Company’s investment in Surface as of December 31, 2023 and 2022: SCHEDULE OF INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Share of Equity Method Losses</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zMwYsL3hJ54f" title="Cost Basis"><span id="xdx_909_eus-gaap--InvestmentOwnedAtCost_iI_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zyXh9iOldm66" title="Cost Basis">5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_903_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_ziIuBq5kMzGc" title="Share of Equity Method Losses"><span id="xdx_90B_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zdDKKRH4M5Gk" title="Share of Equity Method Losses">(5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_905_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zoMrUFnyhtF1" title="Net carrying value"><span id="xdx_902_eus-gaap--Investments_iI_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zvyNmv7bHOKj" title="Net carrying value">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> See Note 6 for more information and related party disclosure regarding Surface. Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful life of the asset. Leasehold improvements and finance lease equipment are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer hardware and furniture and equipment are depreciated over three to five years. Capitalized Software Costs The Company capitalizes certain costs related to the development of internal-use software. Costs incurred during the application development phase are capitalized only when the Company believes it is probable the development will result in new or additional functionality. The types of costs capitalized during the application development phase include consulting fees for third-party developers working on these projects. Costs related to the preliminary project stage and post-implementation activities are expensed as incurred. Internal-use software is amortized on a straight-line basis over the estimated useful life of the asset, which ranges from two to five years. When internal-use software that was previously capitalized is abandoned, the cost less the accumulated amortization, if any, is recorded as amortization expense. Fully amortized capitalized internal-use software costs are removed from their respective accounts. Goodwill and Intangible Assets Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain. At that time, the Company capitalizes third-party legal costs and filing fees associated with obtaining and prosecuting claims related to its patents and trademarks. Once the patents have been issued, the Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life, generally 20 years, using the straight-line method. Acquired product rights, including new drug applications (“NDAs”), are amortized over their estimated useful lives, generally <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember__srt--RangeAxis__srt--MinimumMember_zUCOVMuVPs54" title="Estimated useful life">4-<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember__srt--RangeAxis__srt--MaximumMember_zC5aRoNB9Xyb" title="Estimated useful life">15 years, based on a straight-line method. Trademarks are an indefinite-lived intangible asset and are assessed for impairment based on future projected cash flows as further described below. The Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment indicators include but are not limited to the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">significant underperformance of the Company’s business relative to expected operating results;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">significant adverse economic and industry trends;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">significant decline in the Company’s market capitalization for an extended period of time relative to net book value; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">expectations that a reporting unit will be sold or otherwise disposed.</td></tr> </table> The goodwill impairment test consists of a two-step process as follows: Step 1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, goodwill is considered impaired and the Company then performs the second step of the impairment test to measure the impairment loss. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required. Step 2. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to the excess, limited to the total amount of goodwill allocated to that reporting unit. As a result of its assessment in 2023, the Company concluded that goodwill is not impaired as of December 31, 2023. Impairment of Other Long-Lived Assets Other long-lived assets, such as property, plant and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Such circumstances could include, but are not limited to (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The fair value of the asset is based on the discounted value of its estimated future cash flows. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material. As a result of its assessment in 2023, the Company recorded an impairment charge of $380,000 related to the impairment of certain licenses, trademarks, patents and patent applications (see Note 11). Leases At the inception of a contract the Company determines if the arrangement is, or contains, a lease. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Lease expense is recognized on a straight-line basis over the lease term. The Company has made certain accounting policy elections whereby it (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12-months of less) and (ii) combines lease and non-lease elements of its operating leases as a single lease component. As of December 31, 2023 and 2022, the Company did not have any finance leases. Fair Value Measurements Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.</td></tr> </table> At December 31, 2023 and 2022, the Company measured its investment in Eton on a recurring basis. The Company’s investment in Eton is classified as Level 1 as the fair value is determined using quoted market prices in active markets for the same securities. As of December 31, 2023 and 2022, the fair market value of the Company’s investment in Eton was $8,681,000 and $5,589,000, respectively. The Company’s 2026 Notes (as defined in Note 13) are carried at face value, including the unamortized premium, less unamortized debt issuance costs, the 2027 Notes (as described in Note 13) are carried at face value less unamortized debt issuance costs, and the Oaktree Loan (as defined in Note 13) is carried at face value less the original issue discount and unamortized debt issuance costs on the consolidated balance sheets and the Company presents fair value for disclosure purposes only. The 2026 Notes and 2027 Notes are classified as Level 1 instruments as the fair value is determined using quoted market prices in active markets for the same securities. The Oaktree Loan is classified as a Level 2 instrument and its fair value is determined through an income approach that considers collateral coverage, yield calibration, yield analysis and any adjustments to implied yield associated with the Company’s fundamental measures. <p id="xdx_89C_eus-gaap--ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_zAvM7SkghuL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents the estimated fair values and the carrying values: SCHEDULE OF ESTIMATED FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">2026 Notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zVi46ySmfKHc" style="width: 14%; text-align: right" title="Carrying value">73,218,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zBbSULPXCLt8" style="width: 14%; text-align: right" title="Fair value">70,260,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zev96BeEPhsa" style="width: 14%; text-align: right" title="Carrying value">72,436,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zk3n5J0o6wTc" style="width: 14%; text-align: right" title="Fair value">71,550,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>2027 Notes</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_zpCl1TtbQUrb" style="text-align: right" title="Carrying value">37,413,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_z0W1e8PC9qF5" style="text-align: right" title="Fair value">40,363,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_z2ddrZLMltxj" style="text-align: right" title="Carrying value">31,738,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_zfNdAPh2WZIg" style="text-align: right" title="Fair value">35,112,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Oaktree Loan</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_z8OYFyUgCQ33" style="text-align: right" title="Carrying value">72,541,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zEPn003vazZ" style="text-align: right" title="Fair value">76,627,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zNk4cbx2Sm41" style="text-align: right" title="Carrying value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_z0KXc7NYyYBk" style="text-align: right" title="Fair value">-</td><td style="text-align: left"> </td></tr> </table> The Company’s other financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits and operating lease liabilities. The carrying amount of these financial instruments, except for operating lease liabilities, approximates fair value due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying values of the operating lease liabilities approximate their respective fair values. Stock-Based Compensation All stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units (“RSUs”), performance stock units (“PSUs) and restricted stock, are recognized in the consolidated financial statements based upon their estimated fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo simulation model to estimate the fair value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. Basic and Diluted Net Loss per Common Share Basic net loss per common share is computed by dividing net loss attributable to Harrow, Inc. for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is computed by dividing the net loss attributable to Harrow, Inc. for the year by the weighted average number of common and common equivalent shares, such as stock options, RSUs, PSUs, and warrants, outstanding during the year. Common stock equivalents (using the treasury stock or “if converted” method) from stock options, unvested RSUs, and unvested PSUs were <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndUnvestedPSUsMember_zS9Xm9FWyAlf" title="Stock options, unvested RSUs, and unvested PSUs">4,642,259 and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndUnvestedPSUsMember_zCguypgV4qRd" title="Stock options, unvested RSUs, and unvested PSUs">5,089,420 at December 31, 2023 and 2022, respectively, and are excluded in the calculation of diluted net loss per share for the periods presented, because the effect is anti-dilutive for that time period. Included in the basic and diluted net loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at December 31, 2023 and 2022 was <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfOfKX7WX4w" title="Vested RSU">215,539 and <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCCn8GMUpZj6" title="Vested RSU">319,859, respectively. The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2023 and 2022: SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_496_20230101__20231231_zR9s4uQJE1N1" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_494_20220101__20221231_zEBYxXJyMHa6" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zneioYozyPQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify; padding-bottom: 2.5pt">Numerator – net loss attributable to Harrow, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(24,411,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(14,086,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Denominator – weighted average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,616,777</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,460,968</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.75</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> Recently Adopted Accounting Pronouncements In September 2016, FASB issued Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments. This ASU replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. The ASU, as subsequently amended, is effective for the Company for the fiscal years beginning after December 15, 2022. The Company adopted ASU 2016-13 on January 1, 2023. Based on the composition of the Company’s accounts receivable, investment portfolio, and other financial assets, including current market conditions and historical credit loss activity, the adoption of this standard did not have a material impact on the Company’s consolidated financial statements or disclosures. Specifically, the Company’s estimate of expected credit losses as of January 1, 2023, using its expected credit loss evaluation process described above, resulted in no adjustments to the provision for credit losses and no cumulative-effect adjustment to accumulated deficit on the adoption date of the standard. Accounting Guidance Issued but Not Adopted at December 31, 2023 In August 2023, FASB issued ASU 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement, which applies to the formation of entities that meet the definition of a joint venture (or a corporate joint venture) and requires joint ventures to initially measure all contributions received upon formation at fair value. The new guidance does not impact accounting by the venturers. The new guidance is applicable to joint venture entities with a formation date on or after January 1, 2025 on a prospective basis. Joint ventures formed prior to the effective date may elect to apply the new guidance retrospectively back to their original formation date. The Company will apply the guidance in ASU 2023-05 prospectively to any future arrangements meeting the definition of a joint venture. In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements—Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This ASU modifies the disclosure or presentation requirements of a variety of topics in the codification by aligning them with the SEC’s regulations. The amendments to the various topics should be applied prospectively, and the effective date for the Company for each amendment will be determined based on the effective date of the SEC’s removal of the related disclosure from Regulation S-X or Regulation S-K. If the SEC has not removed the applicable requirement by June 30, 2027, then the related amendment in ASU 2023-06 will be removed from the codification and will not become effective. Early adoption of this ASU is prohibited. The Company does not expect the amendments in this ASU to have a material impact on the disclosures or presentation in its consolidated financial statements. In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures, which enhances the disclosures required for operating segments in the Company’s annual and interim consolidated financial statements. ASU 2023-07 is effective for the Company in our annual reporting for fiscal 2024 and for interim period reporting beginning in fiscal 2025 on a retrospective basis, with all required disclosures to be made for all prior periods presented in the consolidated financial statements. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-07 on its consolidated financial statements. In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures, which enhances the disclosures required for income taxes in the Company’s annual consolidated financial statements. Notably, this ASU requires entities to disclose specific categories in the effective tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for the Company in its annual reporting for fiscal 2025 on a prospective basis. Early adoption and retrospective reporting are permitted. The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements. Reclassifications Certain prior period items and amounts have been reclassified to conform to the classifications used to prepare the consolidated financial statements for the current period. These reclassifications had no material impact on the Company’s consolidated financial position, results of operations, or cash flows as previously reported.

Basis of Presentation Harrow has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries. Harrow consolidates entities in which it has a controlling financial interest. The Company assesses control under the variable interest entity (“VIE”) model to determine whether the Company is the primary beneficiary of that entity. The Company consolidates (i) entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights, and (ii) VIEs for which the Company is deemed to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.

(i) entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights, and (ii) VIEs for which the Company is deemed to be the primary beneficiary.

Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among others, allowance for credit losses, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, renewal periods and discount rates for leases, realizability of inventories, recoverability of investments, realizability of deferred tax assets, recoverability of long-lived assets and goodwill, valuations and purchase price allocations related to business combinations and asset acquisitions, fair value of loans payable, and valuation of stock-based transactions with employees and non-employees. Actual results could differ from those estimates.

Risks, Uncertainties and Liquidity The Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, this may have a material impact on the Company’s financial condition, liquidity and results of operations.

Credit Losses The Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables. Management considers historical collection rates, the current financial status of the Company’s customers, macroeconomic factors, and other industry-specific factors when evaluating current expected credit losses. Forward-looking information is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of accounts receivable, management believes that the carrying value, net of expected losses, approximates fair value and therefore, relies more on historical and current analysis of such financial instruments, including its trade receivables. To determine the provision for credit losses for accounts receivable, the Company has disaggregated its accounts receivable by class of customer at the business component level, as management determined that risk profile of the Company’s customers is consistent based on the type and industry in which they operate, mainly in the pharmaceuticals industry. Each business component is analyzed for estimated credit losses individually. In doing so, the Company establishes a historical loss matrix, based on the previous collections of accounts receivable by the age of such receivables, and evaluates the current and forecasted financial position of its customers, as available. Further, the Company considers macroeconomic factors and the status of the pharmaceuticals industry to estimate if there are current expected credit losses within its trade receivables based on the trends of the Company’s expectation of the future status of such economic and industry-specific factors. Also, specific allowance amounts are established based on review of outstanding invoices to record the appropriate provision for customers that have a higher probability of default. Accounts receivable at December 31, 2023 and 2022 are net of allowances for credit losses of $371,000 and $73,000, respectively. The following table provides a roll-forward of the allowance for credit losses that is deducted from the amortized cost basis of accounts receivable to present the net amount expected to be collected at December 31, 2023 and 2022: SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Balance at January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20230101__20231231_zmB0Uwtp9ove" style="width: 20%; text-align: right" title="Beginning balance">73,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Change in expected credit losses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_c20230101__20231231_zVIX0jQ7Y8Df" style="text-align: right" title="Change in expected credit losses">332,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Write-offs, net of recoveries</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230101__20231231_zRNV98RFWQug" style="border-bottom: Black 1.5pt solid; text-align: right" title="Write-offs, net of recoveries">(34,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20230101__20231231_zBZGYcX40h6" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">371,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

371000

73000

SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Balance at January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_c20230101__20231231_zmB0Uwtp9ove" style="width: 20%; text-align: right" title="Beginning balance">73,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Change in expected credit losses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_c20230101__20231231_zVIX0jQ7Y8Df" style="text-align: right" title="Change in expected credit losses">332,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Write-offs, net of recoveries</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_c20230101__20231231_zRNV98RFWQug" style="border-bottom: Black 1.5pt solid; text-align: right" title="Write-offs, net of recoveries">(34,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_c20230101__20231231_zBZGYcX40h6" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">371,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

73000

332000

34000

371000

Business Combinations and Asset Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether the Company has acquired inputs, process, and output, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). ASC 805, Business Combinations, requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including any contingent assets and liabilities, and any non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. The Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligation for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, would be recognized as a gain or loss and recorded in the consolidated statement of operations. If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, Business Combinations – Related Issues, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity or a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s financial statements. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired, and liabilities assumed, whichever is more clearly evident and more reliably measurable. The obligation for contingent consideration payments is recorded when probable and reasonably estimable. Contingent consideration recognized is included in the initial cost of the assets acquired and any subsequent changes in the recorded amount of contingent consideration are recognized as an adjustment to the cost basis of the acquired assets and allocated to the acquired assets based on the relative fair value at the date of acquisition. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.

Noncontrolling Interests The Company recognizes any noncontrolling interest as a separate line item in equity in the consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors that are considered as well, such as decision-making rights. When applicable, and in prior periods, the Company includes the amount of net loss attributable to noncontrolling interests in consolidated net loss on the face of the consolidated statements of operations. The Company provides in the consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interests that separately discloses: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">net income or loss;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">2.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">3.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">each component of other income or loss.</td></tr> </table> The noncontrolling interests in the consolidated balance sheets as of December 31, 2023 and 2022, relate to consolidated subsidiaries that the Company owns a controlling interest in, but not 100% of the equity interests, and that no longer have active operations, assets and related financial activity.

Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors that are considered as well, such as decision-making rights.

Revenue Recognition and Deferred Revenue The Company recognizes revenue at the time of transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services (see Note 3).

Cost of Sales Cost of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, depreciation and amortization of certain intangible assets and the write-off of obsolete inventory.

Research and Development Research and development (“R&D”) expenses consist of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses, and costs related to clinical trials, contract services and outsourced contracts. We expense all costs related to R&D as they are incurred. Upfront and milestone payments related to the acquisition and licensing of technology for drug and product candidates that are not yet approved by the FDA are considered acquisition of in process R&D and expensed as R&D in the period in which the expense occurs.

Debt Issuance Costs and Debt Discount Debt issuance costs and the debt discount are recorded net of notes payable in the consolidated balance sheets. Amortization of debt issuance costs and the debt discount is calculated using the effective interest method over the term of the related debt and is recorded in interest expense in the accompanying consolidated statements of operations. At December 31, 2022, the Company recorded deferred financing costs of $1,950,000 related to the B. Riley Loan and Security Agreement (the “BR Loan”), which was recorded as a debt issuance cost and net of the related BR Loan when it funded in January 2023 (see Note 13).

1950000

Intellectual Property The costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where we have identified an alternative future use for the acquired rights. Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain (see “Goodwill and Intangible Assets” below). If costs are not capitalized they are expensed as incurred.

Income Taxes As part of the process of preparing the Company’s consolidated financial statements, the Company must estimate the actual current tax assets and liabilities and assess permanent and temporary differences that result from differing treatment of items for tax and accounting purposes. The temporary differences result in deferred tax assets and liabilities, which are included within the consolidated balance sheets. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not more likely than not, a valuation allowance must be established which reduces the amount of deferred tax assets recorded on the consolidated balance sheets. To the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be included in income tax expense in the consolidated statements of operations. The Company accounts for income taxes under the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes. As of December 31, 2023 and 2022, there was $2,853,000 and $0, respectively, of unrecognized tax benefits included in the consolidated balance sheets that would, if recognized, affect the effective tax rate. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties in its consolidated balance sheets at December 31, 2023 and 2022, and has not recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2023 and 2022. The Company is subject to taxation in the United States, California, New Jersey, Tennessee, and various other states. The Company’s tax years since 2000 may be subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses.

2853000

Cash and Cash Equivalents Cash equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.

Concentrations of Credit Risk The Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (“FDIC”) provides basic deposit coverage with limits up to $250,000 per owner. The Company believes the majority of its cash deposits are covered under FDIC limits, however there are various accounts in which the Company has deposits in excess of FDIC limits.

250000

Investment in Eton Pharmaceuticals, Inc. The Company’s investment in Eton Pharmaceuticals, Inc. (“Eton”) consists of common stock with a readily determinable fair value which is carried at fair value with changes in fair value recognized in earnings. In accordance with ASC 321, Investments — Equity Securities, the Company recorded an unrealized holding gain/(loss) from its Eton common stock position of $<span id="xdx_903_eus-gaap--UnrealizedGainLossOnInvestments_c20230101__20231231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zxsNC0QJBJFl" title="Investments related to change in fair market value of its investment">3,092,000 and $<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_c20220101__20221231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zueVmQMO1bQg" title="Investments related to change in fair market value of its investment">(2,914,000), during the years ended December 31, 2023 and 2022, respectively, related to the change in fair market value of its investment in Eton during the measurement period. As of December 31, 2023 and 2022, the Company owned <span id="xdx_907_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_z1rYcL6BzjRa" title="Number of shares owned"><span id="xdx_90A_eus-gaap--InvestmentOwnedBalanceShares_iI_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zppVXmbmc40j" title="Number of shares owned">1,982,000 shares of Eton common stock, which represents less than <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zUqP0mXhjM68" title="Equity method investment ownership, percentage"><span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zAcq5zeJPIwh" title="Equity method investment ownership, percentage">10% of the equity interests of Eton. At December 31, 2023 and 2022, the fair market value of Eton’s common stock was $4.38 and $2.82 per share, respectively. As of December 31, 2023 and 2022, the fair market value of the Company’s investment in Eton was $<span id="xdx_90C_eus-gaap--InvestmentOwnedAtFairValue_iI_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zlyzXAt4SQDk" title="Investment owned, at fair value">8,681,000 and $<span id="xdx_902_eus-gaap--InvestmentOwnedAtFairValue_iI_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zO0VpcVCky1e" title="Investment owned, at fair value">5,589,000, respectively.

3092000

-2914000

1982000

0.10

4.38

2.82

8681000

5589000

Accounts Receivable Accounts receivable are stated net of allowances for credit losses and contractual adjustments. The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. Our gross product revenues are subject to a variety of contractual deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Accounts receivable at December 31, 2023 are presented net of allowances for credit losses of $371,000 and $14,875,000 for contractual adjustments (in aggregate $15,146,000) and at December 31, 2022, net of allowances for credit losses of $73,000 and $706,000 for contractual adjustments (in aggregate $779,000).

371000 14875000

15146000

73000

706000

779000

Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories. The Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses.

Investment in Melt Pharmaceuticals, Inc. – Related Party The Company owns <span id="xdx_905_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember_zunl5JfTU7Fc" title="Investment owned balance shares">3,500,000 shares of common stock and <span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember_zhaa2M67tWAj" title="Investment owned balance shares">2,334,256 shares of preferred stock of Melt (representing in aggregate approximately <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zR8OWuXjFLO4" title="Ownership percentage">47% of the equity interests as of December 31, 2023). The Company analyzes its investment in Melt and related agreements on a regular basis to evaluate its position of variable interests in Melt. The Company has determined that it does not have the ability to control Melt, however it has the ability to exercise significant influence over the operating and financial decisions of Melt and uses the equity method of accounting for this investment. Under this method, the Company recognizes earnings and losses in Melt in its consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company reduced the carrying value of its investment in Melt to $<span id="xdx_90D_ecustom--ReductionInInvestment_c20210101__20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_z0TKBjSFLBc7" title="Reduction in investment">0 as a result of the Company recording its share of equity losses in Melt since its deconsolidation in 2019. As of December 31, 2022, and at the time of entering into the Melt Loan Agreement (see Note 5), the Company owned <span id="xdx_90F_eus-gaap--InvestmentInterestRate_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zY6SwdTJJjM5" title="Investment interest rate">100% of Melt’s indebtedness. Following the reduction of the carrying value of the Company’s common stock investment in Melt to $<span id="xdx_901_ecustom--ReductionInInvestment_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember_zqoTnjw15csj" title="Reduction in investment">0, the Company began recording <span id="xdx_903_eus-gaap--InvestmentInterestRate_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zilUi1O4lha2" title="Investment interest rate">100% of the equity method losses of Melt, based on its ownership of Melt’s total indebtedness. In addition, the Company treated interest paid in kind on the Melt Loan Agreement as an in-substance capital contribution and reduced its investment in Melt accordingly, rather than recording interest income. On a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company’s equity method investments may be other than temporarily impaired. Indicators include financial condition, operating performance, and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity method investments. During the year ended December 31, 2023, the Melt Loan Agreement (as defined in Note 5) was settled in exchange for Melt preferred stock (see Note 5 for loan settlement disclosure). The Company reduced the Melt Loan Agreement and subsequent preferred stock investment in Melt to $<span id="xdx_909_ecustom--ReductionInInvestment_c20230101__20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember_zRLbF5IfKPlf" title="Reduction in investment">0 as a result of the Company recording its share of equity losses of Melt. The Company has no other investments in Melt and no other requirements to advance funds to Melt. <p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zmEbTE94Pfte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the Company’s investments in Melt as of December 31, 2023: SCHEDULE OF INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Share of Equity Method Losses</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify">Common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z9I1fpZhHhWa" style="width: 14%; text-align: right" title="Cost basis">5,810,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zQE3WgDyFCt5" style="width: 14%; text-align: right" title="Share of Equity Method Losses">(5,810,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zf7vl3OounWj" style="width: 14%; text-align: right" title="Net Carrying Value"> -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zRUXdl7j8Yd2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost basis">18,397,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJeMn2AeVVg7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share of Equity Method Losses">(18,397,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z7gw0phnX3gf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Value">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z9HYs707p8v1" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost basis">24,207,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z2hXoFn2S8k2" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses">(24,207,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--Investments_iI_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zLDOFCzO9Te9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the Company’s investments in Melt as of December 31, 2022: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Share of Equity Method Losses</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Paid-in-Kind Interest</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">In-substance Capital Contributions</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify">Common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSGupMWvo1t1" style="width: 11%; text-align: right" title="Cost basis">5,810,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zrfcDREyXKl9" style="width: 11%; text-align: right" title="Share of Equity Method Losses">(5,810,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--InvestmentPaidInKindInterest_iI_pp0p0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zDlg9sSm6lDc" style="width: 11%; text-align: right" title="Paid in Kind Interest">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSXrv6iAkYT3" style="width: 11%; text-align: right" title="In Substance Capital Contributions">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iI_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zfp75lrKQFsh" style="width: 11%; text-align: right" title="Net Carrying Value">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zGuT3xldFvQ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost basis">13,500,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSIzisTS5Rpa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share of Equity Method Losses">(13,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--InvestmentPaidInKindInterest_iI_c20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zn9KWKSGNwB6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Paid in Kind Interest">2,484,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zMyy8nDrJqu4" style="border-bottom: Black 1.5pt solid; text-align: right" title="In Substance Capital Contributions">(2,484,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--Investments_iI_c20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zaLSMp1tfC27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Value">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_ztk6deM36LB4" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost Basis">19,310,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKje2z9tjes" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses">(19,310,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--InvestmentPaidInKindInterest_iI_c20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zuccmpqFMszi" style="border-bottom: Black 2.5pt double; text-align: right" title="Paid in Kind Interest">2,484,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zLgp7W1PNgJa" style="border-bottom: Black 2.5pt double; text-align: right" title="In Substance Capital Contributions">(2,484,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--Investments_iI_c20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zVWkYNS3dKLa" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> At December 31, 2023 and 2022, the Company recorded $89,000 and $139,000, respectively, due from Melt for reimbursable expenses and amounts due under a Management Services Agreement between the Company and Melt (the “Melt MSA”), which are included in prepaid expenses and other current assets in the accompanying consolidated balance sheets. See Note 5 for more information and related party disclosure regarding Melt.

3500000

2334256

0.47

<p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zmEbTE94Pfte" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the Company’s investments in Melt as of December 31, 2023: SCHEDULE OF INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Share of Equity Method Losses</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify">Common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z9I1fpZhHhWa" style="width: 14%; text-align: right" title="Cost basis">5,810,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zQE3WgDyFCt5" style="width: 14%; text-align: right" title="Share of Equity Method Losses">(5,810,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zf7vl3OounWj" style="width: 14%; text-align: right" title="Net Carrying Value"> -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zRUXdl7j8Yd2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost basis">18,397,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJeMn2AeVVg7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share of Equity Method Losses">(18,397,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--PreferredStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z7gw0phnX3gf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Value">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z9HYs707p8v1" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost basis">24,207,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z2hXoFn2S8k2" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses">(24,207,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--Investments_iI_c20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zLDOFCzO9Te9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes the Company’s investments in Melt as of December 31, 2022: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Share of Equity Method Losses</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Paid-in-Kind Interest</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">In-substance Capital Contributions</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: justify">Common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSGupMWvo1t1" style="width: 11%; text-align: right" title="Cost basis">5,810,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zrfcDREyXKl9" style="width: 11%; text-align: right" title="Share of Equity Method Losses">(5,810,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--InvestmentPaidInKindInterest_iI_pp0p0_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zDlg9sSm6lDc" style="width: 11%; text-align: right" title="Paid in Kind Interest">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSXrv6iAkYT3" style="width: 11%; text-align: right" title="In Substance Capital Contributions">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Investments_iI_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zfp75lrKQFsh" style="width: 11%; text-align: right" title="Net Carrying Value">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zGuT3xldFvQ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost basis">13,500,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSIzisTS5Rpa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share of Equity Method Losses">(13,500,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--InvestmentPaidInKindInterest_iI_c20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zn9KWKSGNwB6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Paid in Kind Interest">2,484,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zMyy8nDrJqu4" style="border-bottom: Black 1.5pt solid; text-align: right" title="In Substance Capital Contributions">(2,484,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--Investments_iI_c20221231__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zaLSMp1tfC27" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying Value">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_ztk6deM36LB4" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost Basis">19,310,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKje2z9tjes" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses">(19,310,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--InvestmentPaidInKindInterest_iI_c20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zuccmpqFMszi" style="border-bottom: Black 2.5pt double; text-align: right" title="Paid in Kind Interest">2,484,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zLgp7W1PNgJa" style="border-bottom: Black 2.5pt double; text-align: right" title="In Substance Capital Contributions">(2,484,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--Investments_iI_c20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zVWkYNS3dKLa" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5810000

18397000

24207000

5810000

13500000

2484000

19310000

2484000

89000

139000

Investment in Surface Ophthalmics, Inc. – Related Party The Company owns <span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_zx4vMyD0r83g" title="Investment owned balance shares">3,500,000 common shares of Surface (representing approximately <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_z7AvRdYE6bB2" title="Ownership percentage">20% of Surface’s equity interests following the closing of a round of financing completed by Surface in July 2021) and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company reduced its common stock investment in Surface to $<span id="xdx_90E_ecustom--ReductionInInvestment_c20210101__20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember_zMeHO6aHLgK9" title="Reduction in investment">0 as a result of the Company recording its share of equity losses of Surface. The Company has no other investments in Surface and no other requirements to advance funds to Surface. <p id="xdx_893_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_znk9Pe1rMJBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the Company’s investment in Surface as of December 31, 2023 and 2022: SCHEDULE OF INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Share of Equity Method Losses</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zMwYsL3hJ54f" title="Cost Basis"><span id="xdx_909_eus-gaap--InvestmentOwnedAtCost_iI_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zyXh9iOldm66" title="Cost Basis">5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_903_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_ziIuBq5kMzGc" title="Share of Equity Method Losses"><span id="xdx_90B_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zdDKKRH4M5Gk" title="Share of Equity Method Losses">(5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_905_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zoMrUFnyhtF1" title="Net carrying value"><span id="xdx_902_eus-gaap--Investments_iI_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zvyNmv7bHOKj" title="Net carrying value">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> See Note 6 for more information and related party disclosure regarding Surface.

3500000

0.20

<p id="xdx_893_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_znk9Pe1rMJBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the Company’s investment in Surface as of December 31, 2023 and 2022: SCHEDULE OF INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Share of Equity Method Losses</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--InvestmentOwnedAtCost_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zMwYsL3hJ54f" title="Cost Basis"><span id="xdx_909_eus-gaap--InvestmentOwnedAtCost_iI_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zyXh9iOldm66" title="Cost Basis">5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_903_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_ziIuBq5kMzGc" title="Share of Equity Method Losses"><span id="xdx_90B_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zdDKKRH4M5Gk" title="Share of Equity Method Losses">(5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_905_eus-gaap--Investments_iI_c20231231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zoMrUFnyhtF1" title="Net carrying value"><span id="xdx_902_eus-gaap--Investments_iI_c20221231__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zvyNmv7bHOKj" title="Net carrying value">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5320000

Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful life of the asset. Leasehold improvements and finance lease equipment are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer hardware and furniture and equipment are depreciated over three to five years.

P5Y

Capitalized Software Costs The Company capitalizes certain costs related to the development of internal-use software. Costs incurred during the application development phase are capitalized only when the Company believes it is probable the development will result in new or additional functionality. The types of costs capitalized during the application development phase include consulting fees for third-party developers working on these projects. Costs related to the preliminary project stage and post-implementation activities are expensed as incurred. Internal-use software is amortized on a straight-line basis over the estimated useful life of the asset, which ranges from two to five years. When internal-use software that was previously capitalized is abandoned, the cost less the accumulated amortization, if any, is recorded as amortization expense. Fully amortized capitalized internal-use software costs are removed from their respective accounts.

P5Y

Goodwill and Intangible Assets Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain. At that time, the Company capitalizes third-party legal costs and filing fees associated with obtaining and prosecuting claims related to its patents and trademarks. Once the patents have been issued, the Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life, generally 20 years, using the straight-line method. Acquired product rights, including new drug applications (“NDAs”), are amortized over their estimated useful lives, generally <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember__srt--RangeAxis__srt--MinimumMember_zUCOVMuVPs54" title="Estimated useful life">4-<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember__srt--RangeAxis__srt--MaximumMember_zC5aRoNB9Xyb" title="Estimated useful life">15 years, based on a straight-line method. Trademarks are an indefinite-lived intangible asset and are assessed for impairment based on future projected cash flows as further described below. The Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment indicators include but are not limited to the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">significant underperformance of the Company’s business relative to expected operating results;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">significant adverse economic and industry trends;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">significant decline in the Company’s market capitalization for an extended period of time relative to net book value; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">expectations that a reporting unit will be sold or otherwise disposed.</td></tr> </table> The goodwill impairment test consists of a two-step process as follows: Step 1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, goodwill is considered impaired and the Company then performs the second step of the impairment test to measure the impairment loss. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required. Step 2. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to the excess, limited to the total amount of goodwill allocated to that reporting unit. As a result of its assessment in 2023, the Company concluded that goodwill is not impaired as of December 31, 2023.

P20Y

P4Y

P15Y

Impairment of Other Long-Lived Assets Other long-lived assets, such as property, plant and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Such circumstances could include, but are not limited to (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The fair value of the asset is based on the discounted value of its estimated future cash flows. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material. As a result of its assessment in 2023, the Company recorded an impairment charge of $380,000 related to the impairment of certain licenses, trademarks, patents and patent applications (see Note 11).

380000

Leases At the inception of a contract the Company determines if the arrangement is, or contains, a lease. Operating lease right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Lease expense is recognized on a straight-line basis over the lease term. The Company has made certain accounting policy elections whereby it (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12-months of less) and (ii) combines lease and non-lease elements of its operating leases as a single lease component. As of December 31, 2023 and 2022, the Company did not have any finance leases.

Fair Value Measurements Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.</td></tr> </table> At December 31, 2023 and 2022, the Company measured its investment in Eton on a recurring basis. The Company’s investment in Eton is classified as Level 1 as the fair value is determined using quoted market prices in active markets for the same securities. As of December 31, 2023 and 2022, the fair market value of the Company’s investment in Eton was $8,681,000 and $5,589,000, respectively. The Company’s 2026 Notes (as defined in Note 13) are carried at face value, including the unamortized premium, less unamortized debt issuance costs, the 2027 Notes (as described in Note 13) are carried at face value less unamortized debt issuance costs, and the Oaktree Loan (as defined in Note 13) is carried at face value less the original issue discount and unamortized debt issuance costs on the consolidated balance sheets and the Company presents fair value for disclosure purposes only. The 2026 Notes and 2027 Notes are classified as Level 1 instruments as the fair value is determined using quoted market prices in active markets for the same securities. The Oaktree Loan is classified as a Level 2 instrument and its fair value is determined through an income approach that considers collateral coverage, yield calibration, yield analysis and any adjustments to implied yield associated with the Company’s fundamental measures. <p id="xdx_89C_eus-gaap--ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_zAvM7SkghuL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents the estimated fair values and the carrying values: SCHEDULE OF ESTIMATED FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">2026 Notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zVi46ySmfKHc" style="width: 14%; text-align: right" title="Carrying value">73,218,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zBbSULPXCLt8" style="width: 14%; text-align: right" title="Fair value">70,260,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zev96BeEPhsa" style="width: 14%; text-align: right" title="Carrying value">72,436,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zk3n5J0o6wTc" style="width: 14%; text-align: right" title="Fair value">71,550,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>2027 Notes</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_zpCl1TtbQUrb" style="text-align: right" title="Carrying value">37,413,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_z0W1e8PC9qF5" style="text-align: right" title="Fair value">40,363,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_z2ddrZLMltxj" style="text-align: right" title="Carrying value">31,738,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_zfNdAPh2WZIg" style="text-align: right" title="Fair value">35,112,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Oaktree Loan</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_z8OYFyUgCQ33" style="text-align: right" title="Carrying value">72,541,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zEPn003vazZ" style="text-align: right" title="Fair value">76,627,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zNk4cbx2Sm41" style="text-align: right" title="Carrying value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_z0KXc7NYyYBk" style="text-align: right" title="Fair value">-</td><td style="text-align: left"> </td></tr> </table> The Company’s other financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits and operating lease liabilities. The carrying amount of these financial instruments, except for operating lease liabilities, approximates fair value due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying values of the operating lease liabilities approximate their respective fair values.

8681000

5589000

<p id="xdx_89C_eus-gaap--ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_zAvM7SkghuL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents the estimated fair values and the carrying values: SCHEDULE OF ESTIMATED FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying Value</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">2026 Notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zVi46ySmfKHc" style="width: 14%; text-align: right" title="Carrying value">73,218,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zBbSULPXCLt8" style="width: 14%; text-align: right" title="Fair value">70,260,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zev96BeEPhsa" style="width: 14%; text-align: right" title="Carrying value">72,436,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySixNotesMember_zk3n5J0o6wTc" style="width: 14%; text-align: right" title="Fair value">71,550,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>2027 Notes</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_zpCl1TtbQUrb" style="text-align: right" title="Carrying value">37,413,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_z0W1e8PC9qF5" style="text-align: right" title="Fair value">40,363,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_z2ddrZLMltxj" style="text-align: right" title="Carrying value">31,738,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentySevenNotesMember_zfNdAPh2WZIg" style="text-align: right" title="Fair value">35,112,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Oaktree Loan</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_z8OYFyUgCQ33" style="text-align: right" title="Carrying value">72,541,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zEPn003vazZ" style="text-align: right" title="Fair value">76,627,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_zNk4cbx2Sm41" style="text-align: right" title="Carrying value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--DebtInstrumentAxis__custom--OaktreeLoanMember_z0KXc7NYyYBk" style="text-align: right" title="Fair value">-</td><td style="text-align: left"> </td></tr> </table>

73218000

70260000

72436000

71550000

37413000

40363000

31738000

35112000

72541000

76627000

Stock-Based Compensation All stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units (“RSUs”), performance stock units (“PSUs) and restricted stock, are recognized in the consolidated financial statements based upon their estimated fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo simulation model to estimate the fair value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates.

Basic and Diluted Net Loss per Common Share Basic net loss per common share is computed by dividing net loss attributable to Harrow, Inc. for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is computed by dividing the net loss attributable to Harrow, Inc. for the year by the weighted average number of common and common equivalent shares, such as stock options, RSUs, PSUs, and warrants, outstanding during the year. Common stock equivalents (using the treasury stock or “if converted” method) from stock options, unvested RSUs, and unvested PSUs were <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndUnvestedPSUsMember_zS9Xm9FWyAlf" title="Stock options, unvested RSUs, and unvested PSUs">4,642,259 and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndUnvestedPSUsMember_zCguypgV4qRd" title="Stock options, unvested RSUs, and unvested PSUs">5,089,420 at December 31, 2023 and 2022, respectively, and are excluded in the calculation of diluted net loss per share for the periods presented, because the effect is anti-dilutive for that time period. Included in the basic and diluted net loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at December 31, 2023 and 2022 was <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfOfKX7WX4w" title="Vested RSU">215,539 and <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCCn8GMUpZj6" title="Vested RSU">319,859, respectively. The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2023 and 2022: SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_496_20230101__20231231_zR9s4uQJE1N1" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_494_20220101__20221231_zEBYxXJyMHa6" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zneioYozyPQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify; padding-bottom: 2.5pt">Numerator – net loss attributable to Harrow, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(24,411,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(14,086,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Denominator – weighted average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,616,777</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,460,968</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.75</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

4642259

5089420

215539

319859

The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2023 and 2022: SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_496_20230101__20231231_zR9s4uQJE1N1" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_494_20220101__20221231_zEBYxXJyMHa6" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zneioYozyPQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify; padding-bottom: 2.5pt">Numerator – net loss attributable to Harrow, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(24,411,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(14,086,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Denominator – weighted average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,616,777</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,460,968</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.75</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

-24411000

-14086000

32616777

27460968

-0.75

-0.51

Recently Adopted Accounting Pronouncements In September 2016, FASB issued Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments. This ASU replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information for credit loss estimates on certain types of financial instruments, including trade receivables. In addition, new disclosures are required. The ASU, as subsequently amended, is effective for the Company for the fiscal years beginning after December 15, 2022. The Company adopted ASU 2016-13 on January 1, 2023. Based on the composition of the Company’s accounts receivable, investment portfolio, and other financial assets, including current market conditions and historical credit loss activity, the adoption of this standard did not have a material impact on the Company’s consolidated financial statements or disclosures. Specifically, the Company’s estimate of expected credit losses as of January 1, 2023, using its expected credit loss evaluation process described above, resulted in no adjustments to the provision for credit losses and no cumulative-effect adjustment to accumulated deficit on the adoption date of the standard. Accounting Guidance Issued but Not Adopted at December 31, 2023 In August 2023, FASB issued ASU 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement, which applies to the formation of entities that meet the definition of a joint venture (or a corporate joint venture) and requires joint ventures to initially measure all contributions received upon formation at fair value. The new guidance does not impact accounting by the venturers. The new guidance is applicable to joint venture entities with a formation date on or after January 1, 2025 on a prospective basis. Joint ventures formed prior to the effective date may elect to apply the new guidance retrospectively back to their original formation date. The Company will apply the guidance in ASU 2023-05 prospectively to any future arrangements meeting the definition of a joint venture. In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements—Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This ASU modifies the disclosure or presentation requirements of a variety of topics in the codification by aligning them with the SEC’s regulations. The amendments to the various topics should be applied prospectively, and the effective date for the Company for each amendment will be determined based on the effective date of the SEC’s removal of the related disclosure from Regulation S-X or Regulation S-K. If the SEC has not removed the applicable requirement by June 30, 2027, then the related amendment in ASU 2023-06 will be removed from the codification and will not become effective. Early adoption of this ASU is prohibited. The Company does not expect the amendments in this ASU to have a material impact on the disclosures or presentation in its consolidated financial statements. In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures, which enhances the disclosures required for operating segments in the Company’s annual and interim consolidated financial statements. ASU 2023-07 is effective for the Company in our annual reporting for fiscal 2024 and for interim period reporting beginning in fiscal 2025 on a retrospective basis, with all required disclosures to be made for all prior periods presented in the consolidated financial statements. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-07 on its consolidated financial statements. In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures, which enhances the disclosures required for income taxes in the Company’s annual consolidated financial statements. Notably, this ASU requires entities to disclose specific categories in the effective tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for the Company in its annual reporting for fiscal 2025 on a prospective basis. Early adoption and retrospective reporting are permitted. The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements.

Reclassifications Certain prior period items and amounts have been reclassified to conform to the classifications used to prepare the consolidated financial statements for the current period. These reclassifications had no material impact on the Company’s consolidated financial position, results of operations, or cash flows as previously reported.

NOTE 3. REVENUES The Company accounts for contracts with customers in accordance with ASC 606, Revenues from Contracts with Customers. The Company has three primary streams of revenue (four in 2022): (1) product revenues, including revenue recognized from sales of products through its pharmacy and outsourcing facility and sales of branded products to wholesalers through a third-party logistics (“3PL”) partner, (2) revenue recognized from a commission agreement with a third party in 2022, (3) revenue recognized from transfer of acquired product sales and profits, and (4) revenue recognized from intellectual property licenses. Product Revenues The Company sells prescription medications directly through its pharmacy, outsourcing facility and 3PL partner. Revenue from the Company’s pharmacy services includes: (i) the portion of the price the client pays directly to the Company, net of any volume-related or other discounts paid back to the client, (ii) the price paid to the Company by individuals, and (iii) customer copayments made directly to the pharmacy network. Sales taxes are not included in revenue. Following the core principles of ASC 606, the Company has identified the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">1.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identify the contract(s) with a customer: A contract is deemed to exist when the customer places an order through receipt of a prescription, via an online order or via receipt of a purchase order from a customer. For branded products, orders are received through the Company’s 3PL partner, and the customer takes title of the products via formal purchase orders placed and fulfilled.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">2.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identify the performance obligations in the contract: Obligations for fulfillment of the Company’s contracts consist of delivering the product to customers at their specified destination. For shipping and handling activities under ASC 606, if the customer takes control of the goods after shipment, shipping and handling activities would always be considered a fulfillment activity and not treated as a separate performance obligation. If the customer takes control of the goods before shipment, entities must make an accounting policy election to treat shipping and handling activities as either a fulfillment cost or as a separate performance obligation. The Company has elected to treat its shipping and handling activities as a fulfillment cost.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">3.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determine the transaction price: The transaction price is based on an amount that reflects the consideration to which the Company expects to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts, copay assistance and other deductions (collectively, sales deductions) and an estimate for returns and replacements established at the time of sale. The Company utilizes the services of a third-party professional services firm to estimate rebates and chargebacks associated with sales of its branded products. The transfer of promised goods is satisfied within a year, and therefore there are no significant financing components. There is no non-cash consideration related to product sales.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">4.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocate the transaction price to the performance obligations in the contract: Because there is only one performance obligation for product sales, no allocation is necessary.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">5.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognize revenue when (or as) the entity satisfies a performance obligation: Revenue from products is recognized upon transfer of control of a product to a customer. This generally occurs upon shipment unless contractual terms with a customer state that transfer of control occurs at delivery.</td></tr> </table> Commission Revenues The Company has entered into an agreement whereby it is paid a fee calculated based on sales the Company generates from a pharmaceutical product that is owned by a third party. The revenue earned from this arrangement is recognized, at which point there is no future performance obligation required by the Company and no consequential continuing involvement on the Company’s part to recognize the associated revenue. Revenues From Transfer of Acquired Product Sales and Profits The Company has entered into agreements whereby it purchased the exclusive commercial rights to assets associated with certain ophthalmic products from other pharmaceutical companies (the “Sellers”). During a temporary, transition period, the Sellers continue to manufacture and market these products and transfer the net profit from the sale of the products to the Company. The revenue recognized by the Company from the transfer of net profit was recognized at the time profit from the product sales were calculated by the Sellers and confirmed by the Company, typically on a monthly basis, at which point there is no future performance obligation required by the Company and no consequential continuing involvement on the Company’s part to recognize the associated revenue. On a quarterly basis, the Sellers invoice the Company for all credits and reimbursements (“Chargebacks”) made to customers related to the products. The Company uses historical actual experience to estimate Chargebacks associated with the net sales and profit transferred. The estimated Chargebacks are recorded as a reduction in revenues from transfer of acquired product sales and profits in the Company’s consolidated statements of operations, and recorded as a reduction to accounts receivable in the consolidated balance sheets, at the time the revenue is recognized. Intellectual Property License Revenues The Company currently holds five intellectual property licenses and related agreements pursuant to which the Company has agreed to license or sell to a customer with the right to access the Company’s intellectual property. License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue of which is recognized at the point in time that the performance obligation is met. Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverables are delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term. Revenue disaggregated by revenue source for the years ended December 31, 2023 and 2022, consists of the following: SCHEDULE OF DISAGGREGATED REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20230101__20231231_zVQ8Jw1nkc9h" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20220101__20221231_zZMOKd3h79X8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_zbCo3H9kkuH9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; text-align: justify">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">117,447,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">83,524,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--CommissionsMember_zdpncWKYClAj" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify">Commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,866,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TransferOfAcquiredProductSalesProfitsMember_zPasxW7knku3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Transfer of acquired product sales/profits</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,746,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,205,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zIE12qtv4lp7" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">130,193,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">88,595,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Deferred revenue and customer deposits at December 31, 2023 and 2022, were $75,000 and $113,000, respectively. All deferred revenue and customer deposit amounts at December 31, 2022 were recognized as revenue during the year ended December 31, 2023.

Revenue disaggregated by revenue source for the years ended December 31, 2023 and 2022, consists of the following: SCHEDULE OF DISAGGREGATED REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20230101__20231231_zVQ8Jw1nkc9h" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20220101__20221231_zZMOKd3h79X8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_zbCo3H9kkuH9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; text-align: justify">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">117,447,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">83,524,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--CommissionsMember_zdpncWKYClAj" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify">Commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,866,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TransferOfAcquiredProductSalesProfitsMember_zPasxW7knku3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Transfer of acquired product sales/profits</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,746,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,205,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zIE12qtv4lp7" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">130,193,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">88,595,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

117447000

83524000

3866000

12746000

1205000

130193000

88595000

75000

113000

NOTE 4. RECENT PRODUCT ACQUISITIONS, LICENSES AND DIVESTITURES Acquisition of VEVYETM U.S. and Canadian Commercial Rights In July 2023, the Company acquired commercial rights of VEVYE (cyclosporine ophthalmic solution) 0.1%, an ophthalmic drug product, for the U.S. and Canadian markets (the “VEVYE Acquisition”). The Company acquired the commercial rights to VEVYE by entering into a license agreement with Novaliq GmbH (“Novaliq”). As consideration, the Company made initial payments to Novaliq totaling $8,000,000 and will pay low double-digit royalties on net sales of VEVYE along with potential commercial milestone payments. The Company accounted for the VEVYE Acquisition as an acquisition of assets and capitalized the initial payments of $<span id="xdx_903_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--VEVYEMember_zc9P0l820rga" title="Acquisition of assets and capitalized the initial payments">8,000,000 and costs of $<span id="xdx_90A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--VEVYEMember_zA6J1mhuc9k6" title="Costs associated transaction">70,000 associated with the transaction. Acquisition of Certain U.S. and Canadian Commercial Rights to Santen and Eyevance Products In July 2023, the Company entered into an Asset Purchase Agreement with Eyevance Pharmaceuticals, LLC and a License Agreement with Santen S.A.S. (collectively, the “Santen Agreements”), each a subsidiary of Santen Pharmaceuticals Co., Ltd. (collectively, “Santen”). Pursuant to the Santen Agreements, the Company acquired the exclusive commercial rights to assets associated with the following ophthalmic products (collectively, the “Santen Products”): FLAREX, NATACYN, ZERVIATE, VERKAZIA and FRESHKOTE in the U.S., and VERKAZIA and CATIONORM PLUS in Canada. The transactions pursuant to the Santen Agreements are referred to in these notes as the “Santen Products Acquisition.” Under the terms of the Santen Agreements, the Company made an initial one-time payment of $8,000,000. In addition, the Santen Agreements provide for various one-time contingent milestone payments associated with certain manufacturing-related events as well as low-double digit royalty payments on net sales of VERKAZIA and high-single digit royalty payments on net sales of CATIONORM PLUS. Under the Santen Agreements, the Company also assumed certain obligations associated with other third parties that require mid-single digit royalties on sales of FRESHKOTE and ZERVIATE. Immediately following the closing and subject to certain conditions, prior to the transfer of the Santen Products NDAs and other marketing authorizations to the Company, Santen continued to sell the Santen Products on the Company’s behalf and transfer the net profit from the sale of the Santen Products to the Company. In October 2023, we completed the transfer of the U.S. NDAs and rights of the Santen Products. The assets acquired in the Santen Products Acquisition are identifiable intangible asset groups in similar asset classes and all directly related to the product NDAs and marketing authorizations acquired. The developed technology is within one major intangible asset class. No workforce/employees were included in the Santen Products Acquisition and the Company is required to utilize its own business inputs/processes to transfer and commercialize the Santen Products. The Company incurred $<span id="xdx_90D_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--SantenProductsAcquisitionMember_zvZNk9YJqDPd" title="Costs incurred">139,000 in costs associated with the Santen Products Acquisition, and including such acquisition costs, the payment of $8,000,000 at closing and a near term milestone of $500,000. The total purchase price of the Santen Products Acquisition was $<span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1_c20230101__20231231__us-gaap--BusinessAcquisitionAxis__custom--SantenProductsAcquisitionMember_zbtqwyDZM25a" title="Purchase price acquisition">8,639,000 and was accounted for as an asset acquisition. At the time of the Santen Products Acquisition and as of December 31, 2023, the remaining contingent consideration due was not considered probable and reasonably estimable and therefore, no amount was included in the purchase price of the Santen Products Acquisition. At the time the contingent consideration due becomes probable and reasonably estimable the additional consideration, if any, paid will be allocated to all of the assets on a pro rata basis based on their initial estimated fair values as a percent of the total purchase price. Acquisition of ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE In December 2022, the Company entered into an Asset Purchase Agreement (the “NVS 5 APA”) with Novartis Technology, LLC and Novartis Innovative Therapies AG (together, “Novartis”), pursuant to which the Company agreed to purchase from Novartis the exclusive commercial rights to assets associated with the following ophthalmic products (collectively the “NVS 5 Products”) in the U.S. (the “NVS 5 Acquisition”): ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE. Under the terms of the NVS 5 APA, the Company made a one-time payment of $130,000,000 at closing in January 2023, with up to another $45,000,000 due in a milestone payment related to the timing of the commercial availability of TRIESENCE. The milestone payment due upon commercial availability for TRIESENCE decreased from $45,000,000 to $<span id="xdx_90C_ecustom--MilestonePayment_c20240101__20240120__srt--StatementScenarioAxis__custom--OneTimePaymentMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNYlBEmKwIxk" title="Milestone payment">37,000,000 on January 20, 2024. Pursuant to the NVS 5 APA and various ancillary agreements, immediately following the closing and subject to certain conditions and prior to the transfer of the NVS 5 Products NDAs to the Company, Novartis continued to sell the NVS 5 Products on the Company’s behalf and transfer the net profit from the sale of the NVS 5 Products to the Company. Novartis has agreed to supply certain NVS 5 Products to the Company for a period of time after the NDAs are transferred and to assist with technology transfer of the NVS 5 Products manufacturing to other third-party manufacturers, if needed. The assets acquired in the NVS 5 Acquisition are identifiable intangible asset groups in similar asset classes and all directly related to the five product NDAs acquired. The developed technology is within one major intangible asset class. No workforce/employees were included in the NVS 5 Acquisition and the Company is required to utilize its own business inputs/processes to transfer and commercialize the NVS 5 Products and NDAs. The Company incurred $558,000 in costs associated with the NVS 5 Acquisition and including such acquisition costs and the payment of $130,000,000 at closing. The total purchase price of the NVS 5 Acquisition was $130,558,000 and was accounted for as an asset acquisition. At the time of the NVS 5 Acquisition and as of December 31, 2023, the contingent consideration due related to the commercial availability of TRIESENCE was not considered probable and reasonably estimable and, therefore, no amount was included in the purchase price of the NVS 5 Acquisition. At the time the contingent consideration due related to the commercial availability of TRIESENCE becomes probable and reasonably estimable the additional consideration, if any, paid will be allocated to all of the assets on a pro rata basis based on their initial estimated fair values as a percent of the total purchase price. The Company does not consider any amounts related to TRIESENCE to be in-process research and development (IPR&D) as considered within the scope of ASC 730, Research and Development. Divestiture of Non-Ophthalmic Assets In October 2022, wholly-owned subsidiaries of the Company (collectively, “Imprimis”) entered into an Asset Purchase Agreement (the “RPC Agreement”) with Innovation Compounding Pharmacy, LLC (the “Buyer”). Under the terms of the RPC Agreement, Imprimis agreed to sell substantially all of its assets associated with its non-ophthalmology related compounding product line, including but not limited to, certain intellectual property rights, customer lists, databases, and formulations (the “RPC Assets”). The Buyer agreed to make offers of employment to nine of the Company’s employees that were responsible for the sales activities associated with the RPC Assets. Under the terms of the RPC Agreement, the Buyer paid Imprimis an aggregate cash amount of $6,000,000 in October 2022. In addition, the Buyer is obligated to pay up to $<span id="xdx_909_ecustom--MilestonesReceivableBasedOnAgreedRevenues_iI_pp0p0_c20221030__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zMAIUc4ugFG7" title="Milestones receivable based on agreed revenues">4,500,000 to Imprimis based on mutually agreed upon revenue milestones during the calendar year 2023 (the “Contingent Amount”). During the year ended December 31, 2022, no amount related to the Contingent Amount was recognized by the Company. The Company will recognize a gain related to the Contingent Amount if/when the contingency (in this case, revenue thresholds for 2023) become likely and reasonably estimable. The Company is currently engaged in discussions with RPC related to the contingent payment amount, if any. In connection with the RPC Agreement, Imprimis entered into a separate transition services agreement (the “RPC TSA”) with the Buyer related to providing ongoing services associated with the RPC Assets, such as procuring and dispensing prescription orders, providing accounting and billing services and collecting accounts receivable. Imprimis provided transition services to the Buyer for approximately nine months following the effective date of the RPC Agreement and expects to wind down transition services in subsequent periods. The Company collected and will continue to collect cash on behalf of the Buyer for revenue generated by sales of RPC Assets from October 2022 through the transition period and the Company is obligated to transfer cash generated by such sales to the Buyer. The Company’s consolidated balance sheet as of December 31, 2023 includes accounts receivable of $49,000 for cash to be collected on behalf of the Buyer for sales of RPC Assets through December 31, 2023. There were no amounts due from the Buyer for reimbursement of services performed under the RPC TSA as of December 31, 2023. The receivable amount of $49,000 along with $<span id="xdx_909_eus-gaap--ProceedsFromAccountsReceivableSecuritization_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--RPCAgreementMember_zui47wM0YG68" title="Payments received from accounts receivable">8,000 of payments received from accounts receivable but not yet paid were recorded within accounts payable and accrued expenses on the consolidated balance sheet as of December 31, 2023, and represents a payable to the Buyer of $57,000. The Company recorded a loss from the RPC TSA and disposition and sale of certain related assets and unusable inventory of $330,000 during the year ended December 31, 2023, which is presented in other expense, net on the consolidated statements of operations. <p id="xdx_89F_eus-gaap--ScheduleOfGainLossOnSecuritizationsOfFinancialAssetsAccountedForAsSaleTextBlock_zTZxO1eGvSUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company determined that the disposal of the related net assets does not qualify for reporting as discontinued operations because it does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results. During the year ended December 31, 2022, the Company recognized a net gain on the sale of the non-ophthalmology related compounding assets as follows: SCHEDULE OF NET GAIN ON SALE OF ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20220101__20221231_zmYd2FFn47n9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PaymentsToAcquireBusinessesGross_zMyyXa0ftp3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Gross consideration</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">6,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ClosingAndTransactionCosts_z84aEvvd6zr3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Closing and transaction costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationConsiderationTransferred1_z0rW04KSqiBg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net proceeds</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,945,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Book value of assets transferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--GainLossOnDispositionOfIntangibleAssets_zzvES4canZvd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Customer relations intangible asset</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">686,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GainsLossesOnSalesOfAssets_z01YgCBrShn" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Gain on sale of non-ophthalmology assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,259,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> License and Supply Agreement for IHEEZO In July 2021, the Company entered into a License and Supply Agreement (the “Sintetica Agreement”) with Sintetica S.A. (“Sintetica”), pursuant to which Sintetica granted the Company the exclusive license and marketing rights to its patented ophthalmic drug candidate (“IHEEZO”) in the U.S. and Canada. Pursuant to the Sintetica Agreement, the Company agreed to pay Sintetica a per unit transfer price to supply IHEEZO, along with a per unit royalty for units sold. The Company is required to pay Sintetica up to $<span id="xdx_906_ecustom--MilestonePayment_c20210601__20210630__srt--StatementScenarioAxis__custom--OneTimePaymentMember__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember__srt--RangeAxis__srt--MaximumMember_zDVbB2nHfUZi" title="Milestone payment">18,000,000 in one-time milestone payments including a $<span id="xdx_906_ecustom--MilestonePayment_c20210601__20210630__srt--StatementScenarioAxis__custom--UpfrontPaymentMember__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember_zsegfIzbGOZ2" title="Milestone payment">5,000,000 payment (the “Upfront Payment”) due within 30 days of signing the Sintetica Agreement and the balance of payments due upon achievement of certain regulatory and commercial milestones. Under the terms of the Sintetica Agreement, Sintetica is responsible for regulatory filings for IHEEZO in the U.S. The Upfront Payment along with an additional milestone payment of $<span id="xdx_90B_eus-gaap--PaymentsForRoyalties_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuxKOyn0tlM7" title="Royalty payments">3,117,000 was paid and recorded as R&D expenses during the year ended December 31, 2021. During the year ended December 31, 2022, $<span id="xdx_909_ecustom--PurchaseOfIntangibleAssetIncludedInAccountsPayableAndAccruedExpenses_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember_zFhFWy7tfID5" title="Accrued expense">10,000,000 was paid or accrued under the Sintetica Agreement following the FDA approval of the United States NDA for IHEEZO, and was capitalized as an intangible asset. In August 2023, the Company amended the Sintetica Agreement to allow for early payment of commercial related milestones associated with sales of IHEEZO in exchange for a $550,000 reduction in all of the remaining milestone amounts due. The Company then paid Sintetica $4,450,000. As of December 31, 2023, no milestone amounts are due under the Sintetica Agreement. Subject to certain limitations, the Sintetica Agreement has a ten-year term, and allows for a ten-year extension if certain sales thresholds are met.

0.001

8000000

70000

8000000

139000

8000000 500000

8639000

130000000 45000000 45000000 37000000

558000

130000000

130558000

6000000

4500000

49000

8000

57000

330000

<p id="xdx_89F_eus-gaap--ScheduleOfGainLossOnSecuritizationsOfFinancialAssetsAccountedForAsSaleTextBlock_zTZxO1eGvSUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company determined that the disposal of the related net assets does not qualify for reporting as discontinued operations because it does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results. During the year ended December 31, 2022, the Company recognized a net gain on the sale of the non-ophthalmology related compounding assets as follows: SCHEDULE OF NET GAIN ON SALE OF ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20220101__20221231_zmYd2FFn47n9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PaymentsToAcquireBusinessesGross_zMyyXa0ftp3e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Gross consideration</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">6,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ClosingAndTransactionCosts_z84aEvvd6zr3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Closing and transaction costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationConsiderationTransferred1_z0rW04KSqiBg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net proceeds</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,945,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Book value of assets transferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--GainLossOnDispositionOfIntangibleAssets_zzvES4canZvd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Customer relations intangible asset</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">686,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GainsLossesOnSalesOfAssets_z01YgCBrShn" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Gain on sale of non-ophthalmology assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,259,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6000000

55000

5945000

686000

5259000

18000000 5000000

3117000

10000000 550000 4450000 0

<p id="xdx_804_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zmZ7J10nfXpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">NOTE 5. INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS – RELATED PARTY TRANSACTIONS In December 2018, the Company entered into an asset purchase agreement with Melt (the “Melt APA”). Pursuant to the terms of the Melt APA, Melt was assigned certain intellectual property and related rights from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively, the “Melt Products”). Under the terms of the Melt APA, Melt is required to make mid-single digit royalty payments to the Company on net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions. In February 2019, the Company entered into the Melt MSA, whereby the Company provided to Melt certain administrative services and support, including bookkeeping, web services and human resources related activities, and Melt was required to pay the Company a monthly amount of $<span id="xdx_901_eus-gaap--AdministrativeFeesExpense_c20190201__20190228__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zR30uhKNT7B7" title="Administrative fees expense">10,000. The Melt MSA was terminated effective July 1, 2023. During the year ended December 31, 2023, and 2022, the Company recorded $89,000 and $91,000, respectively, due from Melt for reimbursable expenses and amounts payable pursuant to the Melt MSA, which are included in prepaid expenses and other current assets in the accompanying consolidated balance sheets. As of December 31, 2023 and 2022, the Company was due $228,000 and $139,000, respectively, from Melt for reimbursable expenses and amounts due under the Melt MSA. Melt did not make any payments to the Company during the year ended December 31, 2022. The Company made a cash advance to Melt of $<span id="xdx_903_eus-gaap--ProceedsFromRelatedPartyDebt_c20230101__20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zDYXG4Rs1YPk" title="Cash advance to related party debt">500,000 and Melt repaid the $<span id="xdx_904_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230101__20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zzeCMR5xTmu2" title="Repaid of related parties">500,000 cash advance during the year ended December 31, 2023. During the year ended December 31, 2023, Melt sold <span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodShares_c20230101__20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwRyPoR2mKv9" title="Sold shares">2,421,904 shares of its Series B Preferred Stock and raised over $<span id="xdx_904_eus-gaap--ProceedsFromRelatedPartyDebt_c20230101__20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9dKYh3Aeexi" title="Gross proceeds from third party investors">20,586,000 in gross proceeds from third party investors. The Company’s Chief Executive Officer, Mark L. Baum, was previously a member of the Melt board of directors until his resignation during the year ended December 31, 2021. Mr. Baum re-joined the Melt board of directors in January 2023. At the time Mr. Baum re-joined, the Melt board of directors consisted of five members, including Mr. Baum, who is the only representative of the Company on Melt’s board of directors. Melt Note Receivable – Settled and Terminated in 2023 On September 1, 2021, the Company entered into a loan and security agreement in the principal amount of $13,500,000 (the “Melt Loan Agreement”), as lender, with Melt, as borrower. Amounts borrowed under the Melt Loan Agreement bore interest at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210901__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zGlywb8YimHk" title="Debt instrument interest rate stated percentage">12.50% per annum, which interest could have been paid in-kind at the option of Melt until the maturity date. The Melt Loan Agreement permitted Melt to pay interest only on the principal amount loaned thereunder through the term and all amounts owed were previously due and payable on September 1, 2022. In April 2022, the Company entered into a First Amendment and in September 2022, a Second Amendment (together, the “Amendments”) to the Melt Loan Agreement. The Amendments (i) extended the maturity date of the Melt Loan Agreement to September 1, 2023, which could have been extended further to September 1, 2026 upon Melt completing a qualifying financing of a minimum amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20220430__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_zAGf3lUoghX9" title="Loan amount">10,000,000 from third-party investors, (ii) added conditions related to minimum cash amounts following a qualifying financing, and (iii) clarified the definition of material adverse effects. Melt could have elected to prepay all, but not less than all, of the amounts owed prior to the maturity date at any time without penalty. The net funds received by Melt excluded $908,000 owed to the Company for reimbursable expenses and amounts due under the Melt MSA prior to the effective date of the note receivable. In connection with the Melt Loan Agreement, the Company and Melt entered into a Right of First Refusal Agreement providing the Company with the right, but not the obligation, to match any offer received by Melt associated with the commercial rights to any of Melt’s drug candidates for a period of five years following the effective date of the Melt Loan Agreement. On December 28, 2023, the Company terminated the Melt Loan Agreement. As of the date of termination, approximately $18,395,000 remained outstanding under the Melt Loan Agreement. Pursuant to the terms of a Settlement and Payoff Agreement, dated as of December 28, 2023, by and between the Company and Melt (the “Settlement Agreement”), the Company received <span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_c20231228__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBOnePreferredStockMember_zpHuJtmOGi7l" title="Received shares">2,260,000 shares of Melt’s Series B-1 Preferred Stock and <span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20231228__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyWQ2Z2wuNCl" title="Received shares">74,256 shares of Melt’s Series B Preferred Stock (which both series have similar rights and preferences) in consideration for the full payment of all amounts outstanding under the Melt Loan Agreement. The Settlement Agreement contains customary representations, warranties and releases of the parties and requires the parties to enter into a registration rights agreement providing the Company with rights consistent with other holders of preferred stock of Melt. The Company concluded the Settlement Agreement is in substance a funding of the Company’s share of prior unrecorded losses and, therefore, those suspended losses must be recognized first against the value of the new preferred stock investments. This resulted in reducing the carrying value of the Company’s investment in Melt, including the carrying value of the Preferred Stock received, to zero (the consideration received in the form of an equivalent fair value of Melt’s Preferred Stock to settle the full outstanding note receivable balance of $18,400,000 is essentially offset by an equal amount of the funding of prior unrecorded losses). Accordingly, this settlement transaction had no quantitative effect on either the Company’s consolidated balance sheet or consolidated statement of operations for the year ended December 31, 2023. In accordance with ASC 323, Investments – Equity Method and Joint Ventures, the carrying amount of the note receivable and other investments in Melt have been reduced by the Company’s allocated share of Melt’s losses based on its ownership of Melt and its total indebtedness (see Note 2). The unaudited condensed results of operations information of Melt is summarized below: SCHEDULE OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" id="xdx_30F_134_zj85AqAcaj17" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20230101__20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zC5YUt6M68Fh" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220101__20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSzS0H8WBqTc" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zNFeuZU2OiB2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_zoo2wa6S6Uyl" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Loss from operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,581,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(12,443,000</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_z0iTJcWkt1Db" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(11,271,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(14,446,000</td><td style="text-align: left">)</td></tr> </table> The unaudited condensed balance sheet information of Melt is summarized below: SCHEDULE OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" id="xdx_303_134_zAlrtHuOPrid" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zW6cUClaxoWk" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zL1MRaRbmg6d" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--AssetsCurrent_iI_zOHwHHn5Imze" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">13,404,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">655,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_zXexmSGqOE63" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">107,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Assets_iI_zMYCIFJ8XQC2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,404,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">762,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Liabilities_iI_zQoGizmqEnU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,922,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">19,056,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--StockholdersEquity_iI_z6Um1zpm8rm1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total preferred stock and stockholders’ equity (deficit)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,482,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,294,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zi4qieeeWYE9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,404,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">762,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

10000

89000

91000

228000

139000

500000

2421904

20586000

13500000

0.1250

10000000

908000

18395000

2260000

74256

18400000

The unaudited condensed results of operations information of Melt is summarized below: SCHEDULE OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" id="xdx_30F_134_zj85AqAcaj17" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20230101__20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zC5YUt6M68Fh" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220101__20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSzS0H8WBqTc" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zNFeuZU2OiB2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_zoo2wa6S6Uyl" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Loss from operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,581,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(12,443,000</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_z0iTJcWkt1Db" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(11,271,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(14,446,000</td><td style="text-align: left">)</td></tr> </table>

-7581000

-12443000

-11271000

-14446000

The unaudited condensed balance sheet information of Melt is summarized below: SCHEDULE OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" id="xdx_303_134_zAlrtHuOPrid" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20231231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zW6cUClaxoWk" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20221231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zL1MRaRbmg6d" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--AssetsCurrent_iI_zOHwHHn5Imze" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">13,404,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">655,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_zXexmSGqOE63" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Non-current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">107,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Assets_iI_zMYCIFJ8XQC2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,404,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">762,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Liabilities_iI_zQoGizmqEnU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,922,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">19,056,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--StockholdersEquity_iI_z6Um1zpm8rm1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total preferred stock and stockholders’ equity (deficit)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,482,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,294,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zi4qieeeWYE9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,404,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">762,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

13404000

655000

107000

13404000

762000

3922000

19056000

9482000

-18294000

13404000

762000

NOTE 6. INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS The Company entered into an asset purchase and license agreement with Surface in 2017 and amended it in April 2018 (the “Surface License Agreements”). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual property and related rights associated with Surface’s drug candidates (collectively, the “Surface Products”). Surface is required to make mid-single digit royalty payments to the Company on net sales of the Surface Products while any patent rights remain outstanding. As of December 31, 2023, the Company owned 3,500,000 shares of Surface common stock. Adrienne Graves and Perry J. Sternberg, directors of the Company, also are directors of Surface. Mark L. Baum, who is the Company’s Chief Executive Officer, was previously a member of the Surface board of directors and resigned from his position as a director of Surface on March 31, 2023. During the year ended December 31, 2021, the Company reduced its common stock investment in Surface to $<span id="xdx_90B_ecustom--ReductionInCommonStockInvestment_c20210101__20211231__us-gaap--RelatedPartyTransactionAxis__custom--SurfaceOphthalmicsIncMember_z8tpvWX1TA5a" title="Reduction in common stock investment">0 as a result of the Company recording its share of equity losses of Surface. The Company has no requirements to advance funds to Surface and no obligations to fund its future operating losses, if any. Therefore, the Company’s future financial results will not be negatively affected by Surface’s ongoing operations.

3500000

NOTE 7. INVENTORIES Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, branded pharmaceutical products, including those held at the Company’s 3PL partner, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31, 2023 and 2022 was as follows: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20231231_zOOxhlFUdPFf" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20221231_zsSSJaqa3nL2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_maCzfns_z7XjF0pHSSmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,477,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,707,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryWorkInProcess_iI_maCzfns_zaYzvEDzZttj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_maCzfns_z57TGoOZSLr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,336,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,796,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryNet_iTI_mtCzfns_zM24acuiCaSk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,867,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,541,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, branded pharmaceutical products, including those held at the Company’s 3PL partner, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31, 2023 and 2022 was as follows: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20231231_zOOxhlFUdPFf" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20221231_zsSSJaqa3nL2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_maCzfns_z7XjF0pHSSmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,477,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,707,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryWorkInProcess_iI_maCzfns_zaYzvEDzZttj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InventoryFinishedGoods_iI_maCzfns_z57TGoOZSLr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,336,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,796,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryNet_iTI_mtCzfns_zM24acuiCaSk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,867,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,541,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5477000

3707000

54000

38000

5336000

2796000

10867000

6541000

NOTE 8. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets at December 31, 2023 and 2022 consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20231231_zzpgsWBZ2iF8" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20221231_zwO4wquN0Hl4" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maCz7yK_zdgwHSf8e762" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,241,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">858,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidRoyalties_iI_maCz7yK_zBaGMOKEvShh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Prepaid computer software related expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,613,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,165,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherPrepaidExpenseCurrent_iI_maCz7yK_ziPlV6eflI47" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">906,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">937,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--ReceivableDueFromRelatedParty_iI_maCz7yK_zRWlE24GmXd7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Receivable due from Melt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PrepaidInterest_iI_maCz7yK_zB8BPTSvdWO1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Prepaid PDUFA fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,438,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">394,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredCommitmentFee_iI_maCz7yK_ztGptYLMc4x" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Deferred Oaktree commitment fee (see Note 13)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">409,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_maCz7yK_zYp2oRmd9QEf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Deposits and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,753,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCz7yK_zghcIPI9rgk6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,588,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,611,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Prepaid expenses and other current assets at December 31, 2023 and 2022 consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20231231_zzpgsWBZ2iF8" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20221231_zwO4wquN0Hl4" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maCz7yK_zdgwHSf8e762" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,241,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">858,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidRoyalties_iI_maCz7yK_zBaGMOKEvShh" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Prepaid computer software related expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,613,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,165,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherPrepaidExpenseCurrent_iI_maCz7yK_ziPlV6eflI47" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">906,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">937,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--ReceivableDueFromRelatedParty_iI_maCz7yK_zRWlE24GmXd7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Receivable due from Melt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PrepaidInterest_iI_maCz7yK_zB8BPTSvdWO1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Prepaid PDUFA fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,438,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">394,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredCommitmentFee_iI_maCz7yK_ztGptYLMc4x" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Deferred Oaktree commitment fee (see Note 13)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">409,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_maCz7yK_zYp2oRmd9QEf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Deposits and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,753,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">118,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCz7yK_zghcIPI9rgk6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,588,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,611,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1241000

858000

1613000

1165000

906000

937000

228000 139000

3438000

394000

409000

1753000

118000

9588000

3611000

NOTE 9. PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment, net at December 31, 2023 and 2022 consisted of the following: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20231231_zeDrP0Gx7LHa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zTC66XdiHOe3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Property, plant and equipment, net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ComputerHardwareGross_iI_maCzxAW_maPPAEGz2wu_zIHgzrxp42Z1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify">Computer hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,322,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">979,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FurnitureAndFixturesGross_iI_maCzxAW_maPPAEGz2wu_zlJytjhOeGul" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">936,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">860,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--MachineryAndEquipmentGross_iI_maCzxAW_maPPAEGz2wu_zvxg1NBQP7Rl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Lab and pharmacy equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,564,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,259,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseholdImprovementsGross_iI_maCzxAW_maPPAEGz2wu_zTsNXJK25Vsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,771,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,449,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGz2wu_maPPAENz062_zj5NW6JT23e7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Property, plant and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,593,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,547,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msCzNSh_msPPAENz062_ztsttfIk9MV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,072,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,061,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz062_zKmzGmfpAVZe" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,521,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,486,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the years ended December 31, 2023 and 2022, the Company disposed of property, plant and equipment with a net book value of $168,000 and $69,000, respectively, related to the discontinued use of certain lab equipment, which is included in other expense, net in the consolidated statements of operations. The Company recorded depreciation and amortization expense of $1,055,000 and $1,253,000 during the years ended December 31, 2023 and 2022, respectively.

Property, plant and equipment, net at December 31, 2023 and 2022 consisted of the following: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20231231_zeDrP0Gx7LHa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_zTC66XdiHOe3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Property, plant and equipment, net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ComputerHardwareGross_iI_maCzxAW_maPPAEGz2wu_zIHgzrxp42Z1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify">Computer hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,322,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">979,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FurnitureAndFixturesGross_iI_maCzxAW_maPPAEGz2wu_zlJytjhOeGul" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">936,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">860,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--MachineryAndEquipmentGross_iI_maCzxAW_maPPAEGz2wu_zvxg1NBQP7Rl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Lab and pharmacy equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,564,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,259,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseholdImprovementsGross_iI_maCzxAW_maPPAEGz2wu_zTsNXJK25Vsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,771,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,449,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGz2wu_maPPAENz062_zj5NW6JT23e7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Property, plant and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,593,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,547,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msCzNSh_msPPAENz062_ztsttfIk9MV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,072,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,061,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz062_zKmzGmfpAVZe" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,521,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,486,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1322000 979000

936000

860000

4564000

4259000

6771000

6449000

13593000

12547000

10072000

9061000

3521000

3486000

168000

69000

1055000

1253000

NOTE 10. CAPITALIZED SOFTWARE COSTS Capitalized software costs at December 31, 2023 and 2022 consisted of the following: SCHEDULE OF CAPITALIZED SOFTWARE COSTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20231231_zvoEN7Sk8QDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zySnQaaAwnC4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Capitalized software costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedInternalUseSoftwareMember_zJpxQ6swGqW9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Capitalized internal-use software development costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,780,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,413,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThirdPartySoftwareLicenseMember_ztbAOUBe6tth" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Acquired third-party software license for internal-use</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNzLFa_zPyYO2kLSkw4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total gross capitalized software for internal-use</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,939,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,572,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNzLFa_z1u8eu1dUCob" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,268,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(793,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--CapitalizedComputerSoftwareInternalUseInProcess_iI_maCCSNzLFa_zVbACBMqgGXh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Capitalized internal-use software in process</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">467,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,333,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CapitalizedComputerSoftwareNet_iI_mtCCSNzLFa_zUbakLxz85Z1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total capitalized software costs net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,138,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,112,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company recorded amortization expense of $<span id="xdx_904_eus-gaap--AdjustmentForAmortization_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zZI48QE6Rv69" title="Amortization expenses">475,000 and $<span id="xdx_900_eus-gaap--AdjustmentForAmortization_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zRKS8o2Xe1Ua" title="Amortization expenses">224,000 during the years ended December 31, 2023 and 2022, respectively. Capitalized software costs at December 31, 2023 and 2022 consisted of the following: SCHEDULE OF CAPITALIZED SOFTWARE COSTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20231231_zvoEN7Sk8QDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zySnQaaAwnC4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Capitalized software costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedInternalUseSoftwareMember_zJpxQ6swGqW9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Capitalized internal-use software development costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,780,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,413,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThirdPartySoftwareLicenseMember_ztbAOUBe6tth" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Acquired third-party software license for internal-use</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNzLFa_zPyYO2kLSkw4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total gross capitalized software for internal-use</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,939,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,572,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNzLFa_z1u8eu1dUCob" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,268,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(793,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--CapitalizedComputerSoftwareInternalUseInProcess_iI_maCCSNzLFa_zVbACBMqgGXh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Capitalized internal-use software in process</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">467,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,333,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CapitalizedComputerSoftwareNet_iI_mtCCSNzLFa_zUbakLxz85Z1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total capitalized software costs net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,138,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,112,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2780000

1413000

159000

2939000

1572000

1268000

793000

467000 1333000

2138000

2112000

475000

224000

NOTE 11. INTANGIBLE ASSETS AND GOODWILL The Company’s intangible assets at December 31, 2023 consisted of the following: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">Amortization</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">periods</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">amortization</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: justify">Patents</td><td style="width: 2%"> </td> <td style="width: 10%; text-align: justify"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdA3l4i2VOH9" title="Useful life">7-<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuHByy1sNBj" title="Useful life">19 years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zmC038cvWoo7" style="width: 10%; text-align: right" title="Cost">984,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgGfB1ihLmS4" style="width: 10%; text-align: right" title="Accumulated amortization">(253,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zmts6G6evHl1" style="width: 10%; text-align: right" title="Impairment">(276,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zOfb1NRrg7z" style="width: 10%; text-align: right" title="Net Carrying value">455,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Licenses</td><td> </td> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember__srt--RangeAxis__srt--MinimumMember_zOJc5p5qwAtd" title="Useful life">7 - <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember__srt--RangeAxis__srt--MaximumMember_znHmwd0YXHJh" title="Useful life">20 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zhBFUK2ReqGh" style="text-align: right" title="Cost">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zNJA7BLetvMf" style="text-align: right" title="Accumulated amortization">(30,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zBcCGPi6pifi" style="text-align: right" title="Impairment">(22,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zHF8KptSKMwh" style="text-align: right" title="Net Carrying value">48,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Trademarks</td><td> </td> <td style="text-align: justify"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zYwS61NMAPIa" title="Useful life, description">Indefinite</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVciNIKRzC5f" style="text-align: right" title="Cost">281,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zv9pJId1iha3" style="text-align: right" title="Accumulated amortization">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_ztw7bVY51TUd" style="text-align: right" title="Impairment">(82,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zk24esNvz4Kd" style="text-align: right" title="Net Carrying value">199,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Acquired NDAs</td><td> </td> <td style="text-align: justify"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember__srt--RangeAxis__srt--MinimumMember_zB9oAleJ2L2d" title="Useful life">4 - <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember__srt--RangeAxis__srt--MaximumMember_zL5hDLbB2wRg" title="Useful life">15 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zjIAysmHfBb5" style="text-align: right" title="Cost">170,353,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zlgdUCR79BQk" style="text-align: right" title="Accumulated amortization">(11,300,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zSyK3Vvc0YU6" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zPsYb0BQsEU2" style="text-align: right" title="Net Carrying value">159,053,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer relationships</td><td> </td> <td style="text-align: justify"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zs69p9R0EH89">3-<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zCc8t3CNENn6" title="Useful life">15 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zIX4gA0ZvS41" style="text-align: right" title="Cost">596,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMQahnVCbNfg" style="text-align: right" title="Accumulated amortization">(516,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z4XoJJlwQKh" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z33PMLldv3D1" style="text-align: right" title="Net Carrying value">80,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trade name</td><td> </td> <td style="text-align: justify">5 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zpmYcXE3Yus7" style="text-align: right" title="Accumulated amortization">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zv5pMzpKT3q9" style="text-align: right" title="Accumulated amortization">(5,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zfMWoxJIUn22" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z1003l0ZQPm9" style="text-align: right" title="Net Carrying value">70,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Non-competition clause</td><td> </td> <td style="text-align: justify"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zeSB2q2F43d8" title="Useful life">3-<span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zXUydm8i5Vwj" title="Useful life">4 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zsBQHrhB0tY2" style="text-align: right" title="Cost">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zAkDn9fI7Feb" style="text-align: right" title="Accumulated amortization">(50,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zPsCLdA1wL1a" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zGKoufIH6gKg" style="text-align: right" title="Net Carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: justify; padding-bottom: 1.5pt">25 years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zdx5epW9XnL5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zdcNw5aazWUc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zYoK6uQApn39" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zy0d9ifYxWy6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value">1,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zYKXyj8zCInj" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">172,447,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231_z6KdkbejvyL6" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(12,161,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231_zDPt8MkgW4Ie" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">(380,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231_zH6S5qVDNCS6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value">159,906,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the year ended December 31, 2023, the Company recorded a charge of $380,000 related to the impairment of certain licenses, trademarks, patents and patent applications. The Company determined that the sum of the expected undiscounted cash flows attributable to these intangible assets was less than their carrying value and that an impairment charge was required. Accordingly, the Company calculated the estimated fair value of the intangible assets based on the present value of the expected cash flows over their estimated lives. The impairment amount was calculated by deducting the present value of the expected cash flows from the carrying value. Significant estimates and assumptions used by the Company included sales and expense growth rates, and discounted projected cash flows. The estimates and assumptions used in our assessment represent a Level 3 measurement because they are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. The assumptions used in the impairment analysis are inherently subject to uncertainty and, therefore, changes in these assumptions could have a significant impact on the concluded fair value. The Company’s intangible assets at December 31, 2022 consisted of the following: <div id="xdx_C09_gL3SOIAAGTTB-ZNBVC_z66lLhXIuqbf"> <table cellpadding="0" cellspacing="0" id="xdx_304_134_zQTqT47lbkkb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">Amortization</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">periods</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">amortization</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sold</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: justify">Patents</td><td style="width: 2%"> </td> <td style="width: 10%; text-align: justify"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zSTrrIzEzt25" title="Useful life">7-<span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8TACjSyiXkd" title="Useful life">19 years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zsfl1db18BN" style="width: 10%; text-align: right" title="Cost">980,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVeoRRWDHxU2" style="width: 10%; text-align: right" title="Accumulated amortization">(161,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zChy5sW8ID32" style="width: 10%; text-align: right" title="Impairment">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zrp1Gxws1VQ6" style="width: 10%; text-align: right" title="Net Carrying value">819,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Licenses</td><td> </td> <td style="text-align: justify">20 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zhZb0esFU9g3" style="text-align: right" title="Cost">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z0f5pxVbBdCa" style="text-align: right" title="Accumulated amortization">(23,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zooTWJNGhYG" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zAMPV2tvKgPa" style="text-align: right" title="Net Carrying value">77,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Trademarks</td><td> </td> <td style="text-align: justify"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z7TmhNB387zb" title="Useful life, description">Indefinite</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zsOHBVSzJFh" style="text-align: right" title="Cost">267,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zkjOUZBEq7qd" style="text-align: right" title="Accumulated amortization">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zTX3uCAZZfih" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zayMSjXiTMpj" style="text-align: right" title="Net Carrying value">267,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Acquired NDAs</td><td> </td> <td style="text-align: justify">10 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zmzFiXwhxlX6" style="text-align: right" title="Cost">23,720,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_z9EBlfiedPT4" style="text-align: right" title="Accumulated amortization">(1,363,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zuJhEIOcJYa6" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zmw7vxavvfH5" style="text-align: right" title="Net Carrying value">22,357,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer relationships</td><td> </td> <td style="text-align: justify"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zB6QLtIdIul" title="Useful life">3-<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zk8NzuZCvXdb" title="Useful life">15 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zc5mWAWTpeS4" style="text-align: right" title="Cost">1,519,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zmCVLGvQTmq9" style="text-align: right" title="Accumulated amortization">(759,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zIFqrAf1dNg1" style="text-align: right" title="Impairment">(626,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z52xDI7JQjl2" style="text-align: right" title="Net Carrying value">134,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trade name</td><td> </td> <td style="text-align: justify">5 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zf87BrTASjA" style="text-align: right" title="Cost">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zurGDTX9gafb" style="text-align: right" title="Accumulated amortization">(5,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zTy3WTJAj8dc" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z6qALienodA9" style="text-align: right" title="Net Carrying value">70,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Non-competition clause</td><td> </td> <td style="text-align: justify"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z3KmA933wdt2" title="Useful life">3-<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zuk83qP316V1" title="Useful life">4 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zLKbspf9vEfi" style="text-align: right" title="Cost">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zXsSrS11zYL5" style="text-align: right" title="Accumulated amortization">(50,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z74Ee1AuCV6" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zGqNGW3RAtwa" style="text-align: right" title="Net Carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: justify; padding-bottom: 1.5pt"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z9tc1tdZDpP7" title="Intangible assets, Useful life">25 years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zhxR94V4OIV6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zlpMo1fXy3oj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zSBi4yzqzNRa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zqNsXtgLVpa2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value">1,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_z4NPO0Y6FVtc" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Cost">26,719,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zQFFsIph8T7f" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Accumulated amortization">(2,368,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231_zkVHXwn7CTW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Impairment">(626,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231_z1pwq8kICCtc" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Net Carrying value">23,725,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div> During the year ended December 31, 2022, the Company recorded a net reduction to customer relationships intangible assets of $<span id="xdx_904_ecustom--FiniteLivedIntangibleAssetsImpairment_iNI_di_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z73JO0lnkKZi" title="Impairment charge">626,000 related to customer relationships that were associated with the non-ophthalmology assets sold by the Company. The amount was reflected net of the gross proceeds received related to the sale of the Company’s non-ophthalmology assets (see Note 4). See Note 4 related to other intangible assets acquired and divested during the years ended December 31, 2023 and 2022. Amortization expense for intangible assets for the years ended December 31, 2023 and 2022 were as follows: SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230101__20231231_zb9bKMuloT42" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20220101__20221231_zVfQUypr0Azd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z4Uy2VqCw8Rf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">84,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">86,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zCdrCDX9vqJ8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Licenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zSExdGeGU7dd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Acquired NDAs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,937,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,363,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zOMNqLxLSQl5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Customer relationships</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">113,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AmortizationOfIntangibleAssets_zVrHq09WYcDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Amortization of intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,082,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,578,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zTySCWH102j2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Estimated future amortization expense for the Company’s intangible assets at December 31, 2023 is as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231_zoeKXK3Rx4G3" style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left">Years ending December 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzNeK_zGfz2wAjU4vg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">2024</td><td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">13,658,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzNeK_zcE4KPeYHTr1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">13,658,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzNeK_zEujSaNzd56i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">13,658,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzNeK_zgJW7zpUCVg6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">13,309,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzNeK_zYkF3EWTEjY8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">12,961,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzNeK_ztnNiUfOZMef" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">92,463,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzNeK_zRkbtfwI4GM7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Intangible assets </td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">159,707,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> There were no changes in the carrying value of the Company’s goodwill during the years ended December 31, 2023 and 2022.

The Company’s intangible assets at December 31, 2023 consisted of the following: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">Amortization</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">periods</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">amortization</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: justify">Patents</td><td style="width: 2%"> </td> <td style="width: 10%; text-align: justify"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdA3l4i2VOH9" title="Useful life">7-<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuHByy1sNBj" title="Useful life">19 years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zmC038cvWoo7" style="width: 10%; text-align: right" title="Cost">984,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgGfB1ihLmS4" style="width: 10%; text-align: right" title="Accumulated amortization">(253,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zmts6G6evHl1" style="width: 10%; text-align: right" title="Impairment">(276,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zOfb1NRrg7z" style="width: 10%; text-align: right" title="Net Carrying value">455,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Licenses</td><td> </td> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember__srt--RangeAxis__srt--MinimumMember_zOJc5p5qwAtd" title="Useful life">7 - <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember__srt--RangeAxis__srt--MaximumMember_znHmwd0YXHJh" title="Useful life">20 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zhBFUK2ReqGh" style="text-align: right" title="Cost">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zNJA7BLetvMf" style="text-align: right" title="Accumulated amortization">(30,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zBcCGPi6pifi" style="text-align: right" title="Impairment">(22,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zHF8KptSKMwh" style="text-align: right" title="Net Carrying value">48,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Trademarks</td><td> </td> <td style="text-align: justify"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zYwS61NMAPIa" title="Useful life, description">Indefinite</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVciNIKRzC5f" style="text-align: right" title="Cost">281,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zv9pJId1iha3" style="text-align: right" title="Accumulated amortization">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_ztw7bVY51TUd" style="text-align: right" title="Impairment">(82,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zk24esNvz4Kd" style="text-align: right" title="Net Carrying value">199,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Acquired NDAs</td><td> </td> <td style="text-align: justify"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember__srt--RangeAxis__srt--MinimumMember_zB9oAleJ2L2d" title="Useful life">4 - <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember__srt--RangeAxis__srt--MaximumMember_zL5hDLbB2wRg" title="Useful life">15 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zjIAysmHfBb5" style="text-align: right" title="Cost">170,353,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zlgdUCR79BQk" style="text-align: right" title="Accumulated amortization">(11,300,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zSyK3Vvc0YU6" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zPsYb0BQsEU2" style="text-align: right" title="Net Carrying value">159,053,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer relationships</td><td> </td> <td style="text-align: justify"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zs69p9R0EH89">3-<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zCc8t3CNENn6" title="Useful life">15 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zIX4gA0ZvS41" style="text-align: right" title="Cost">596,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMQahnVCbNfg" style="text-align: right" title="Accumulated amortization">(516,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z4XoJJlwQKh" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z33PMLldv3D1" style="text-align: right" title="Net Carrying value">80,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trade name</td><td> </td> <td style="text-align: justify">5 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zpmYcXE3Yus7" style="text-align: right" title="Accumulated amortization">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zv5pMzpKT3q9" style="text-align: right" title="Accumulated amortization">(5,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zfMWoxJIUn22" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z1003l0ZQPm9" style="text-align: right" title="Net Carrying value">70,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Non-competition clause</td><td> </td> <td style="text-align: justify"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zeSB2q2F43d8" title="Useful life">3-<span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zXUydm8i5Vwj" title="Useful life">4 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zsBQHrhB0tY2" style="text-align: right" title="Cost">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zAkDn9fI7Feb" style="text-align: right" title="Accumulated amortization">(50,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zPsCLdA1wL1a" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zGKoufIH6gKg" style="text-align: right" title="Net Carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: justify; padding-bottom: 1.5pt">25 years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zdx5epW9XnL5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zdcNw5aazWUc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zYoK6uQApn39" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zy0d9ifYxWy6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value">1,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20231231_zYKXyj8zCInj" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">172,447,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20231231_z6KdkbejvyL6" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(12,161,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20231231_zDPt8MkgW4Ie" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">(380,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20231231_zH6S5qVDNCS6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value">159,906,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_304_134_zQTqT47lbkkb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">Amortization</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">periods</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Carrying</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">amortization</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sold</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: justify">Patents</td><td style="width: 2%"> </td> <td style="width: 10%; text-align: justify"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zSTrrIzEzt25" title="Useful life">7-<span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8TACjSyiXkd" title="Useful life">19 years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zsfl1db18BN" style="width: 10%; text-align: right" title="Cost">980,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVeoRRWDHxU2" style="width: 10%; text-align: right" title="Accumulated amortization">(161,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zChy5sW8ID32" style="width: 10%; text-align: right" title="Impairment">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zrp1Gxws1VQ6" style="width: 10%; text-align: right" title="Net Carrying value">819,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Licenses</td><td> </td> <td style="text-align: justify">20 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zhZb0esFU9g3" style="text-align: right" title="Cost">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z0f5pxVbBdCa" style="text-align: right" title="Accumulated amortization">(23,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zooTWJNGhYG" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zAMPV2tvKgPa" style="text-align: right" title="Net Carrying value">77,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Trademarks</td><td> </td> <td style="text-align: justify"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z7TmhNB387zb" title="Useful life, description">Indefinite</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zsOHBVSzJFh" style="text-align: right" title="Cost">267,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zkjOUZBEq7qd" style="text-align: right" title="Accumulated amortization">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zTX3uCAZZfih" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zayMSjXiTMpj" style="text-align: right" title="Net Carrying value">267,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Acquired NDAs</td><td> </td> <td style="text-align: justify">10 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zmzFiXwhxlX6" style="text-align: right" title="Cost">23,720,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_z9EBlfiedPT4" style="text-align: right" title="Accumulated amortization">(1,363,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zuJhEIOcJYa6" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zmw7vxavvfH5" style="text-align: right" title="Net Carrying value">22,357,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer relationships</td><td> </td> <td style="text-align: justify"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zB6QLtIdIul" title="Useful life">3-<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zk8NzuZCvXdb" title="Useful life">15 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zc5mWAWTpeS4" style="text-align: right" title="Cost">1,519,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zmCVLGvQTmq9" style="text-align: right" title="Accumulated amortization">(759,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zIFqrAf1dNg1" style="text-align: right" title="Impairment">(626,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z52xDI7JQjl2" style="text-align: right" title="Net Carrying value">134,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trade name</td><td> </td> <td style="text-align: justify">5 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zf87BrTASjA" style="text-align: right" title="Cost">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zurGDTX9gafb" style="text-align: right" title="Accumulated amortization">(5,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zTy3WTJAj8dc" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z6qALienodA9" style="text-align: right" title="Net Carrying value">70,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Non-competition clause</td><td> </td> <td style="text-align: justify"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z3KmA933wdt2" title="Useful life">3-<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zuk83qP316V1" title="Useful life">4 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zLKbspf9vEfi" style="text-align: right" title="Cost">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zXsSrS11zYL5" style="text-align: right" title="Accumulated amortization">(50,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z74Ee1AuCV6" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zGqNGW3RAtwa" style="text-align: right" title="Net Carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: justify; padding-bottom: 1.5pt"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z9tc1tdZDpP7" title="Intangible assets, Useful life">25 years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zhxR94V4OIV6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zlpMo1fXy3oj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zSBi4yzqzNRa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zqNsXtgLVpa2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value">1,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_z4NPO0Y6FVtc" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Cost">26,719,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zQFFsIph8T7f" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Accumulated amortization">(2,368,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_c20221231_zkVHXwn7CTW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Impairment">(626,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20221231_z1pwq8kICCtc" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, Net Carrying value">23,725,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

P7Y

P19Y

984000

-253000

-276000

455000

P7Y

P20Y

100000

-30000

-22000

48000

Indefinite

281000

-82000

199000

P4Y

P15Y

170353000

-11300000

159053000

P3Y

P15Y

596000

-516000

80000

P5Y

75000

-5000

70000

P3Y

P4Y

50000

-50000

P25Y

8000

-7000

1000

172447000

-12161000

-380000

159906000

-380000

P7Y

P19Y

980000

-161000

819000

P20Y

100000

-23000

77000

Indefinite

267000

P10Y

23720000

-1363000

22357000

P3Y

P15Y

1519000

-759000

-626000

134000

P5Y

75000

-5000

70000

P3Y

P4Y

50000

-50000

P25Y

8000

-7000

1000

26719000

-2368000

-626000

23725000

-626000

Amortization expense for intangible assets for the years ended December 31, 2023 and 2022 were as follows: SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230101__20231231_zb9bKMuloT42" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20220101__20221231_zVfQUypr0Azd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z4Uy2VqCw8Rf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">84,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">86,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zCdrCDX9vqJ8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Licenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AcquiredNewDrugApplicationsMember_zSExdGeGU7dd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Acquired NDAs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,937,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,363,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zOMNqLxLSQl5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Customer relationships</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">113,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AmortizationOfIntangibleAssets_zVrHq09WYcDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Amortization of intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,082,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,578,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

84000

86000

7000

16000

9937000

1363000

54000

113000

10082000

1578000

<p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zTySCWH102j2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Estimated future amortization expense for the Company’s intangible assets at December 31, 2023 is as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20231231_zoeKXK3Rx4G3" style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left">Years ending December 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzNeK_zGfz2wAjU4vg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">2024</td><td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">13,658,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzNeK_zcE4KPeYHTr1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">13,658,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzNeK_zEujSaNzd56i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">13,658,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzNeK_zgJW7zpUCVg6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">13,309,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzNeK_zYkF3EWTEjY8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">12,961,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzNeK_ztnNiUfOZMef" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">92,463,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzNeK_zRkbtfwI4GM7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Intangible assets </td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">159,707,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

13658000

13309000

12961000

92463000

159707000

<p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zJNb19GAzp06" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in">NOTE 12. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at December 31, 2023 and 2022 consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zQl30Wy3UFa6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231_zIBbJbm7jVG6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALzsSJ_zS4A7KixQT38" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">21,424,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,440,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedInsuranceCurrentAndNoncurrent_iI_maAPAALzsSJ_zTJkYumdHMq3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued insurance premium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">873,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">575,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maAPAALzsSJ_zrKuaEWRMLXb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accrued IHEEZO milestone payments (see Note 4)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedTransitionalFeesCurrentAndNoncurrent_iI_maAPAALzsSJ_zfmGQpLoRsTe" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued RPC transition payments (see Note 4)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">453,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AccruedExitFeeForNotePayableCurrentAndNonCurrent_iI_maAPAALzsSJ_zGwnSIhzQfZj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accrued exit fee for note payable (see Note 13)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,713,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--AccruedLigitationSettlementsCurrentAndNoncurrent_iI_maAPAALzsSJ_zDINhnh5qXhi" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued litigation settlements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maAPAALzsSJ_zbD12T95VyDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Accrued interest (see Note 13)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,978,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,254,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALzsSJ_zdiMSECr0iQ4" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total accounts payable and accrued expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,294,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,771,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_di_zUqqpTssmVej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,581,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,771,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iTI_zTzgD6AZPH0j" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Non-current total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,713,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company financed all insurance policies for the policy terms of August 17, 2023 through August 16, 2024 and August 17, 2022 through August 16, 2023. The financing agreements have an interest rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20220817__20230816__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zoebvZHmJ4Pi" title="Debt instrument interest rate, during period">7.48% and <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20230817__20240816__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zFuinkhCO3j6" title="Debt instrument interest rate, during period">4.13% per annum, respectively, and require nine monthly payments of $169,000 and eight monthly payments of $<span id="xdx_904_ecustom--AccruedMonthlyPayments_c20230817__20240816__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zTkkqPVvKLv1" title="Accrued monthly payments">114,000, respectively.

Accounts payable and accrued expenses at December 31, 2023 and 2022 consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20231231_zQl30Wy3UFa6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231_zIBbJbm7jVG6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALzsSJ_zS4A7KixQT38" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">21,424,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,440,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedInsuranceCurrentAndNoncurrent_iI_maAPAALzsSJ_zTJkYumdHMq3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued insurance premium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">873,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">575,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maAPAALzsSJ_zrKuaEWRMLXb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accrued IHEEZO milestone payments (see Note 4)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,000,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedTransitionalFeesCurrentAndNoncurrent_iI_maAPAALzsSJ_zfmGQpLoRsTe" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued RPC transition payments (see Note 4)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">453,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AccruedExitFeeForNotePayableCurrentAndNonCurrent_iI_maAPAALzsSJ_zGwnSIhzQfZj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accrued exit fee for note payable (see Note 13)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,713,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--AccruedLigitationSettlementsCurrentAndNoncurrent_iI_maAPAALzsSJ_zDINhnh5qXhi" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued litigation settlements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maAPAALzsSJ_zbD12T95VyDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Accrued interest (see Note 13)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,978,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,254,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALzsSJ_zdiMSECr0iQ4" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total accounts payable and accrued expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,294,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,771,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_di_zUqqpTssmVej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,581,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,771,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iTI_zTzgD6AZPH0j" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Non-current total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,713,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

21424000

6440000

873000

575000

5000000

57000 453000 2713000 249000 49000

1978000

1254000

27294000

13771000

24581000

13771000

2713000

0.0748

0.0413

169000 114000

NOTE 13. DEBT Oaktree Loan Due 2026 In March 2023, the Company entered into a Credit Agreement and Guaranty, (the “Oaktree Loan”) with Oaktree Fund Administration, LLC, as administrative agent for the lenders (together, “Oaktree”), providing for a senior secured term loan facility to the Company with a principal amount of up to $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredTermLoanMember__srt--RangeAxis__srt--MaximumMember_zyHWnWi5YrO2" title="Face amount">100,000,000. Upon entering into the Oaktree Loan, the Company drew a principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember_zXGemS5jZaB7" title="Face amount">65,000,000 (“Tranche A”) from the Oaktree Loan and used the net proceeds to repay all amounts owed by the Company pursuant to the Loan and Security Agreement the Company previously entered into with B. Riley Commercial Capital, LLC on December 14, 2022 (the “B. Riley Loan”) – see subheading B. Riley Loan and Security Agreement – Paid in Full within this Note 13. The additional principal loan amount of up to $<span id="xdx_90D_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20230301__20230331__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember__srt--RangeAxis__srt--MaximumMember_zZRRspWT8lHk" title="Debt instrument increase decrease for period net">35,000,000 available under the Oaktree Loan (“Tranche B”) will be made available to the Company upon the commercialization of TRIESENCE. If Tranche B is not drawn by the Company on or before March 27, 2024, the amount available under Tranche B will be decreased to $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfDebt_c20230301__20230331__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember_z5LF3pV0Lim7" title="Proceeds from issuance of debt">30,000,000. While undrawn, the Company is required to pay a commitment fee related to Tranche B amount equal to <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230303__us-gaap--TypeOfArrangementAxis__custom--OaktreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember_zUFixejBWw8h" title="Debt instrument interest rate effective percentage">2% per annum, payable quarterly. This fee is recorded within prepaid expenses and other current assets and is being amortized on a straight-line basis over the access period. The Oaktree Loan is secured by nearly all of the assets, including intellectual property, of the Company and its material subsidiaries. The Oaktree Loan has a maturity date of <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember_zZpJ0i6cHfmi" title="Debt instrument maturity date">January 19, 2026 and carries an interest rate equal to the Secured Overnight Financing Rate plus <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember__us-gaap--VariableRateAxis__us-gaap--SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_zR5qriLikdQ7" title="Interest rate, during period">6.5% per annum (totaling <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember_zZjBu5lg4vR" title="Interest rate, during period">11.83% at December 31, 2023). From proceeds, the Company paid fees, offering expenses, and the Oaktree Loan was issued at an original issue discount, resulting in an aggregate discount of $<span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember_zidNxj4qIBbh" title="Original debt discount">3,415,000. The Oaktree Loan also carries an exit fee equal to <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20231231__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember_ziXv6QkqI4j2" title="Interest rate">3.5% of the aggregate principal amount owed, payable at maturity, and the Company accrued $<span id="xdx_90C_eus-gaap--ExtinguishmentOfDebtAmount_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember_zQwfnfqWtLj8" title="Accrued expences of debt">2,275,000 related to the exit fee. The original issue discount, fees and expenses (including the exit fee) are being amortized over the term of the Oaktree Loan using the effective interest rate method. The Oaktree Loan requires quarterly interest-only payments with all of the unpaid principal, interest and fees due on the maturity date, January 19, 2026. In July 2023, the Company entered into the First Amendment to the Oaktree Loan (the “Oaktree Amendment”). Under the Oaktree Amendment, the overall credit facility size was increased from $<span id="xdx_90C_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20230701__20230731__us-gaap--TypeOfArrangementAxis__custom--OaktreeCreditAgreementAmendmentMember__srt--RangeAxis__srt--MinimumMember_zSyKpe7C2nea" title="Debt instrument, increase (decrease)">100,000,000 to $<span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20230701__20230731__us-gaap--TypeOfArrangementAxis__custom--OaktreeCreditAgreementAmendmentMember__srt--RangeAxis__srt--MaximumMember_zb7qU1C3547d" title="Debt instrument, increase (decrease)">112,500,000, and the Company made other changes related to the Santen Products Acquisition (see Note 4). Upon satisfaction of certain conditions to funding, the Company drew down a principal amount of $12,500,000 (the “Loan Increase”) to fund the initial one-time payment associated with the Santen Products Acquisition and for other working capital and general corporate purposes. No other material changes to the Oaktree Loan were made pursuant to the Oaktree Amendment. Following entry into the Oaktree Amendment and the funding of the Loan Increase upon closing of the Santen Products Acquisition, the Company has drawn down a total principal loan amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230731__us-gaap--TypeOfArrangementAxis__custom--OaktreeCreditAgreementAmendmentMember__us-gaap--BusinessAcquisitionAxis__custom--SantenProductsAcquisitionMember__us-gaap--DebtInstrumentAxis__custom--OakTreeLoanMember_z80wwAaR8EI4" title="Debt instrument, face amount">77,500,000 under the Oaktree Loan. The Oaktree Loan exit fee was increased from $<span id="xdx_90A_eus-gaap--ExtinguishmentOfDebtAmount_c20230701__20230731__us-gaap--TypeOfArrangementAxis__custom--OaktreeCreditAgreementAmendmentMember__srt--RangeAxis__srt--MinimumMember_zFfiMEskAsn2" title="Extinguishment of debt fee">2,275,000 to $<span id="xdx_907_eus-gaap--ExtinguishmentOfDebtAmount_c20230701__20230731__us-gaap--TypeOfArrangementAxis__custom--OaktreeCreditAgreementAmendmentMember__srt--RangeAxis__srt--MaximumMember_zbcqctCQjmR" title="Extinguishment of debt fee">2,713,000 pursuant to the Oaktree Amendment. As of December 31, 2023, the Company has recorded in accrued expenses the total exit fee liability of $<span id="xdx_905_eus-gaap--AccruedLiabilitiesCurrent_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--OaktreeCreditAgreementAmendmentMember__srt--RangeAxis__srt--MaximumMember_z6WXU6Q23rni" title="Accrued expenses">2,713,000. The Oaktree Loan contains customary guarantees and covenants, including financial covenants related to minimum liquidity and minimum net revenues. As of December 31, 2023, the Company was in compliance with the financial covenants. As of the end of the fiscal quarter ending December 31, 2024, if the Company’s Total Leverage Ratio (as defined in the Oaktree Loan) is greater than or equal to five times, but less than seven times, the Company will be required to issue to Oaktree warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zC0qeqAymZ0d" title="Warrants to purchase shares">375,000 shares of the Company’s common stock, and if the Total Leverage Ratio is greater than or equal to seven times, the Company will be required to issue to Oaktree warrants to purchase an additional <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTWhQHGgCIlk" title="Warrants to purchase shares">375,000 shares of the Company’s common stock (equaling <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--OakTreeLoanMember__dei--LegalEntityAxis__custom--OaktreeFundAdministrationLLCMember_zDXV41hUTZw6" title="Warrants to purchase shares">750,000 shares in aggregate). If the Total Leverage Ratio as of the end of the fiscal quarter ending December 31, 2024 is less than five times, no warrants will be issued to Oaktree. Based on current projections, the Company does not expect to issue any warrants related to the Oaktree Loan. Interest expense related to the Oaktree Loan totaled $8,804,000 for the year ended December 31, 2023, and included the amortization of debt issuance costs and discount of $<span id="xdx_908_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--OakTreeLoanMember_zNIP3dqX44Rb" title="Amortization of financing costs and discount">1,680,000 and amortization of deferred commitment fees of $<span id="xdx_90C_eus-gaap--AmortizationOfDeferredLoanOriginationFeesNet_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--OakTreeLoanMember_zYxrF4WLxHKh" title="Amortization of deferred commitment fees">543,000. HROWM - 11.875% Senior Notes Due 2027 In December 2022 and in January 2023, the Company closed an offering of $35,000,000 and $5,250,000, respectively, aggregate principal amount of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zqphstpZc8U4" title="Interest rate"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230131__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zwpfVJcV1un2" title="Interest rate">11.875% senior notes due in December 2027 (the “2027 Notes”). The 2027 Notes were sold to investors at a par value of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_z2XVx4ueoAQ" title="Shares issued price per share"><span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230131__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_z0gF8cXQfaTd" title="Shares issued price per share">25.00 per 2027 Note, and the offering resulted in net proceeds to the Company of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20221201__20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_ztIZiKoqbe7c" title="Proceeds from issuance of debt"><span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfDebt_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_z5pJN3EjjHe5" title="Proceeds from issuance of debt">36,699,000 after deducting underwriting discounts and commissions and other offering expenses of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zzStbAnW8Hx6" title="Deducting underwriting discounts and commissions and expenses"><span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20230131__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zBEnR5ljX0Yb" title="Deducting underwriting discounts and commissions and expenses">3,551,000. The 2027 Notes are senior unsecured obligations of the Company and rank equally in right of payment with all of the Company’s other existing and future senior unsecured and unsubordinated indebtedness. The 2027 Notes are effectively subordinated in right of payment to all of the Company’s existing and future secured indebtedness and structurally subordinated to all existing and future indebtedness of the Company’s subsidiaries, including trade payables. The 2027 Notes bear interest at the rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zrymH9eCqD8b" title="Interest rate, during period">11.875% per annum. Interest on the 2027 Notes is payable quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing on January 31, 2023. The 2027 Notes will mature on <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_pid_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_z7vbItIsH6C7" title="Debt instrument maturity date">December 31, 2027. The issuance costs were recorded as a debt discount and are being amortized as interest expense over the term of the 2027 Notes using the effective interest rate method. At any time prior to December 31, 2024, the Company may, at its option, redeem the 2027 Notes, in whole at any time or in part from time to time, at a <span id="xdx_90B_eus-gaap--DebtInstrumentRedemptionDescription_pid_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zJWSa0jjOq5d" title="Redemption description">redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus a make-whole amount, if any, plus accrued and unpaid interest to, but excluding, the date of redemption. The Company may redeem the 2027 Notes for cash in whole or in part at any time at its option (i) on or after December 31, 2024 and prior to December 31, 2025, at a price equal to $25.50 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, (ii) on or after December 31, 2025 and prior to December 31, 2026, at a price equal to $25.25 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, and (iii) on or after December 31, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption. In addition, the Company is required to redeem the 2027 Notes, for cash, in whole but not in part, at the price of $25.50 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, upon occurrence of certain events including the occurrence of a Material Change, as defined in the Second Supplemental Indenture. The 2027 Notes trade on the Nasdaq Stock Market LLC under the symbol “HROWM.” Interest expense related to the 2027 Notes totaled $<span id="xdx_90A_eus-gaap--InterestExpenseOtherLongTermDebt_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zVKjpY8Hl1oa" title="Interest expense other than long term debt">5,516,000 and $<span id="xdx_907_eus-gaap--InterestExpenseOtherLongTermDebt_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zDqo9oAZLQUg" title="Interest expense other than long term debt">140,000 for the years ended December 31, 2023 and 2022, respectively, and included the amortization of debt issuance costs and discount of $<span id="xdx_90F_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zyAyDwG7YaL3" title="Amortization of financing costs and discount">736,000 and $<span id="xdx_908_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_z1YABeOFl0Q4" title="Amortization of financing costs and discount">0, respectively. Our Chief Executive Officer, Mark L. Baum, Chief Financial Officer, Andrew R. Boll, and former directors R. Lawrence Van Horn and Dr. Richard Lindstrom, in the aggregate, purchased $950,000 in principal amount of the 2027 Notes at the time of their offering. HROWL – 8.625% Senior Notes Due 2026 In April 2021, the Company closed an offering of $50,000,000 aggregate principal amount of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210430__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zMXjEgoiVu1b" title="Interest rate">8.625% senior notes due April 2026, and in May 2021 issued an additional $<span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210501__20210531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zntmRGMGYOqb" title="Debt instrument increase (decrease) period for net">5,000,000 of such notes pursuant to the full exercise of the underwriters’ option to purchase additional notes (collectively, the “April Notes”). The April Notes were sold to investors at a par value of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zNY5fqjUd2Ia" title="Shares issued price per share">25.00 per April Note and the offering resulted in net proceeds to the Company of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfDebt_c20210401__20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zisifaWIOghl" title="Proceeds from issuance of debt">51,909,000 after deducting underwriting discounts and commissions and other offering expenses of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zqrlcuMYjpM2" title="Deducting underwriting discounts and commissions and expenses">3,091,000. In September 2021, in a further issuance of the April Notes, the Company sold an additional $<span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210901__20210930__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zqJDfBfPsOn8" title="Debt instrument increase (decrease) for period net">20,000,000 aggregate principal amount of such notes (the “September Notes,” and together with the April Notes, the “2026 Notes”), at a price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zcre9jWlLt5c" title="Shares issued price per share">25.75 per September Note, with interest of $<span id="xdx_905_eus-gaap--InterestExpenseDebt_c20210901__20210930__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zliOikUS6ZX" title="Interest expense debt">278,000 on the September Notes being accrued from April 20, 2021, the date of issuance of the April Notes. The September offering resulted in net proceeds to the Company of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_c20210901__20210930__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zK39cp23kRVf" title="Proceeds from issuance of debt">19,164,000 after deducting underwriting discounts and commissions and other offering expenses of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20210930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zQGKuvhjPJVh" title="Deducting underwriting discounts and commissions and expenses">1,158,000 and a premium on note issuance of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedPremium_iI_c20210930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zLW4UNLwr7dj" title="Debt instrument unamortized premium">322,000. The September Notes are treated as a single series with the April Notes under the indenture governing the April Notes, dated as of April 20, 2021, and have the same terms as the April Notes (other than the initial offering price and issue date). The 2026 Notes are senior unsecured obligations of the Company and rank equally in right of payment with all of our other existing and future senior unsecured and unsubordinated indebtedness. The 2026 Notes are effectively subordinated in right of payment to all of the Company’s existing and future secured indebtedness and structurally subordinated to all existing and future indebtedness of the Company’s subsidiaries, including trade payables. The 2026 Notes bear interest at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_z44chhMmxde3" title="Interest rate, during period">8.625% per annum. Interest on the 2026 Notes is payable quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing on July 31, 2021. The 2026 Notes will mature on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_pid_dp_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zKkvUHSB8F47" title="Debt instrument maturity date">April 30, 2026. The issuance costs were recorded as a debt discount and are being amortized as interest expense, net of the amortization of the premium on note issuance, over the term of the 2026 Notes using the effective interest rate method. Prior to February 1, 2026, the Company may, at its option, redeem the 2026 Notes, in whole at any time or in part from time to time, at a <span id="xdx_909_eus-gaap--DebtInstrumentRedemptionDescription_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zJxMAvKx3Cm7" title="Redemption description">redemption price equal to 100% of the principal amount of the 2026 Notes to be redeemed, plus a make-whole amount, if any, plus accrued and unpaid interest to, but excluding, the date of redemption. The Company may redeem the 2026 Notes for cash in whole or in part at any time at our option on or after February 1, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption. On and after any redemption date, interest will cease to accrue on the redeemed Notes. The 2026 Notes trade on the Nasdaq Stock Market LLC under the symbol “HROWL”. Interest expense related to the 2026 Notes totaled $<span id="xdx_901_eus-gaap--InterestExpenseOtherLongTermDebt_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zhZdglM8gvoe" title="Interest expense other than long term debt">7,251,000 and $<span id="xdx_90E_eus-gaap--InterestExpenseOtherLongTermDebt_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zO81NIWWvsbi" title="Interest expense other than long term debt">7,238,000 for the years ended December 31, 2023 and 2022, respectively, and included amortization of debt issuance costs and discount of $<span id="xdx_903_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_z8Y8QfTd3Hqa" title="Amortization of financing costs and discount">782,000, and $<span id="xdx_904_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20220101__20221231__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zRAQBYfvwl24" title="Amortization of financing costs and discount">782,000 for the years ended December 31, 2023 and 2022, respectively. B. Riley Loan and Security Agreement – Paid in Full On December 14, 2022 (the “Effective Date”), the Company entered into a Loan and Security Agreement (the “BR Loan”) with B. Riley Commercial Capital, LLC, as administrative agent for the lenders. The BR Loan provided for a loan facility of up to $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20221214__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_zy1yegIMZMyf" title="Debt principal amount">100,000,000 to the Company with a maturity date of <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_c20221213__20221214__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_z4L98rAsGt9" title="Debt instrument maturity date">December 14, 2025 (the “Maturity Date”), at an interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221214__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_zOtjiO5qgQT6" title="Interest rate">10.875% per annum. In January 2023, $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230131__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_zfCvKEJ3zE6j" title="Debt principal amount">59,750,000 of principal amount was funded pursuant to the BR Loan simultaneously with the consummation of the NVS 5 Acquisition (see Note 4). In March 2023, the Company repaid all amounts owed under the BR Loan, in connection with the Oaktree Loan, and no exit or prepayment fees were paid as a result of the payoff of the BR Loan pursuant to a side letter agreement among the parties. Interest expense related to the BR Loan totaled $<span id="xdx_901_eus-gaap--InterestExpenseOtherLongTermDebt_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_zICldIvykVOa" title="Interest expense">1,565,000 for the year ended December 31, 2023, and included amortization of debt issuance costs and debt discount of $<span id="xdx_909_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_zJDq22h7CAxj" title="Amortization of debt issuance costs and debt discount">356,000. The Company recorded a loss of $<span id="xdx_90F_eus-gaap--ExtinguishmentOfDebtAmount_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAndSecurityAgreementMember__us-gaap--DebtInstrumentAxis__custom--BRLoanMember_zQg2QQ6yhMsi" title="Loss on extinguishment of debt">5,465,000 related to the early extinguishment of debt associated with the BR Loan. A summary of the Company’s debt at December 31, 2023 and 2022 is described as follows: SCHEDULE OF LONG TERM DEBT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20231231_z6U0HHCikMS7" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20221231_zU5mMnddF9ch" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zuISByJitEcl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">8.625% Senior Notes due April 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">75,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">75,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zoZslWx7ZPAi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">11.875% Senior Notes due December 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,000,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--OakTreeLoanMember_zmUZLKtGIFV" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Oaktree Loan due January 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,500,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentCarryingAmount_iI_zrKLCTclKDn1" style="vertical-align: bottom; background-color: White"> <td>Notes payable gross </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110,000,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_zwMEPMGYaCzc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Unamortized debt discount and issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,578,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,826,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--LongTermNotesPayable_iI_zS6OHqPla5Nd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Notes payable net </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">183,172,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">104,174,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> For the years ended December 31, 2023 and 2022, the total effective interest rate of the Company’s debt was 10.93%, and 8.97%, respectively. At December 31, 2023, future minimum payments under the Company’s debt were as follows: SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20231231_zXBxSP39jiO1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maCzgXJ_zluSv4IKY1u8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">21,201,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maCzgXJ_z0Xff68foUAc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,590,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maCzgXJ_z8F5PDkLneyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159,896,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maCzgXJ_ztE8292MFALa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,030,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebt_iTI_mtCzgXJ_zAsBnkVlLXBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">246,717,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InterestPayableCurrent_iNI_di_zsyqt8PMG5N" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,967,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_zURMOl8Ca8Z8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes payable, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,750,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_z9zmE6p3E8h2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: unamortized discount, net of premium</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,578,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--LongTermNotesPayable_iI_z2NdCMsoLB2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Notes payable, net of unamortized discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">183,172,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

100000000

65000000

35000000

30000000

0.02

2026-01-19

0.065

0.1183

3415000

0.035

2275000

100000000

112500000

12500000

77500000

2275000

2713000

375000

750000

8804000

1680000

543000

35000000

5250000

0.11875

25.00

36699000

3551000

0.11875

2027-12-31

redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus a make-whole amount, if any, plus accrued and unpaid interest to, but excluding, the date of redemption. The Company may redeem the 2027 Notes for cash in whole or in part at any time at its option (i) on or after December 31, 2024 and prior to December 31, 2025, at a price equal to $25.50 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, (ii) on or after December 31, 2025 and prior to December 31, 2026, at a price equal to $25.25 per note, plus accrued and unpaid interest to, but excluding, the date of redemption, and (iii) on or after December 31, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption. In addition, the Company is required to redeem the 2027 Notes, for cash, in whole but not in part, at the price of $25.50 per note,

5516000

140000

736000

950000

50000000

0.08625

5000000

25.00

51909000

3091000

20000000

25.75

278000

19164000

1158000

322000

0.08625

2026-04-30

redemption price equal to 100% of the principal amount of the 2026 Notes to be redeemed

7251000

7238000

782000

100000000

2025-12-14

0.10875

59750000

1565000

356000

5465000

A summary of the Company’s debt at December 31, 2023 and 2022 is described as follows: SCHEDULE OF LONG TERM DEBT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20231231_z6U0HHCikMS7" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20221231_zU5mMnddF9ch" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zuISByJitEcl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">8.625% Senior Notes due April 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">75,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">75,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--SeniorNotesDueTwoThousandTwentySevenMember_zoZslWx7ZPAi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">11.875% Senior Notes due December 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,000,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--DebtInstrumentAxis__custom--OakTreeLoanMember_zmUZLKtGIFV" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Oaktree Loan due January 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,500,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DebtInstrumentCarryingAmount_iI_zrKLCTclKDn1" style="vertical-align: bottom; background-color: White"> <td>Notes payable gross </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110,000,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_zwMEPMGYaCzc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Unamortized debt discount and issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,578,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,826,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--LongTermNotesPayable_iI_zS6OHqPla5Nd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Notes payable net </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">183,172,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">104,174,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

75000000

40250000

35000000

77500000

192750000

110000000

-9578000

-5826000

183172000

104174000

0.1093

0.0897

At December 31, 2023, future minimum payments under the Company’s debt were as follows: SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 55%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20231231_zXBxSP39jiO1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maCzgXJ_zluSv4IKY1u8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">21,201,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maCzgXJ_z0Xff68foUAc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,590,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maCzgXJ_z8F5PDkLneyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159,896,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maCzgXJ_ztE8292MFALa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,030,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebt_iTI_mtCzgXJ_zAsBnkVlLXBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">246,717,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InterestPayableCurrent_iNI_di_zsyqt8PMG5N" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,967,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_zURMOl8Ca8Z8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes payable, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,750,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_z9zmE6p3E8h2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: unamortized discount, net of premium</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,578,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--LongTermNotesPayable_iI_z2NdCMsoLB2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Notes payable, net of unamortized discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">183,172,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

21201000

20590000

159896000

45030000

246717000

53967000

192750000

-9578000

183172000

NOTE 14. LEASES The Company leases office and laboratory space under the non-cancelable operating leases listed below. These lease agreements have remaining terms between <span id="xdx_900_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zpgQ0XbsQKC6" title="Lease term::XDX::P1Y">one to <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_z8dTcEW0CPMf" title="Lease term">five years and contain various clauses for renewal at the Company’s option. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 5,789 square feet of office space in Carlsbad, California, which commenced in January 2022 that expires in March 2025.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 38,153 square feet of lab, warehouse and office space in Ledgewood, New Jersey that expires in July 2027, with an option to extend the term for two additional five-year periods. This lease was amended, effective July 2020, to extend the term of the original lease and add 1,400 of additional square footage to the lease, amended again in May 2021 to extend the term of the lease to July 2027 and add <span id="xdx_901_ecustom--AdditionalAreaOfLand_uSquareFoot_c20230101__20231231__srt--StatementGeographicalAxis__custom--LedgewoodMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_zibOYaLmD2P3" title="Area of land">8,900 square feet of space, and amended in May 2023 to add another <span id="xdx_909_eus-gaap--AreaOfLand_iI_uSquareFoot_c20231231__srt--StatementGeographicalAxis__custom--LedgewoodMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_zTTeZbP7isUb" title="Area of land">2,861 square feet of space to the existing lease, which the Company took possession of in January 2024.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 5,500 square feet of office space in Nashville, Tennessee that expires in December 2024.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 11,552 square feet of lab and office space in Nashville, Tennessee which commenced in September 2022 and expires in September 2027.</td></tr> </table> At December 31, 2023 and 2022, the weighted-average discount rate and the weighted-average remaining lease term for the operating leases held by the Company were 6.6% and 6.6% and 10.4 years and 10.9 years, respectively. During the years ended December 31, 2023 and 2022, cash paid for amounts included for the operating lease liabilities was $1,231,000 and $925,000, respectively, and the Company recorded operating lease expense of $1,232,000 and $1,117,000, respectively, included in selling, general and administrative expenses. Future lease payments under operating leases as of December 31, 2023 were as follows (excluding lease transactions entered into in 2024): SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231_zHVhXuZE2Quj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzv0z_zBuxR5RIAfP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,261,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzv0z_z8jTOSjkr5I1" style="vertical-align: bottom; background-color: White"> <td>2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,093,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzv0z_zBe1kvqCwul" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,114,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzv0z_zINv4PRmpjCc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">972,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_maLOLLPzv0z_zF4jGAohjKaj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">657,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzv0z_zxY03QDewQZ3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,173,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzv0z_z5o5siIxiLp2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,270,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zeXDXZ0LZwTc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing imputed interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,940,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_ztgGETAttcF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,330,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_z6tXqbGJxgIc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(806,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease obligations, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,524,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

P5Y

5789

March 2025

38153

July 2027 1400 8900

2861

5500

December 2024

11552

September 2027

0.066

P10Y4M24D

P10Y10M24D

1231000

925000

1232000

1117000

Future lease payments under operating leases as of December 31, 2023 were as follows (excluding lease transactions entered into in 2024): SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20231231_zHVhXuZE2Quj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzv0z_zBuxR5RIAfP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,261,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzv0z_z8jTOSjkr5I1" style="vertical-align: bottom; background-color: White"> <td>2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,093,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzv0z_zBe1kvqCwul" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,114,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzv0z_zINv4PRmpjCc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">972,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_maLOLLPzv0z_zF4jGAohjKaj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">657,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzv0z_zxY03QDewQZ3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,173,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzv0z_z5o5siIxiLp2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,270,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zeXDXZ0LZwTc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing imputed interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,940,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_ztgGETAttcF1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,330,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_z6tXqbGJxgIc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(806,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease obligations, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,524,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1261000

1093000

1114000

972000

657000

5173000

10270000

2940000

7330000

806000

6524000

<p id="xdx_806_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zJMYeeWRtcti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in">NOTE 15. STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Preferred Stock At December 31, 2023 and 2022, the Company had 5,000,000 shares of preferred stock, $0.001 par value, authorized and no shares of preferred stock issued and outstanding. Common Stock At each of December 31, 2023 and 2022, the Company had 50,000,000 shares of common stock, $0.001 par value, authorized. Issuances During the Year Ended December 31, 2023 During the year ended December 31, 2023: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company closed a public offering of shares of its common stock at an offering price of $17.75 per share (the “Offering”). The Company sold <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOfferingMember_zf3pgOlZdLN7" title="Number of shares sold">3,887,324 shares of its common stock in the Offering, resulting in the Company receiving aggregate net proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOfferingMember_ziTSuMpX0ikf" title="Proceeds from issuance of common stock">64,520,000, after deducting underwriting discounts and commissions and other offering expenses of $4,480,000;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company settled <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zSrsppo0Zcge" title="Number of shares outstanding">1,567,913 outstanding PSUs as a result of the achievement of the total stockholder returns (“TSR”) targets set forth in equity incentive awards (the “PSU Agreements”) previously issued to members of the Company’s management team in 2021 (the “2021 Awards”). The 2021 Awards were separated into four tranches and required that the Company achieve and maintain certain levels of TSR ranging from <span id="xdx_90D_ecustom--PercentageOfStockholdersReturn_iI_pid_dp_uPure_c20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember__srt--RangeAxis__srt--MinimumMember_z0XJnlDt8Kab" title="TSR percentage">50% to <span id="xdx_90A_ecustom--PercentageOfStockholdersReturn_iI_dp_uPure_c20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember__srt--RangeAxis__srt--MaximumMember_zuGfQ1IZNfDk" title="TSR percentage">175% per share during the five-year period following the grant date. TSR was based on the aggregate of: (i) the percent increase of the closing price of the Company’s common stock from July 22, 2021; and (ii) any dividends or like stockholder distributions as specified in the PSU Agreements. In connection with the settlement of the 2021 Awards, an aggregate of <span id="xdx_902_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zg49IaugQr49" title="Number of shares withheld">616,984 shares of the Company’s common stock was withheld by Harrow for payroll tax obligations totaling $<span id="xdx_906_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsMember_zxpwsY8EoNg6" title="Payroll tax obligations">11,273,000;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT0h9XbvXBDk" title="Number of common stock issued">168,963 shares of its common stock underlying RSUs held by directors that ceased providing services to the Company. The RSUs had previously vested, including <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR1kSNntfa2e" title="Number of common stock vested">21,620 RSUs during the year ended December 31, 2023, but the issuance and delivery of the shares were deferred until the director ceased providing services to the Company;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zV0mYoFlqoPl" title="Number of share issued">65,148 shares of common stock and received proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcfxOextMWAh" title="Proceeds from stock option exercise">379,000 upon the exercise of options to purchase <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zn7pRqHiN3f9" title="Exercise of option, shares">65,148 shares of common stock with exercise prices ranging from $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoCKQPiZcTq4" title="Exercise price, minimum">1.70 to $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoDxOCalRgUi" title="Exercise price, maximum">8.50 per share;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z98xQ6PDwjR3" title="Number of granted, sharess">62,367 shares of common stock to Mark L. Baum, the Company’s Chief Executive Officer, upon the cashless exercise of options to purchase <span id="xdx_907_ecustom--CashlessExerciseOfOptionsShares_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgEgeSArJp8" title="Cashless exercise of options, shares">180,000 shares at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z7Vo98EcWuo7" title="Exercise price per share">8.99 per share. The Company withheld from Mr. Baum <span id="xdx_908_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZCTJUYHhwvb" title="Shares withheld for tax withholding obligation">77,167 shares as consideration for the cashless exercise and an additional <span id="xdx_905_ecustom--AddtionalSharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTHhoo9CFUq5" title="Additional shares withheld for tax withholding obligation">40,466 shares for payroll tax obligations totaling $<span id="xdx_909_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z74YvkiqEFGd" title="Payroll tax obligations, value">849,000;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPvHABG0aZee" title="Number of shares issued">55,558 shares of common stock to Andrew R. Boll, the Company’s Chief Financial Officer, upon the cashless exercise of options to purchase <span id="xdx_909_ecustom--CashlessExerciseOfOptionsShares_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlO0pRQmnrPb" title="Cashless exercise of options, shares">90,000 shares at an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zoFoTWUsecC3" title="Exercise price per share">6.00 per share. The Company withheld from Mr. Boll <span id="xdx_904_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbiDVeGuhRVf" title="Shares withheld for tax withholding obligation">25,521 shares as consideration for the cashless exercise and an additional <span id="xdx_90F_ecustom--AddtionalSharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmmSsKqDRH5g" title="Additional shares withheld for tax withholding obligation">8,921 shares for payroll tax obligations totaling $<span id="xdx_90D_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zYJxLAASIYDi" title="Payroll tax obligations, value">189,000; </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb7n2HIOjJW7" title="Number of shares issued">10,222 shares of common stock to John Saharek, the Company’s Chief Commercial Officer, upon the cashless exercise of options to purchase <span id="xdx_904_ecustom--CashlessExerciseOfOptionsShares_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkNLRKOynUni" title="Cashless exercise of options, shares">20,000 shares at an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember_z90bS6pXWsUg" title="Exercise price per share">4.16 per share. The Company withheld from Mr. Saharek <span id="xdx_90D_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpFQOZmQfJRd" title="Shares withheld for tax withholding obligation">6,485 shares as consideration for the cashless exercise and an additional <span id="xdx_90B_ecustom--AddtionalSharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD3oC53mudbb" title="Additional shares withheld for tax withholding obligation">3,293 shares for payroll tax obligations totaling $<span id="xdx_902_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember_zWx9zXgJKXWl" title="Payroll tax obligations, value">41,000; </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">upon vesting of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZfbmmT5fU58" title="Number of shares granted">23,000 RSUs granted in January 2020 to Andrew R. Boll, the Company’s Chief Financial Officer, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQDkG6cbpaz8" title="Number of shares issued">13,398 shares of common stock to Mr. Boll, net of <span id="xdx_90E_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWuFzpUKARli" title="Shares withheld for tax withholding obligation, shares">9,602 shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_901_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zF91KQ5A3Yy3" title="Payroll tax obligations, value">142,000;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">upon vesting of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zItmrN2pMGg7" title="Number of shares granted">88,000 RSUs granted in January 2020 to Mark L. Baum, the Company’s Chief Executive Officer, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE2kyPXeUAA8" title="Number of shares issued">52,821 shares of common stock to Mr. Baum, net of <span id="xdx_904_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQsshaMt19Ad" title="Shares withheld for tax withholding obligation, shares">35,179 shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_90B_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znuomFcv5U4k" title="Payroll tax obligations, value">519,000; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zm3PLys1yqdk" title="Number of shares granted">43,023 shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares were deferred until the applicable director ceased providing services to the Company.</td></tr> </table> Issuances During the Year Ended December 31, 2022 During the year ended December 31, 2022: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z8NHGqLIJkff" title="Number of shares of common stock">53,594 shares of common stock to Mark L. Baum, the Company’s Chief Executive Officer, upon the cashless exercise of options to purchase <span id="xdx_90D_ecustom--CashlessExerciseOfOptionsShares_pid_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z92b74FRExX6" title="Cashless exercise of options, shares">125,000 shares at an exercise price of $<span id="xdx_907_ecustom--CashlessExerciseOfOptionsPricePerShares_pid_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z6J6sfIUqVp8" title="Cashless exercise of options, price per shares">2.40 per share. The Company withheld from Mr. Baum <span id="xdx_90D_ecustom--CommonStockWithheldOnCashlessExercise_pid_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zNHRN2cgSCx2" title="Common stock withheld on cashless exercise">36,014 shares as consideration for the cashless exercise and an additional <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z9V7WzHlnYLg" title="Common stock withheld for payroll tax withholdings, shares">35,392 shares for payroll tax obligations totaling $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueOther_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zhyuTTIWMy8f" title="Common stock withheld for payroll tax withholdings, value">295,000;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company issued 306,347 shares of its common stock upon the cashless exercise of warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zts7zb7Orjs9" title="Number of securities called by warrants">373,847 shares of common stock with an exercise price of $2.08 per share;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company issued 4,054 shares of common stock to a consultant upon the cashless exercise of options to purchase 15,995 shares at an exercise price of $7.07 per share. The Company withheld <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantMember_zXWql9PyxQn6" title="Number of stock withheld for payroll tax purposes">11,941 shares as consideration for the cashless exercise;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company issued 15,625 shares of common stock to a consultant and received net proceeds of $55,000 upon the exercise of options to purchase 15,625 shares of common stock at an exercise price of $3.50 per share;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company issued 132,100 shares of common stock and received net proceeds of $587,000 upon the exercise of options to purchase 132,100 shares of common stock with exercise prices between $<span id="xdx_902_ecustom--CashlessExerciseOfOptionsPricePerShares_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantTwoMember__srt--RangeAxis__srt--MinimumMember_zbjWKEE5Ibhj" title="Warrants exercise price">1.70 to $<span id="xdx_905_ecustom--CashlessExerciseOfOptionsPricePerShares_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ConsultantTwoMember__srt--RangeAxis__srt--MaximumMember_z6kSjD7Ir6x8" title="Warrants exercise price">8.40 per share;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_z8tT3Xhzk05g" title="Number of restricted stock units granted">185,000 RSUs granted at various dates to employees of the Company vested, and the Company issued 110,621 shares of common stock to the employees, net of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqn3NwctNd42" title="Common stock withheld for payroll tax withholdings, shares">74,379 shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueOther_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zAeEYWLkbgCh" title="Common stock withheld for payroll tax withholdings, value">581,000; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh45Zpfgsyve" title="Shares vested during period">35,693 shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the applicable director resigns.</td></tr> </table> Stock Option Plan On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “2007 Plan”). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this plan, however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company’s Board of Directors and stockholders adopted the Company’s 2017 Incentive Stock and Awards Plan which was subsequently amended on June 3, 2021 (as amended, the “2017 Plan” together with the 2007 Plan, the “Plans”). As of December 31, 2023, the 2017 Plan provides for the issuance of a maximum of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember__srt--RangeAxis__srt--MaximumMember_zMmgE3jLkx94" title="Number of shares authorized">6,000,000 shares of the Company’s common stock. The purpose of the Plans are to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plans, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended, non-qualified stock options, restricted stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company’s Board of Directors. The Company had <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_ze6LTJQP1qBg" title="Common shares available for future issuances">405,612 shares available for future issuances under the 2017 Plan at December 31, 2023. Stock Options A summary of stock option activity under the Plan for the year ended December 31, 2023 is as follows: SCHEDULE OF STOCK OPTION PLAN ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Remaining Contractual Life</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Options outstanding – January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zt33LcyTH265" style="width: 11%; text-align: right" title="Number of shares, outstanding, beginning balance">3,027,701</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zwHJY0tXMVfa" style="width: 11%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">5.90</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWQ3eb5k60a3" style="text-align: right" title="Number of shares, options granted">135,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zo7XL9u9zs14" style="text-align: right" title="Weighted average exercise price, outstanding, beginning balance">17.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zi0xzWprIOM5" style="text-align: right" title="Number of shares, options exercised">(355,148</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zaRwPcpaM1D" style="text-align: right" title="Weighted average exercise price, options exercised">7.36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Options cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zcW47KPiyDAc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options cancelled/forfeited">(96,736</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zYzScFmmRrT2" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, options cancelled/forfeited">7.49</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options outstanding – December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zOXPDXDYPTE1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance">2,711,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zXKA6ElA8hdk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, outstanding, ending balance">6.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZL1XmeloxDc" title="Weighted average. remaining contractual life, options outstanding">4.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zHOfpBKcu3D4" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options outstanding">14,303,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zGt5F3EUuATa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable">2,432,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zh6RpJbACmf7" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, options exercisable">5.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z9JSbYJ1I8O9" title="Weighted average. remaining contractual life, options exercisable">3.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zhTvXgKste9g" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options exercisable">13,760,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zCKqUSGQ2iuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest">2,673,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZsm2O97FI3f" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, options vested and expected to vest">6.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zE7yn3vTEsK5" title="Weighted average. remaining contractual life, options vested and expected to vest">3.93</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zwxGCeIXWmKe" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options exercisable">14,243,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A summary of stock option activity under the Plan for the year ended December 31, 2022 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Remaining Contractual Life</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Options outstanding – January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zA3DJ1JlLyO8" style="width: 11%; text-align: right" title="Number of shares, outstanding, beginning balance">3,039,546</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zKQi3HZPDEK4" style="width: 11%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">5.52</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zk9UBNbrH1Tl" style="text-align: right" title="Number of shares, options granted">351,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zOgTUpr1MtAc" style="text-align: right" title="Weighted average exercise price, options granted">7.71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zivX3AKIlUb7" style="text-align: right" title="Number of shares, options exercised">(288,720</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZ6wxuMQNCL6" style="text-align: right" title="Weighted average exercise price, options exercised">3.65</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Options cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z1x2pq8SPPK3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options cancelled/forfeited">(74,375</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLVRnIGH7oRb" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, options cancelled/forfeited">7.46</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options outstanding – December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z40BOq1n4lQ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance">3,027,701</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zUhKYaHpp0s7" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, outstanding, ending balance">5.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zYqgVRq95HTe" title="Weighted average. remaining contractual life, options outstanding">4.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJiuYhPkiS9l" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options outstanding">26,822,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zKmB3shuEXk8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable">2,457,769</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z82PJ7KLCZq9" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, options exercisable">5.51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zV67mCPEsXXl" title="Weighted average. remaining contractual life, options exercisable">3.97</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zxBeiyUpwzpf" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options exercisable">22,731,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_za3v3GmH3LUk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest">3,026,942</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zUtmfzMBv79g" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, options vested and expected to vest">5.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zztYCugK9oWa" title="Weighted average. remaining contractual life, options vested and expected to vest">4.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z1R14L5Dytr9" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options exercisable">26,817,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price on December 31, 2023 and 2022, based on the closing price of the Company’s common stock of $11.20 and $14.76, respectively, on that date. The intrinsic value of the options exercised in 2023 and 2022 was $4,580,000 and $2,008,000, respectively. During the year ended December 31, 2023, the Company granted stock options to certain employees. <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zE7250dtOZ13" title="Vesting term description">The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of 10 years. Vesting terms for options granted to employees during the year ended December 31, 2023 generally included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The Company calculates expected volatility based solely on the historical volatilities of the common stock of the Company. The expected term of options granted was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureFactor_pid_dp_uPure_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zkj3yfmePga2" title="Forfeiture factor rate">10%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant. <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEcqzTaElg81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: SCHEDULE OF FAIR VALUE ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za5w6Lh80Wde" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted">11.49</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgq2iwpRNBxk" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted">4.72</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected terms (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbeKqTvpjY1l" title="Expected terms (in years)">6.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zudocSXWQaR6" title="Expected terms (in years)">6.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zIpudnT0NVkj" title="Expected volatility, minimum">68 – <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOaxZN3eH5A4" title="Expected volatility, maximum">70</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoyUbETsGvf6" title="Expected volatility, minimum">68 – <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwkGns2AKhG4" title="Expected volatility, maximum">72</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNmVKb8Fw1Z3" title="Risk-free interest rate, minimum">3.59 – <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx8h1HSIX8vf" title="Risk-free interest rate, maximum">4.80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrJULpQvuCx9" title="Risk-free interest rate, minimum">1.54 – <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zl4MbOaPc0G9" title="Risk-free interest rate, maximum">3.70</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYkbPQPQ6g11" style="text-align: right" title="Dividend yield">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMPPnmX9zh9f" style="text-align: right" title="Dividend yield">-</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zC2wvlJq7Rq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in">The following table summarizes information about stock options outstanding and exercisable at December 31, 2023: SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range of Exercise Prices</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life in Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zlwfkqM4fAek" title="Range of Exercise Prices, minimum">1.47 - $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zAgaNJnBYtw6" title="Range of Exercise Prices, maximum">1.73</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zGQoIj2nl6V5" style="width: 12%; text-align: right" title="Number of Options Outstanding">295,852</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXX49cLcwAP6" title="Weighted Average Remaining Contractual Life in Years">3.95</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zevAIojVcKek" style="width: 12%; text-align: right" title="Weighted Average Exercise Price">1.72</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zyF5wEmS0Fy8" style="width: 12%; text-align: right" title="Number Exercisable">295,852</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqyyqERhv379" style="width: 12%; text-align: right" title="Weighted Average Exercisable Exercise Price">1.72</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zuIunILng151" title="Range of Exercise Prices, minimum">2.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zXsKT5i5FKV2" style="text-align: right" title="Number of Options Outstanding">285,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zwcgdgolGKtd" title="Weighted Average Remaining Contractual Life in Years">3.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zcc0Tn1WUeU6" style="text-align: right" title="Weighted Average Exercise Price">2.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zetlflrFR4A1" style="text-align: right" title="Number Exercisable">285,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zE32TMryg20h" style="text-align: right" title="Weighted Average Exercisable Exercise Price">2.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zqps4pVE0OJe" title="Range of Exercise Prices">2.40 - $<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zslaT4wOa2u2" title="Range of Exercise Prices">2.60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zwEDbMlYREK1" style="text-align: right" title="Number of Options Outstanding">24,068</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zqMeDpxY901i" title="Weighted Average Remaining Contractual Life in Years">3.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zqhfoaUGIXrj" style="text-align: right" title="Weighted Average Exercise Price">2.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zUDfEBzI1uM6" style="text-align: right" title="Number Exercisable">24,068</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zFUClfch0lN9" style="text-align: right" title="Weighted Average Exercisable Exercise Price">2.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zGeyPFFGUC4c" title="Range of Exercise Prices, maximum">3.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zi1r1xJwbOhf" style="text-align: right" title="Number of Options Outstanding">310,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_za6ckYhRPEa6" title="Weighted Average Remaining Contractual Life in Years">2.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z9bk8gyw6ou3" style="text-align: right" title="Weighted Average Exercise Price">3.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z2q9AV859rSa" style="text-align: right" title="Number Exercisable">310,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zKN7O7Xd3Ts2" style="text-align: right" title="Weighted Average Exercisable Exercise Price">3.95</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zDxFfB0NblZf" title="Range of Exercise Prices, minimum">4.49 - $<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zP3Ot9Xz71Fk" title="Range of Exercise Prices, maximum">5.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z8wPVqiFs995" style="text-align: right" title="Number of Options Outstanding">100,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zlTaEaS3OKTd" title="Weighted Average Remaining Contractual Life in Years">5.47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z1hl2fWYvtb8" style="text-align: right" title="Weighted Average Exercise Price">5.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zQmxTCUPE2Th" style="text-align: right" title="Number Exercisable">94,416</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zYJ85TFY4K3c" style="text-align: right" title="Weighted Average Exercisable Exercise Price">5.53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zYChuftYKLb" title="Range of Exercise Prices, maximum">6.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zrDdudvGc5e8" style="text-align: right" title="Number of Options Outstanding">285,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zo4IytG18Csg" title="Weighted Average Remaining Contractual Life in Years">5.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zTDL1Grnzhdg" style="text-align: right" title="Weighted Average Exercise Price">6.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zVs5vspAqsDh" style="text-align: right" title="Number Exercisable">285,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zstzmOYsh73e" style="text-align: right" title="Weighted Average Exercisable Exercise Price">6.30</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z3IPBRNxcncc" title="Range of Exercise Prices">6.75 - $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zUCpO2Lr985l" title="Range of Exercise Prices">7.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zpHC2ew06qA2" style="text-align: right" title="Number of Options Outstanding">103,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zSrsGWv3M7l5" title="Weighted Average Remaining Contractual Life in Years">8.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z9HKpeCJ8fH5" style="text-align: right" title="Weighted Average Exercise Price">6.96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zqvB6gl03rYh" style="text-align: right" title="Number Exercisable">39,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zCVgeumAQDu4" style="text-align: right" title="Weighted Average Exercisable Exercise Price">6.96</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zNDoYXHexxz" title="Range of Exercise Prices, maximum">7.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zd4EmGVla6H7" style="text-align: right" title="Number of Options Outstanding">274,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zTGDgs3xQ8jl" title="Weighted Average Remaining Contractual Life in Years">6.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zaORQqf68I3b" style="text-align: right" title="Weighted Average Exercise Price">7.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zmyY4mMvqDw1" style="text-align: right" title="Number Exercisable">274,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zabcQeDABBOi" style="text-align: right" title="Weighted Average Exercisable Exercise Price">7.30</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zeHRKughVuIg" title="Range of Exercise Prices">7.37 - $<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zSVGWtUL47x" title="Range of Exercise Prices">7.79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zNmeVeeD3gFf" style="text-align: right" title="Number of Options Outstanding">229,187</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zOzP8J9KmqYe" title="Weighted Average Remaining Contractual Life in Years">3.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zRiVVDOaKg12" style="text-align: right" title="Weighted Average Exercise Price">7.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zPXb28QTO9be" style="text-align: right" title="Number Exercisable">172,818</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z3Gmp2F6bLFf" style="text-align: right" title="Weighted Average Exercisable Exercise Price">7.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zL7zrmUlfUla" title="Range of Exercise Prices">7.87 - $<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z70InVwBKJi6" title="Range of Exercise Prices">25.86</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zLtOAyXwzwM6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding">804,173</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zxpVm0oH0uui" title="Weighted Average Remaining Contractual Life in Years">3.27</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zxDPWuRXOiz1" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price">9.59</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z30wH5l4eOkf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">651,547</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zJkXVfY57nG9" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">7.93</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">1.47 - $25.86</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231_zhRtN9WZOW5e" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding">2,711,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zRfh8TKzhsTj" title="Weighted Average Remaining Contractual Life in Years">4.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231_zFi5TBwRW4S3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price">6.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231_z9UjWTOe0wWl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Options Exercisable">2,432,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231_zyScOFulRuP9" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">5.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of December 31, 2023, there was approximately $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zq2TdcRlUcL" title="Unrecognized compensation expense related to unvested stock options granted under the plan">1,966,000 of total unrecognized compensation expense related to unvested stock options granted under the Plan. That expense is expected to be recognized over the weighted-average remaining vesting period of <span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxlwnTcWMeKd" title="Expense expected to recognize over the weighted-average remaining vesting period">2.77 years. The stock-based compensation for all stock options was $782,000 and $1,130,000 during the years ended December 31, 2023 and 2022, respectively. Performance Stock Units Grants During the Year Ended December 31, 2023 In April 2023, the Company granted an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230401__20230430__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zX8wWNKQ159d" title="Number of shares granted">1,567,913 PSUs to members of its senior management including Mark Baum, Chief Executive Officer, Andrew Boll, Chief Financial Officer, and John Saharek, Chief Commercial Officer, which are subject to the satisfaction of certain market-based and continued service conditions (the “2023 PSUs”). The vesting of the 2023 PSUs require (i) a minimum of a two-year service period, and (ii) during a five-year term, the achievement and maintenance of Company common stock price targets for ten consecutive trading days ranging between $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20230430__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDZHX6qb0gwg" title="Share price">25.00 to $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20230430__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjFDjcAAdWG7" title="Share price">50.00 per share, separated into four separate tranches as described further in the table below. <p id="xdx_898_eus-gaap--ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_zubYgYILbtcf" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify">SCHEDULE OF PERFORMANCE STOCK UNITS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: justify">Tranche</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Target Share Price*</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: justify">Tranche 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20230101__20231231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zWXkuWuoirY6" style="width: 22%; text-align: right" title="Tranche of shares">223,988</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_c20231231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_fKg_____z5Vp4mghJr55" style="width: 22%; text-align: right" title="Share price">25.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Tranche 2</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20230101__20231231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zMZZSmL2CVQj" style="text-align: right" title="Tranche of shares">335,981</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_c20231231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_fKg_____z05Ztw7PaMAj" style="text-align: right" title="Share price">35.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Tranche 3</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20230101__20231231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zbd4GSBsclaf" style="text-align: right" title="Tranche of shares">447,975</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_c20231231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_fKg_____zajPCqMRxF45" style="text-align: right" title="Share price">45.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Tranche 4</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20230101__20231231__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember_zZIg4Y2CZtBk" style="text-align: right" title="Number of Shares">559,969</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharePrice_iI_c20231231__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember_fKg_____zjia86w3arp6" style="text-align: right" title="Target Share Price">50.00</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">*</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Target Share Price assumes that no dividends or like distributions are made to stockholders of the Company. If such distributions are made, the Target Share Price would decrease accordingly, to the benefit of the employee, to account for the dividend/distribution as a part of the Target Share Price. </td></tr> </table> The aggregate fair value of the 2023 PSUs was $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_z9HFI5Z1gsFg" title="Share-based compensation shares fair value">29,106,000 using a Monte Carlo Simulation with a five-year life, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_z2t18kWJsHti" title="Volatality rate">65% volatility and a risk free interest rate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zBHuVCnbGSm3" title="Risk free intrest rate">10.34%. This amount is being amortized over a two-year derived service period. <p id="xdx_896_ecustom--ScheduleOfShareBasedCompensationPerformanceStockUnitsAwardActivityTableTextBlock_zhfEpLcYMQH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of the Company’s PSU activity and related information for the year ended December 31, 2023 is as follows: SCHEDULE OF PERFORMANCE STOCK UNITS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of PSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">PSUs unvested – January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zIYr4SKAoPc8" style="width: 16%; text-align: right" title="Number of Shares, PSUs unvested, outstanding, beginning balance">1,567,913</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zTDPhOyY4crl" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning balance">6.45</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">PSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zMNOV7396qLh" style="text-align: right" title="Number of Shares, PSUs granted">1,567,913</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zPsAMQdwEjic" style="text-align: right" title="Weighted average grant date fair value, PSUs granted">18.56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zBUuYzAGNkLi" style="text-align: right" title="Number of Shares, PSUs vested">(1,567,913</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_z6yPUXz9sVQ2" style="text-align: right" title="Weighted average grant date fair value, PSUs vested">6.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">PSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zzkKgNXqOsW" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, PSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_z6D2WXu3J32h" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average grant date fair value, PSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">PSUs unvested – December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_znPCYHg9nnGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, PSUs unvested, outstanding, ending balance">1,567,913</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_ztIpIkKfuy5l" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">18.56</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Grants During the Year Ended December 31, 2022 No PSUs were issued during the year ended December 31, 2022. A summary of the Company’s PSU activity and related information for the year ended December 31, 2022 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of PSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">PSUs unvested – January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_z2gZMYYtAF" style="width: 16%; text-align: right" title="Number of Shares, PSUs unvested, outstanding, beginning balance">1,567,913</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zRy0Oryo0vmk" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning balance">6.45</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">PSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zNyJTjz5izB4" style="text-align: right" title="Number of Shares, PSUs granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zHNQSq4Kp2bl" style="text-align: right" title="Weighted average grant date fair value, PSUs granted">- </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zGIoM9JWNvk6" style="text-align: right" title="Number of Shares, PSUs vested">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zCb2NYc2utS" style="text-align: right" title="Weighted average grant date fair value, PSUs vested">- </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">PSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zkKxYRrDcgyk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, PSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zHGwdEfGlMUk" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average grant date fair value, PSUs cancelled/forfeited">- </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">PSUs unvested – December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_z3ntUc2mEVB5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, PSUs unvested, outstanding, ending balance">1,567,913</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zdQTgcoosvyk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">6.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of December 31, 2023, the total unrecognized compensation expense related to unvested PSUs was approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__custom--UnvestedPSUMember_zWRm9UtspCS3" title="Unrecognized compensation expense">18,191,000 which is expected to be recognized over a weighted-average period of <span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--UnvestedPSUMember_zNI8J2Voayil" title="Weighted-average period years">1.26 years, based on estimated vesting schedules. The stock-based compensation for PSUs was $13,753,000 and $5,056,000 during the years ended December 31, 2023 and 2022, respectively. Restricted Stock Units RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria. The grant date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs. Grants During the Year Ended December 31, 2023 During the year ended December 31, 2023, the Company’s board of directors were granted <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zMftehfcfN6b" title="Shares issued of restricted common stock, shares">41,301 time-based vesting RSUs with a fair market value of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20230101__20231231__srt--TitleOfIndividualAxis__custom--DirectorsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWvKmVf6qSKb" title="Number of restrcited shares, value">800,000, which vest in equal quarterly installments over one year. The Company also granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znCL6hxj6Ke5" title="Number of shares granted">86,873 time-based vesting RSUs with a fair market value of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zG8y4YES2d4d" title="Number of restrcited shares, value">697,000 to certain employees, which vest in full on the third anniversary of the grant date. <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zqhLCDHWqO3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of the Company’s RSU activity and related information for the year ended December 31, 2023 is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">RSUs unvested – January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231_zqS9NgNztAoj" style="width: 16%; text-align: right" title="Number of Shares, RSUs unvested, outstanding, beginning balance">493,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231_zw38mHbsP9s" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning balance">7.99</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231_zkwgcwOIRNVk" style="text-align: right" title="Number of Shares, RSUs granted">128,174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_zWvWSiQLnQG1" style="text-align: right" title="Weighted average grant date fair value, RSUs granted">11.68</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231_zt6IaisujKtl" style="text-align: right" title="Number of Shares, RSUs vested">(175,643</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zBeTQIMvV2S" style="text-align: right" title="Weighted average grant date fair value, RSUs vested">8.67</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231_zDzJfsZ0Opu9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, RSUs cancelled/forfeited">(83,308</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231_zpHjG062vBD6" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average grant date fair value, RSUs cancelled/forfeited">6.84</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">RSUs unvested at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231_z6CBpmb1mv12" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, RSUs unvested, outstanding, ending balance">363,029</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231_z78qhhoU8wrl" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">9.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Grants During the Year Ended December 31, 2022 During the year ended December 31, 2022, the Company’s board of directors were granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIssBAm0Suud" title="Number of shares granted">65,615 RSUs with a fair market value of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20220101__20221231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zT0DyfcY0hkf" title="Shares vested, fair market value">500,000, which vest in equal quarterly installments over one year. A summary of the Company’s RSU activity and related information for the year ended December 31, 2022 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">RSUs unvested – January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231_zwlE3oFYfjk7" style="width: 16%; text-align: right" title="Number of Shares, RSUs unvested, outstanding, beginning balance">665,288</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231_z5CYtf2foi6l" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning balance">7.57</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231_zshCZJCLIKPd" style="text-align: right" title="Number of Shares, RSUs granted">65,615</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zWDZ1nTafTsa" style="text-align: right" title="Weighted average grant date fair value, RSUs granted">7.62</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231_z5FyFPc6SLAa" style="text-align: right" title="Number of Shares, RSUs vested">(237,098</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_z9BeKXp2JIC1" style="text-align: right" title="Weighted average grant date fair value, RSUs vested">6.67</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20221231_zSmUPNG0YeKa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20221231_zMRjoTvZQZUf" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average grant date fair value, RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">RSUs unvested at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231_zTVkAlYSa0jb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, RSUs unvested, outstanding, ending balance">493,806</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231_zHi3AUgP6PT8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">7.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of December 31, 2023, the total unrecognized compensation expense related to unvested RSUs was approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zStmlwuMnKH" title="Unrecognized compensation expense">1,234,000 which is expected to be recognized over a weighted-average period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--UnvestedRSUAndPSUMember_zyJMqP3S41K9" title="Weighted-average period years">0.68 years, based on estimated vesting schedules. The stock-based compensation for RSUs was $1,161,000 and $1,788,000 during the years ended December 31, 2023 and 2022, respectively. The Company recorded total stock-based compensation (including issuance of common stock for services and accrual for stock-based compensation) related to equity instruments granted to employees, directors and consultants as follows: SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES, DIRECTORS AND CONSULTANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231_zC5gctMzDq5l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zywo8uzk2Tii" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zElOfewBuiuc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Employees – selling, general and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">13,279,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,669,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zT33oWInGzI9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Employees – R&D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,662,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">689,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zGOzGW37ljv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Directors – selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">462,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z1zAK9vXTe6c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Consultants – selling, general and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">67,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">154,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_za4gd1w89XY" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,696,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,974,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5000000

0.001

50000000

0.001

17.75

3887324

64520000

4480000

1567913

0.50 1.75

616984

11273000

168963

21620

65148

379000

65148

1.70

8.50

62367

180000

8.99

77167

40466

849000

55558

90000

6.00

25521

8921

189000

10222

20000

4.16

6485

3293

41000

23000

13398

9602

142000

88000

52821

35179

519000

43023

53594

125000 2.40 36014

35392

295000

306347

373847

2.08

4054

15995 7.07

11941

15625

55000

15625 3.50

132100

587000

132100 1.70 8.40

185000

110621

74379

581000

35693

6000000

405612

A summary of stock option activity under the Plan for the year ended December 31, 2023 is as follows: SCHEDULE OF STOCK OPTION PLAN ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Remaining Contractual Life</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Options outstanding – January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zt33LcyTH265" style="width: 11%; text-align: right" title="Number of shares, outstanding, beginning balance">3,027,701</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zwHJY0tXMVfa" style="width: 11%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">5.90</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWQ3eb5k60a3" style="text-align: right" title="Number of shares, options granted">135,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zo7XL9u9zs14" style="text-align: right" title="Weighted average exercise price, outstanding, beginning balance">17.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zi0xzWprIOM5" style="text-align: right" title="Number of shares, options exercised">(355,148</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zaRwPcpaM1D" style="text-align: right" title="Weighted average exercise price, options exercised">7.36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Options cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zcW47KPiyDAc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options cancelled/forfeited">(96,736</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zYzScFmmRrT2" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, options cancelled/forfeited">7.49</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options outstanding – December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zOXPDXDYPTE1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance">2,711,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zXKA6ElA8hdk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, outstanding, ending balance">6.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZL1XmeloxDc" title="Weighted average. remaining contractual life, options outstanding">4.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zHOfpBKcu3D4" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options outstanding">14,303,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zGt5F3EUuATa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable">2,432,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zh6RpJbACmf7" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, options exercisable">5.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z9JSbYJ1I8O9" title="Weighted average. remaining contractual life, options exercisable">3.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zhTvXgKste9g" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options exercisable">13,760,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zCKqUSGQ2iuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest">2,673,670</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZsm2O97FI3f" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, options vested and expected to vest">6.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zE7yn3vTEsK5" title="Weighted average. remaining contractual life, options vested and expected to vest">3.93</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20231231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zwxGCeIXWmKe" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options exercisable">14,243,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A summary of stock option activity under the Plan for the year ended December 31, 2022 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Remaining Contractual Life</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Options outstanding – January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zA3DJ1JlLyO8" style="width: 11%; text-align: right" title="Number of shares, outstanding, beginning balance">3,039,546</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zKQi3HZPDEK4" style="width: 11%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">5.52</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zk9UBNbrH1Tl" style="text-align: right" title="Number of shares, options granted">351,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zOgTUpr1MtAc" style="text-align: right" title="Weighted average exercise price, options granted">7.71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zivX3AKIlUb7" style="text-align: right" title="Number of shares, options exercised">(288,720</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZ6wxuMQNCL6" style="text-align: right" title="Weighted average exercise price, options exercised">3.65</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Options cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z1x2pq8SPPK3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options cancelled/forfeited">(74,375</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zLVRnIGH7oRb" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, options cancelled/forfeited">7.46</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options outstanding – December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z40BOq1n4lQ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance">3,027,701</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zUhKYaHpp0s7" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, outstanding, ending balance">5.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zYqgVRq95HTe" title="Weighted average. remaining contractual life, options outstanding">4.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJiuYhPkiS9l" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options outstanding">26,822,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Options exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zKmB3shuEXk8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable">2,457,769</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z82PJ7KLCZq9" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, options exercisable">5.51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zV67mCPEsXXl" title="Weighted average. remaining contractual life, options exercisable">3.97</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zxBeiyUpwzpf" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options exercisable">22,731,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Options vested and expected to vest</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_za3v3GmH3LUk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest">3,026,942</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zUtmfzMBv79g" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, options vested and expected to vest">5.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zztYCugK9oWa" title="Weighted average. remaining contractual life, options vested and expected to vest">4.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20221231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z1R14L5Dytr9" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options exercisable">26,817,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3027701

5.90

135500

17.81

355148

7.36

96736

7.49

2711317

6.25

P4Y

14303000

2432826

5.55

P3Y5M12D

13760000

2673670

6.15

P3Y11M4D

14243000

3039546

5.52

351250

7.71

288720

3.65

74375

7.46

3027701

5.90

P4Y5M23D

26822000

2457769

5.51

P3Y11M19D

22731000

3026942

5.90

P4Y5M23D

26817000

11.20 14.76

4580000

2008000

The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of 10 years. Vesting terms for options granted to employees during the year ended December 31, 2023 generally included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years

0.10

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEcqzTaElg81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: SCHEDULE OF FAIR VALUE ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za5w6Lh80Wde" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted">11.49</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgq2iwpRNBxk" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted">4.72</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected terms (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbeKqTvpjY1l" title="Expected terms (in years)">6.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zudocSXWQaR6" title="Expected terms (in years)">6.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zIpudnT0NVkj" title="Expected volatility, minimum">68 – <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOaxZN3eH5A4" title="Expected volatility, maximum">70</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoyUbETsGvf6" title="Expected volatility, minimum">68 – <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwkGns2AKhG4" title="Expected volatility, maximum">72</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNmVKb8Fw1Z3" title="Risk-free interest rate, minimum">3.59 – <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx8h1HSIX8vf" title="Risk-free interest rate, maximum">4.80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrJULpQvuCx9" title="Risk-free interest rate, minimum">1.54 – <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zl4MbOaPc0G9" title="Risk-free interest rate, maximum">3.70</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYkbPQPQ6g11" style="text-align: right" title="Dividend yield">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMPPnmX9zh9f" style="text-align: right" title="Dividend yield">-</td><td style="text-align: left"> </td></tr> </table>

11.49

4.72

P6Y1M9D

0.68

0.70

0.68

0.72

0.0359

0.0480

0.0154

0.0370

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zC2wvlJq7Rq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in">The following table summarizes information about stock options outstanding and exercisable at December 31, 2023: SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range of Exercise Prices</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life in Years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zlwfkqM4fAek" title="Range of Exercise Prices, minimum">1.47 - $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zAgaNJnBYtw6" title="Range of Exercise Prices, maximum">1.73</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zGQoIj2nl6V5" style="width: 12%; text-align: right" title="Number of Options Outstanding">295,852</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXX49cLcwAP6" title="Weighted Average Remaining Contractual Life in Years">3.95</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zevAIojVcKek" style="width: 12%; text-align: right" title="Weighted Average Exercise Price">1.72</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zyF5wEmS0Fy8" style="width: 12%; text-align: right" title="Number Exercisable">295,852</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqyyqERhv379" style="width: 12%; text-align: right" title="Weighted Average Exercisable Exercise Price">1.72</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zuIunILng151" title="Range of Exercise Prices, minimum">2.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zXsKT5i5FKV2" style="text-align: right" title="Number of Options Outstanding">285,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zwcgdgolGKtd" title="Weighted Average Remaining Contractual Life in Years">3.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zcc0Tn1WUeU6" style="text-align: right" title="Weighted Average Exercise Price">2.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zetlflrFR4A1" style="text-align: right" title="Number Exercisable">285,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zE32TMryg20h" style="text-align: right" title="Weighted Average Exercisable Exercise Price">2.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zqps4pVE0OJe" title="Range of Exercise Prices">2.40 - $<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zslaT4wOa2u2" title="Range of Exercise Prices">2.60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zwEDbMlYREK1" style="text-align: right" title="Number of Options Outstanding">24,068</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zqMeDpxY901i" title="Weighted Average Remaining Contractual Life in Years">3.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zqhfoaUGIXrj" style="text-align: right" title="Weighted Average Exercise Price">2.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zUDfEBzI1uM6" style="text-align: right" title="Number Exercisable">24,068</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zFUClfch0lN9" style="text-align: right" title="Weighted Average Exercisable Exercise Price">2.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zGeyPFFGUC4c" title="Range of Exercise Prices, maximum">3.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zi1r1xJwbOhf" style="text-align: right" title="Number of Options Outstanding">310,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_za6ckYhRPEa6" title="Weighted Average Remaining Contractual Life in Years">2.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z9bk8gyw6ou3" style="text-align: right" title="Weighted Average Exercise Price">3.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z2q9AV859rSa" style="text-align: right" title="Number Exercisable">310,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zKN7O7Xd3Ts2" style="text-align: right" title="Weighted Average Exercisable Exercise Price">3.95</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zDxFfB0NblZf" title="Range of Exercise Prices, minimum">4.49 - $<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zP3Ot9Xz71Fk" title="Range of Exercise Prices, maximum">5.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z8wPVqiFs995" style="text-align: right" title="Number of Options Outstanding">100,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zlTaEaS3OKTd" title="Weighted Average Remaining Contractual Life in Years">5.47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z1hl2fWYvtb8" style="text-align: right" title="Weighted Average Exercise Price">5.54</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zQmxTCUPE2Th" style="text-align: right" title="Number Exercisable">94,416</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zYJ85TFY4K3c" style="text-align: right" title="Weighted Average Exercisable Exercise Price">5.53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zYChuftYKLb" title="Range of Exercise Prices, maximum">6.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zrDdudvGc5e8" style="text-align: right" title="Number of Options Outstanding">285,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zo4IytG18Csg" title="Weighted Average Remaining Contractual Life in Years">5.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zTDL1Grnzhdg" style="text-align: right" title="Weighted Average Exercise Price">6.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zVs5vspAqsDh" style="text-align: right" title="Number Exercisable">285,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zstzmOYsh73e" style="text-align: right" title="Weighted Average Exercisable Exercise Price">6.30</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z3IPBRNxcncc" title="Range of Exercise Prices">6.75 - $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zUCpO2Lr985l" title="Range of Exercise Prices">7.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zpHC2ew06qA2" style="text-align: right" title="Number of Options Outstanding">103,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zSrsGWv3M7l5" title="Weighted Average Remaining Contractual Life in Years">8.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z9HKpeCJ8fH5" style="text-align: right" title="Weighted Average Exercise Price">6.96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zqvB6gl03rYh" style="text-align: right" title="Number Exercisable">39,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zCVgeumAQDu4" style="text-align: right" title="Weighted Average Exercisable Exercise Price">6.96</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zNDoYXHexxz" title="Range of Exercise Prices, maximum">7.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zd4EmGVla6H7" style="text-align: right" title="Number of Options Outstanding">274,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zTGDgs3xQ8jl" title="Weighted Average Remaining Contractual Life in Years">6.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zaORQqf68I3b" style="text-align: right" title="Weighted Average Exercise Price">7.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zmyY4mMvqDw1" style="text-align: right" title="Number Exercisable">274,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zabcQeDABBOi" style="text-align: right" title="Weighted Average Exercisable Exercise Price">7.30</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zeHRKughVuIg" title="Range of Exercise Prices">7.37 - $<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zSVGWtUL47x" title="Range of Exercise Prices">7.79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zNmeVeeD3gFf" style="text-align: right" title="Number of Options Outstanding">229,187</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zOzP8J9KmqYe" title="Weighted Average Remaining Contractual Life in Years">3.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zRiVVDOaKg12" style="text-align: right" title="Weighted Average Exercise Price">7.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zPXb28QTO9be" style="text-align: right" title="Number Exercisable">172,818</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_z3Gmp2F6bLFf" style="text-align: right" title="Weighted Average Exercisable Exercise Price">7.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zL7zrmUlfUla" title="Range of Exercise Prices">7.87 - $<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z70InVwBKJi6" title="Range of Exercise Prices">25.86</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zLtOAyXwzwM6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding">804,173</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zxpVm0oH0uui" title="Weighted Average Remaining Contractual Life in Years">3.27</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zxDPWuRXOiz1" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price">9.59</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z30wH5l4eOkf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">651,547</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zJkXVfY57nG9" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">7.93</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">1.47 - $25.86</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231_zhRtN9WZOW5e" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding">2,711,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zRfh8TKzhsTj" title="Weighted Average Remaining Contractual Life in Years">4.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231_zFi5TBwRW4S3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price">6.25</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20231231_z9UjWTOe0wWl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Options Exercisable">2,432,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231_zyScOFulRuP9" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">5.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1.47

1.73

295852

P3Y11M12D

1.72

295852

1.72

2.23

285000

P3Y1M2D

2.23

285000

2.23

2.40

2.60

24068

P3Y7D

2.58

24068

2.58

3.95

310000

P2Y3M

3.95

310000

3.95

4.49

5.72

100225

P5Y5M19D

5.54

94416

5.53

6.30

285000

P5Y1M20D

6.30

285000

6.30

6.75

7.26

103312

P8Y14D

6.96

39625

6.96

7.30

274500

P6Y3D

7.30

274500

7.30

7.37

7.79

229187

P3Y11M26D

7.52

172818

7.50

7.87

25.86

804173

P3Y3M7D

9.59

651547

7.93

1.47

25.86

2711317

P4Y

6.25

2432826

5.55

1966000

P2Y9M7D

782000

1130000

1567913

25.00

50.00

<p id="xdx_898_eus-gaap--ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_zubYgYILbtcf" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify">SCHEDULE OF PERFORMANCE STOCK UNITS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: justify">Tranche</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Target Share Price*</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: justify">Tranche 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20230101__20231231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zWXkuWuoirY6" style="width: 22%; text-align: right" title="Tranche of shares">223,988</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_c20231231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_fKg_____z5Vp4mghJr55" style="width: 22%; text-align: right" title="Share price">25.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Tranche 2</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20230101__20231231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zMZZSmL2CVQj" style="text-align: right" title="Tranche of shares">335,981</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_c20231231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_fKg_____z05Ztw7PaMAj" style="text-align: right" title="Share price">35.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Tranche 3</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20230101__20231231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_zbd4GSBsclaf" style="text-align: right" title="Tranche of shares">447,975</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_c20231231__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_fKg_____zajPCqMRxF45" style="text-align: right" title="Share price">45.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Tranche 4</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_c20230101__20231231__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember_zZIg4Y2CZtBk" style="text-align: right" title="Number of Shares">559,969</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharePrice_iI_c20231231__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember_fKg_____zjia86w3arp6" style="text-align: right" title="Target Share Price">50.00</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">*</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Target Share Price assumes that no dividends or like distributions are made to stockholders of the Company. If such distributions are made, the Target Share Price would decrease accordingly, to the benefit of the employee, to account for the dividend/distribution as a part of the Target Share Price. </td></tr> </table>

223988

25.00

335981

35.00

447975

45.00

559969

50.00

29106000

0.65

0.1034

<p id="xdx_896_ecustom--ScheduleOfShareBasedCompensationPerformanceStockUnitsAwardActivityTableTextBlock_zhfEpLcYMQH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of the Company’s PSU activity and related information for the year ended December 31, 2023 is as follows: SCHEDULE OF PERFORMANCE STOCK UNITS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of PSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">PSUs unvested – January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zIYr4SKAoPc8" style="width: 16%; text-align: right" title="Number of Shares, PSUs unvested, outstanding, beginning balance">1,567,913</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zTDPhOyY4crl" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning balance">6.45</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">PSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zMNOV7396qLh" style="text-align: right" title="Number of Shares, PSUs granted">1,567,913</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zPsAMQdwEjic" style="text-align: right" title="Weighted average grant date fair value, PSUs granted">18.56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zBUuYzAGNkLi" style="text-align: right" title="Number of Shares, PSUs vested">(1,567,913</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_z6yPUXz9sVQ2" style="text-align: right" title="Weighted average grant date fair value, PSUs vested">6.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">PSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zzkKgNXqOsW" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, PSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_z6D2WXu3J32h" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average grant date fair value, PSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">PSUs unvested – December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_znPCYHg9nnGj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, PSUs unvested, outstanding, ending balance">1,567,913</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_ztIpIkKfuy5l" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">18.56</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Grants During the Year Ended December 31, 2022 No PSUs were issued during the year ended December 31, 2022. A summary of the Company’s PSU activity and related information for the year ended December 31, 2022 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of PSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">PSUs unvested – January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_z2gZMYYtAF" style="width: 16%; text-align: right" title="Number of Shares, PSUs unvested, outstanding, beginning balance">1,567,913</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zRy0Oryo0vmk" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning balance">6.45</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">PSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zNyJTjz5izB4" style="text-align: right" title="Number of Shares, PSUs granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zHNQSq4Kp2bl" style="text-align: right" title="Weighted average grant date fair value, PSUs granted">- </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">PSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zGIoM9JWNvk6" style="text-align: right" title="Number of Shares, PSUs vested">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zCb2NYc2utS" style="text-align: right" title="Weighted average grant date fair value, PSUs vested">- </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">PSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zkKxYRrDcgyk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, PSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zHGwdEfGlMUk" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average grant date fair value, PSUs cancelled/forfeited">- </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">PSUs unvested – December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_z3ntUc2mEVB5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, PSUs unvested, outstanding, ending balance">1,567,913</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PerformanceStockUnitsPSUMember_zdQTgcoosvyk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">6.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1567913

6.45

1567913

18.56

1567913

6.45

1567913

18.56

1567913

6.45

1567913

6.45

18191000

P1Y3M3D

13753000

5056000

41301

800000

86873

697000

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zqhLCDHWqO3h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of the Company’s RSU activity and related information for the year ended December 31, 2023 is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">RSUs unvested – January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231_zqS9NgNztAoj" style="width: 16%; text-align: right" title="Number of Shares, RSUs unvested, outstanding, beginning balance">493,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231_zw38mHbsP9s" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning balance">7.99</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231_zkwgcwOIRNVk" style="text-align: right" title="Number of Shares, RSUs granted">128,174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_zWvWSiQLnQG1" style="text-align: right" title="Weighted average grant date fair value, RSUs granted">11.68</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231_zt6IaisujKtl" style="text-align: right" title="Number of Shares, RSUs vested">(175,643</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zBeTQIMvV2S" style="text-align: right" title="Weighted average grant date fair value, RSUs vested">8.67</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20230101__20231231_zDzJfsZ0Opu9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, RSUs cancelled/forfeited">(83,308</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231_zpHjG062vBD6" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average grant date fair value, RSUs cancelled/forfeited">6.84</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">RSUs unvested at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231_z6CBpmb1mv12" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, RSUs unvested, outstanding, ending balance">363,029</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231_z78qhhoU8wrl" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">9.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Grants During the Year Ended December 31, 2022 During the year ended December 31, 2022, the Company’s board of directors were granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIssBAm0Suud" title="Number of shares granted">65,615 RSUs with a fair market value of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20220101__20221231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zT0DyfcY0hkf" title="Shares vested, fair market value">500,000, which vest in equal quarterly installments over one year. A summary of the Company’s RSU activity and related information for the year ended December 31, 2022 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">RSUs unvested – January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231_zwlE3oFYfjk7" style="width: 16%; text-align: right" title="Number of Shares, RSUs unvested, outstanding, beginning balance">665,288</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231_z5CYtf2foi6l" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning balance">7.57</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231_zshCZJCLIKPd" style="text-align: right" title="Number of Shares, RSUs granted">65,615</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zWDZ1nTafTsa" style="text-align: right" title="Weighted average grant date fair value, RSUs granted">7.62</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231_z5FyFPc6SLAa" style="text-align: right" title="Number of Shares, RSUs vested">(237,098</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_z9BeKXp2JIC1" style="text-align: right" title="Weighted average grant date fair value, RSUs vested">6.67</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20220101__20221231_zSmUPNG0YeKa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20221231_zMRjoTvZQZUf" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average grant date fair value, RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">RSUs unvested at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231_zTVkAlYSa0jb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, RSUs unvested, outstanding, ending balance">493,806</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231_zHi3AUgP6PT8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance">7.99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

493806

7.99

128174

11.68

175643

8.67

83308

6.84

363029

9.23

65615

500000

665288

7.57

65615

7.62

237098

6.67

493806

7.99

1234000

P0Y8M4D

1161000

1788000

The Company recorded total stock-based compensation (including issuance of common stock for services and accrual for stock-based compensation) related to equity instruments granted to employees, directors and consultants as follows: SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES, DIRECTORS AND CONSULTANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231_zC5gctMzDq5l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zywo8uzk2Tii" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zElOfewBuiuc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Employees – selling, general and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">13,279,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,669,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zT33oWInGzI9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Employees – R&D</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,662,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">689,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zGOzGW37ljv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Directors – selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">462,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z1zAK9vXTe6c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Consultants – selling, general and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">67,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">154,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_za4gd1w89XY" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,696,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,974,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

13279000

6669000

1662000

689000

688000

462000

67000

154000

15696000

7974000

NOTE 16. INCOME TAXES The Company is subject to taxation in the United States, California, New Jersey, Tennessee and various other states. The Company’s income tax provision consists of the following for the years ended December 31, 2023 and 2022 are summarized below: SCHEDULE OF PROVISION FOR INCOME TAXES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zzbsMzpsZWH4" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20221231_zDYrMZjilYCe" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zO2IA4iJhQah" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Current:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzp3T_zhjW2hZ0Idi5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzp3T_zWBNng0Zgu54" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1.5pt">State</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">701,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">75,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzp3T_maITEBzQH8_zVCoyVrGMTi9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">701,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z3EgvBLHOA18" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzJuM_zTzsdXSRTld6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzJuM_zUFl4IwTQ4L9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBzJuM_maITEBzQH8_zaWiUQsqazBc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total deferred</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzQH8_zVGPVKw5feGa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">75,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company’s loss before income tax provision to the income tax provision is as follows: SCHEDULE OF INCOME TAX PROVISION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231_zMUwOR9hn0Wa" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_zRpuQNFRd8Eg" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maKL001_z5xypfdeMu2g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify">U.S. federal statutory tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.00</td><td style="width: 3%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.00</td><td style="width: 3%; text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maKL001_zF62GBCTeiEl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State tax benefit, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.77</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2.82</td><td style="text-align: left">)%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_iN_pid_dpi_uPure_maKL001_zdhwazL4XQka" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Rate change</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8.02</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pid_dp_uPure_maKL001_zDKsBJPkheab" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Employee stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19.93</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.34</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationExcessEmployeeRemuneration_pid_dp_uPure_msKL001_z12kuJx1h9v4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Excess employee remuneration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30.83</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(28.15</td><td style="text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlements_iN_pid_dpi_uPure_maKL001_zSlGovY9gyTe" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Melt loan settlement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4.52</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_pid_dpi_uPure_maKL001_zB7eUW2cYsxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.43</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.18</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationUncertainTaxPosition_pid_dp_uPure_msKL001_zpcaEupPZGJk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Uncertain tax positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11.71</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_uPure_msKL001_zoxst944e9sa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Research and development tax credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.53</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationProvisionToReturnTrueUps_pid_dp_uPure_maKL001_znaXyGdTy21g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Provision-to-return true-ups</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.72</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.06</td><td style="text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maKL001_zFQhwyjrKdyd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other true-ups</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.97</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maKL001_zIspDh6Liv2" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.71</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.22</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKL001_zaYjxmUOrI07" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.88</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.53</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr> </table> Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231_zQmtNDBMWfu4" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20221231_z9uRKtPLaqOe" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax assets (liabilities):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANz5SE_z3RETQUA2r9d" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 62%; text-align: justify">NOL</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,669,000</td><td style="width: 2%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,401,000</td><td style="width: 2%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_iI_maDTANz5SE_z6JXaO2xTAFi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,637,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,387,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_maDTANz5SE_z1dJMVdn04Z2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">854,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">349,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetsResearchAndDevelopment_iI_maDTANz5SE_z6t0cFjxj9Ne" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">220,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANz5SE_zpkjJOONK6U7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Deferred stock compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,059,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">945,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--IncomeTaxBasisDifferenceInRelatedPartyTwo_iNI_di_maDTANz5SE_zaO4Qs9D0V5h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Basis difference in Eton</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(583,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,684,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--IncomeTaxBasisDifferenceInInvestments_iI_msDTANz5SE_zpVHMRPeWLU3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Basis difference in Melt investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.405,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,240,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetsFederalBenefitOfStateReserves_iI_maDTANz5SE_zbffv0IS9cDi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Federal benefit of state ASC740-10 reserves</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredTaxAssetsLimitations_iI_maDTANz5SE_zX67GHyE79yf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Limitation Under 163(j)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,893,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">536,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DeferredTaxAssetsTaxDeferredCapitalizedExpensesLimitations_iI_maDTANz5SE_z6GHi00wUxuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Section 174 capitalized expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,261,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">594,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetsTaxDeferredLeaseLiabilityExpenseLimitations_iI_maDTANz5SE_z6eYYbFRf4I3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">ASC 842 lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,710,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,427,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsTaxDeferredRightOfUseAssetsExpenseLimitations_iNI_di_maDTANz5SE_zqFCI2cQDlC5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">ASC 842 ROU asset</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,582,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,263,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz5SE_maDTALNzuBa_z08XCiEyA6Hf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total deferred tax assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,631,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,022,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzuBa_z7AQZGk0fqO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,631,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,022,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzuBa_zChpOwinZ889" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance decreased by approximately $1,391,000 and $1,182,000 during 2023 and 2022, respectively. As of December 31, 2023, the Company had federal and state net operating loss carryforwards of approximately $8,596,000 and $26,134,000, respectively, which will begin to expire in 2036, unless previously utilized, and will begin to expire for state purposes in 2028. In addition, the Company has federal net operating loss carryforward of $4,936,000 generated after 2017 that can be carried over indefinitely and may be used to offset up to 80% of federal taxable income. As of December 31, 2023 the Company had federal and state research and development credit carryforwards of approximately $<span id="xdx_90B_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zgEWdoR82htd" title="Research and development tax credits">177,000 and $<span id="xdx_900_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z5fD9k1IeSCi" title="Research and development tax credits">54,000, respectively, which will begin to expire in <span id="xdx_90A_ecustom--FederalAndStateResearchAndDevelopmentTaxCreditsExpirationDate_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--ReasearchAndDevelopmentMember_z3EsZaib7FX6" title="Federal and state research and development tax credits expiration date">2031, unless previously utilized. For state purposes, the state research and development credit carryforwards can be carried over indefinitely. Utilization of the net operating losses and research and development carryforwards may be subject to a substantial annual limitation due to ownership change limitations that might have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state and foreign provisions. These ownership changes may limit the amount of NOL and R&D credit carryforward that can be utilized annually to offset future taxable income and tax. Respectively. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since the Company’s formation, the Company has raised capital through the issuance of capital stock on several occasions which, combined with the purchasing stockholders’ subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition. As of December 31, 2023, the Company determined that it had net operating loss carryforwards of approximately $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zOLMPkQ3P8ef" title="Net operating loss carryforwards">12,500,000 and state net operating loss carryforwards of approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zEPQWBfGgV6l" title="State operating loss carryforwards">9,400,000 restricted under IRC Section 382 of the Internal Revenue Code related to a 2011 change in ownership. Section 382 of the Internal Revenue Code limits the utilization of net operating losses when ownership changes, as defined by that section, occur. Due to the Section 382 limitation, and the length of time available to fully utilize the net operating loss carryforwards, the Company removed these NOLs from deferred tax assets with a corresponding reduction of the valuation allowance. Similarly, under IRC Section 383 which limits the utilization of credits when ownership changes occur, the Company removed approximately $<span id="xdx_90C_ecustom--FederalTaxCreditFromDeferredTaxAssetsWithCorrespondingReductionOfValuationAllowance_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zf8oTnrf6MKa" title="Federal credit">300,000 of federal credit and $<span id="xdx_90C_ecustom--StateTaxCreditFromDeferredTaxAssetsWithCorrespondingReductionOfValuationAllowance_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zEHVmNtAXdc5" title="State credits">300,000 of state credits from deferred tax assets with a corresponding reduction of the valuation allowance. As of December 31, 2023, the Company had approximately $2,853,000 of unrecognized tax benefits of which $2,853,000 if fully recognized, would decrease its effective tax rate. There were interest or penalties accrued of $40,000 relating to unrecognized tax benefits as of December 31, 2023. A reconciliation of the change in the unrecognized tax benefits balance from January 1, 2023 to December 31, 2023 is as follows: SCHEDULE OF UNRECOGNIZED TAX BENEFITS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_z5z2UQ9XkUU9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Federal & State Tax</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--UnrecognizedTaxBenefits_iS_z4XiLgbHYv3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance at January 1, 2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_z1kt051BpZnd" style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: justify">Additions for tax positions related to current year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">36,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zij3HfK2OBe9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: justify">Additions for tax positions related to prior years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,817,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--UnrecognizedTaxBenefits_iE_z61EiuAzvS8b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,853,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The Company is subject to taxation in the United States, California, New Jersey, Tennessee and various other states. The Company’s income tax provision consists of the following for the years ended December 31, 2023 and 2022 are summarized below: SCHEDULE OF PROVISION FOR INCOME TAXES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zzbsMzpsZWH4" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20221231_zDYrMZjilYCe" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zO2IA4iJhQah" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Current:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzp3T_zhjW2hZ0Idi5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzp3T_zWBNng0Zgu54" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%; text-align: justify; padding-bottom: 1.5pt">State</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">701,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">75,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzp3T_maITEBzQH8_zVCoyVrGMTi9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">701,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_z3EgvBLHOA18" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzJuM_zTzsdXSRTld6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzJuM_zUFl4IwTQ4L9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBzJuM_maITEBzQH8_zaWiUQsqazBc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total deferred</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzQH8_zVGPVKw5feGa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">75,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

701000

75000

701000

75000

701000

75000

A reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company’s loss before income tax provision to the income tax provision is as follows: SCHEDULE OF INCOME TAX PROVISION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231_zMUwOR9hn0Wa" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_zRpuQNFRd8Eg" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maKL001_z5xypfdeMu2g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify">U.S. federal statutory tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.00</td><td style="width: 3%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.00</td><td style="width: 3%; text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maKL001_zF62GBCTeiEl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State tax benefit, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.77</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2.82</td><td style="text-align: left">)%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_iN_pid_dpi_uPure_maKL001_zdhwazL4XQka" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Rate change</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8.02</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_pid_dp_uPure_maKL001_zDKsBJPkheab" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Employee stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19.93</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.34</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationExcessEmployeeRemuneration_pid_dp_uPure_msKL001_z12kuJx1h9v4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Excess employee remuneration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(30.83</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(28.15</td><td style="text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlements_iN_pid_dpi_uPure_maKL001_zSlGovY9gyTe" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Melt loan settlement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4.52</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_pid_dpi_uPure_maKL001_zB7eUW2cYsxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.43</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.18</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationUncertainTaxPosition_pid_dp_uPure_msKL001_zpcaEupPZGJk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Uncertain tax positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11.71</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_iN_pid_dpi_uPure_msKL001_zoxst944e9sa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Research and development tax credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.53</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationProvisionToReturnTrueUps_pid_dp_uPure_maKL001_znaXyGdTy21g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Provision-to-return true-ups</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.72</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.06</td><td style="text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maKL001_zFQhwyjrKdyd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other true-ups</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.97</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maKL001_zIspDh6Liv2" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.71</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.22</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKL001_zaYjxmUOrI07" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.88</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.53</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr> </table>

0.2100

0.0077

-0.0282

0.0802

0.1993

0.0134

-0.3083 -0.2815

0.0452

0.0043

0.0018

-0.1171

-0.0053

0.0172 0.0206

0.0297

0.0571

0.0622

-0.0288

-0.0053

Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231_zQmtNDBMWfu4" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20221231_z9uRKtPLaqOe" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax assets (liabilities):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANz5SE_z3RETQUA2r9d" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 62%; text-align: justify">NOL</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,669,000</td><td style="width: 2%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,401,000</td><td style="width: 2%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_iI_maDTANz5SE_z6JXaO2xTAFi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,637,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,387,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_maDTANz5SE_z1dJMVdn04Z2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">854,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">349,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetsResearchAndDevelopment_iI_maDTANz5SE_z6t0cFjxj9Ne" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">220,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANz5SE_zpkjJOONK6U7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Deferred stock compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,059,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">945,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--IncomeTaxBasisDifferenceInRelatedPartyTwo_iNI_di_maDTANz5SE_zaO4Qs9D0V5h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Basis difference in Eton</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(583,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,684,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--IncomeTaxBasisDifferenceInInvestments_iI_msDTANz5SE_zpVHMRPeWLU3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Basis difference in Melt investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.405,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,240,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DeferredTaxAssetsFederalBenefitOfStateReserves_iI_maDTANz5SE_zbffv0IS9cDi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Federal benefit of state ASC740-10 reserves</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">88,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredTaxAssetsLimitations_iI_maDTANz5SE_zX67GHyE79yf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Limitation Under 163(j)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,893,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">536,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--DeferredTaxAssetsTaxDeferredCapitalizedExpensesLimitations_iI_maDTANz5SE_z6GHi00wUxuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Section 174 capitalized expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,261,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">594,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetsTaxDeferredLeaseLiabilityExpenseLimitations_iI_maDTANz5SE_z6eYYbFRf4I3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">ASC 842 lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,710,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,427,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsTaxDeferredRightOfUseAssetsExpenseLimitations_iNI_di_maDTANz5SE_zqFCI2cQDlC5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">ASC 842 ROU asset</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,582,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,263,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz5SE_maDTALNzuBa_z08XCiEyA6Hf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total deferred tax assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,631,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,022,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzuBa_z7AQZGk0fqO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,631,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,022,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzuBa_zChpOwinZ889" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4669000

9401000

1637000 2387000

854000

349000

220000 90000

1059000

945000

583000 1684000 3405.000 4240000 88000 2893000 536000 1261000 594000 1710000 2427000 1582000 2263000

15631000

17022000

15631000

17022000

1391000

1182000

8596000

26134000

2036 the Company has federal net operating loss carryforward of $4,936,000 generated after 2017 that can be carried over indefinitely and may be used to offset up to 80% of federal taxable income

177000

54000

2031

12500000

9400000

300000 300000

2853000

40000

A reconciliation of the change in the unrecognized tax benefits balance from January 1, 2023 to December 31, 2023 is as follows: SCHEDULE OF UNRECOGNIZED TAX BENEFITS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_z5z2UQ9XkUU9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Federal & State Tax</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--UnrecognizedTaxBenefits_iS_z4XiLgbHYv3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance at January 1, 2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_z1kt051BpZnd" style="vertical-align: bottom; background-color: White"> <td style="width: 76%; text-align: justify">Additions for tax positions related to current year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">36,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zij3HfK2OBe9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: justify">Additions for tax positions related to prior years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,817,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--UnrecognizedTaxBenefits_iE_z61EiuAzvS8b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,853,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

36000

2817000

2853000

NOTE 17. EMPLOYEE SAVINGS PLAN The Company has established an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code, effective January 1, 2014. The plan allows participating employees to deposit into tax deferred investment accounts up to 100% of their salary, subject to annual limits. The Company makes certain matching contributions to the plan in amounts up to 4% of the participants’ annual cash compensation, subject to annual limits. The Company contributed approximately $594,000 and $397,000 to the plan during the years ended December 31, 2023 and 2022, respectively.

0.04

594000

397000

<p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zsWADOyOqaOj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in">NOTE 18. COMMITMENTS AND CONTINGENCIES Legal General and Other In the ordinary course of business, the Company is involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See also Part I, Item 1A. Risk Factors. The Company describes legal proceedings and other matters that are/were significant or that it believes could become significant in this footnote. The Company records accruals for loss contingencies to the extent that it concludes it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of a liability that has been accrued previously. The Company’s legal proceedings involve various aspects of its business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. Typically, a number of the matters pending against the Company are at early stages of the legal process, which in complex proceedings of the sort the Company face often extend for several years. While it is not possible to accurately predict or determine the eventual outcomes of matters that have not concluded, an adverse determination in one or more of matter (whether discussed in this footnote or not) currently pending may have a material adverse effect on the Company’s consolidated results of operations, financial position or cash flows. Certain recent developments concerning the Company’s legal proceedings it believes are or were material to its business and other matters are discussed below: Ocular Science, Inc. et. al In July 2021, ImprimisRx, LLC, a subsidiary of the Company, filed a lawsuit against Ocular Science, Inc. and OSRX, Inc. (together, “OSRX”) in the U.S. District Court for the Southern District of California, asserting claims for copyright infringement, trademark infringement, unfair competition and false advertising (Lanham Act). Since July 2021, the complaint has been amended and OSRX added counterclaims alleging ImprimisRx, LLC is violating the Lanham Act with false advertising. The Court granted cross motions for summary judgement on each party’s Lanham Act claims thus leaving only ImprimisRx, LLC’s copyright infringement, trademark infringement and unfair competition claims for trial. ImprimisRx, LLC is seeking damages from OSRX. The Company expects the trial to take place in August 2024. Product and Professional Liability Product and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We utilize traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any given time reflects current market conditions, including cost and availability, when the policy is written. Indemnities In addition to the indemnification provisions contained in the Company’s charter documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. Several of the Company’s asset purchase and license agreements contain customary representations, warranties, covenants and confidentiality provisions, and also contain mutual indemnification obligations related primarily to performance under the respective agreements. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying consolidated balance sheets. Sales and Marketing Agreements The Company has entered various sales and marketing agreements with certain organizations, to provide sales and marketing representation services to ImprimisRx in select geographies in the U.S., in connection with the Company’s ophthalmic compounded formulations. <span id="xdx_90E_ecustom--DescriptionForCommissionPayments_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_z8LDakRL7Ngj" title="Description for commission payments">Under the terms of the sales and marketing agreements, the Company is required to make commission payments generally equal to <span id="xdx_90D_ecustom--CommissionPaymentsPercentage_dp_uPure_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--RangeAxis__srt--MinimumMember_z8qcSxLGXCNg" title="Commission payments percentage">10% to <span id="xdx_900_ecustom--CommissionPaymentsPercentage_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zW7T7wtHM4J1" title="Commission payments percentage">14% of net sales for products above and beyond the initial existing sales amounts. In addition, the Company is required to make periodic milestone payments to certain organizations in shares of the Company’s restricted common stock if net sales in the assigned territory reach certain future levels by the end of their terms, as applicable. The Company incurred $196,000 and $4,274,000 under these agreements for commission expenses during the years ended December 31, 2023 and 2022, respectively, which are included in selling, general and administrative expenses. Other Asset Purchase, License and Related Agreements The Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors and related parties (the “Inventors”) through multiple asset purchase agreements, license agreements, strategic agreements and commission agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors. In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. At December 31, 2023 and 2022, $<span id="xdx_902_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zqOzUVKs8Vlh" title="Accounts payable and other accrued liabilities">106,000 and $<span id="xdx_903_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_z2X5HFwVPWWg" title="Accounts payable and other accrued liabilities">228,000 were accrued in accounts payable and accrued expenses related to these agreements. During the years ended December 31, 2023 and 2022, $811,000 and $910,000, respectively, were incurred under these agreements as royalty expenses, which are included in selling, general and administrative expenses. Klarity License Agreement – Related Party In April 2017, the Company entered into a license agreement (the “Klarity License Agreement”) with Richard L. Lindstrom, M.D., a former member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic solution Klarity designed to protect and rehabilitate the ocular surface (the “Klarity Product”). <span id="xdx_909_ecustom--RoyaltyPaymentDescription_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zTLlEqdVUmKb" title="Royalty payment description">Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including: (i) an initial payment of $<span id="xdx_903_eus-gaap--RoyaltyExpense_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--AwardTypeAxis__custom--InitialPaymentMember_zMISNupGXWbc" title="Royalty payments">50,000 upon execution of the Klarity License Agreement, (ii) a second payment of $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--AwardTypeAxis__custom--SecondPaymentMember_zPsZbB72Cgk5" title="Royalty payments">50,000 following the first $<span id="xdx_907_ecustom--NetSalesRevenue_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--AwardTypeAxis__custom--SecondPaymentMember_zqsiWxyC4gbh" title="Net sales">50,000 in net sales of the Klarity Product; and (iii) a final payment of $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--AwardTypeAxis__custom--FinalPaymentMember_zM8ikkvl5CJ9" title="Royalty expense">50,000 following the first $<span id="xdx_904_ecustom--NetSalesRevenue_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--AwardTypeAxis__custom--FinalPaymentMember_zDnZ7xYb3rgf" title="Net sales">100,000 in net sales of the Klarity Product. All of the above referenced milestone payments were payable at the Company’s election in cash or shares of the Company’s restricted common stock. Dr. Lindstrom was paid $292,000 and $274,000 in cash during the years ended December 31, 2023 and 2022, respectively, and was due an additional $67,000 and $71,000 at December 31, 2023 and 2022, respectively. The Company incurred $287,000 and $315,000 for royalty expenses related to the Klarity License Agreement during the years ended December 31, 2023 and 2022, respectively, which are included in selling, general and administrative expenses. Injectable Asset Purchase Agreement – Related Party In December 2019, the Company entered into an asset purchase agreement (the “Lindstrom APA”) with Dr. Lindstrom, a former member of its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the “Lindstrom Product”). <span id="xdx_90A_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z1Fch3RBIuxi" title="Royalty payment description">Under the terms of the Lindstrom APA, the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including an initial payment of $<span id="xdx_903_ecustom--InitialMilestonePayment_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zVx5cK0I5WRa" title="Initial milestone payment">33,000 upon execution of the Lindstrom APA. Dr. Lindstrom was paid $35,000 and $32,000 in cash during the years ended December 31, 2023 and 2022, respectively, and was due $6,000 and $9,000 at December 31, 2023 and 2022, respectively. The Company incurred $32,000 and $33,000 for royalty expenses related to the Lindstrom APA during the years ended December 31, 2023 and 2022, respectively, which are included in selling, general and administrative expenses. Presbyopia Asset Purchase Agreement – Related Party In December 2019, the Company entered into an asset purchase agreement (the “Presbyopia APA”) with Richard L. Lindstrom, M.D., a former member of its Board of Directors. Pursuant to the terms of the Presbyopia APA, the Company acquired certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic topical product to treat presbyopia (the “Presbyopia Product”). <span id="xdx_904_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zWFoSAOFz8T2" title="Royalty payment description">Under the terms of the Presbyopia Product, the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold. Dr. Lindstrom was paid $0 in cash during the years ended December 31, 2023 and 2022, and was due $0 at December 31, 2023 and 2022. The Company incurred $0 for royalty expenses related to the Presbyopia APA during the years ended December 31, 2023 and 2022. Eyepoint Commercial Alliance Agreement - Terminated In August 2020, the Company, through its wholly owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the “Dexycu Agreement”) with Eyepoint Pharmaceuticals, Inc. (“Eyepoint”), pursuant to which Eyepoint granted the Company the non-exclusive right to co-promote DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in the U.S. Pursuant to the Dexycu Agreement, Eyepoint paid the Company a fee calculated based on the quarterly sales of DEXYCU in excess of predefined volumes to specific customers of the Company in the U.S. Under the terms of the Dexycu Agreement, the Company agreed to use commercially reasonable efforts to promote and market DEXYCU in the U.S. Pursuant to a mutual termination agreement entered into on October 7, 2022 the Dexycu Agreement terminated on January 1, 2023. During the years ended December 31, 2023 and 2022, the Company recorded $0 and $3,866,000, respectively, in commission revenues related to the Dexycu Agreement.

Under the terms of the sales and marketing agreements, the Company is required to make commission payments generally equal to 10% to 14% of net sales for products above and beyond the initial existing sales amounts 0.10 0.14

196000

4274000

106000

228000

811000

910000

Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold

50000

100000 292000 274000 67000 71000

287000

315000

Under the terms of the Lindstrom APA, the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold 33000 35000 32000

6000

9000

32000

33000

Under the terms of the Presbyopia Product, the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold 0 0 0 0

0 3866000

NOTE 19. SEGMENTS AND CONCENTRATIONS The Company operates its business on the basis of a single reportable segment, which is the business of discovery, development, and commercialization of innovative ophthalmic therapies. The Company’s chief operating decision-maker is the Chief Executive Officer, who evaluates the Company as a single operating segment. Concentrations The Company has three and two products that each comprised more than 10% of total revenues during the years ended December 31, 2023 and 2022, respectively. These products collectively accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z7GZGZlBv576" title="Concentration risk percentage">38% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zIg2C5JpiSwi" title="Concentration risk percentage">34% of revenues, respectively. As of December 31, 2023 and 2022, accounts receivable from a single customer accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--SingleCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZtZ2DAAkVt6" title="Concentration risk percentage">80% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--SingleCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8a0pe494eD1" title="Concentration risk percentage">0% of total accounts receivable, respectively. For the years ended December 31, 2023 and 2022, revenues from a single customer accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--SingleCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxZWmYHJSeo" title="Concentration risk percentage">29% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--SingleCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zjjURKor6AUd" title="Concentration risk percentage">0% of total revenues, respectively. The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--ThreeSuppliersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zzBdHSSB2juk" title="Concentration risk percentage">64% of active pharmaceutical ingredient purchases during the year ended December 31, 2023, and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--ThreeSuppliersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zJyiSlyDCpt7" title="Concentration risk percentage">61% during the year ended December 31, 2022.

0.38

0.34

0.80

0.29

0.64

0.61

NOTE 20. SUBSEQUENT EVENTS In February 2024, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6IGXlussmIe" title="Number of shares granted">45,000 RSUs granted in February 2021 to Andrew R. Boll, the Company’s Chief Financial Officer, vested, and <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMslOPonxcjg" title="Number of shares of common stock">26,520 shares the Company’s common stock were issued to Mr. Boll, net of <span id="xdx_905_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqQjBQf26KD6" title="Shares withheld for tax withholding obligation, shares">18,480 shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_90B_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zL1fGt9xLAB" title="Payroll tax obligations, value">197,000. In February 2024, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTj5yy214oM5" title="Number of shares granted">150,000 RSUs granted in February 2021 to Mark L. Baum, the Company’s Chief Executive Officer, vested, and <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdrBR7dwZ6f4" title="Number of shares of common stock">90,164 shares the Company’s common stock were issued to Mr. Baum, net of <span id="xdx_90F_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ziQl1VuQzZ0b" title="Shares withheld for tax withholding obligation, shares">59,836 shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_903_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zv9qENXIuW8" title="Payroll tax obligations, value">638,000. In February 2024, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwT4Bbdw4lJg" title="Number of shares granted">30,000 RSUs granted in February 2021 to John Saharek, the Company’s Chief Commercial Officer, vested, and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuWFcFCnSFH5" title="Number of shares of common stock">17,384 shares the Company’s common stock were issued to Mr. Saharek, net of <span id="xdx_90B_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zieSfXCqVaK1" title="Shares withheld for tax withholding obligation, shares">12,616 shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_903_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnSaharekMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMLX47R9r8ph" title="Payroll tax obligations, value">135,000. In February 2024, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5BETpEI6xbd" title="Number of shares granted">50,000 RSUs granted in February 2021 to employees, vested, and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zygxU95x4tU" title="Number of shares of common stock">32,452 shares the Company’s common stock were issued, net of <span id="xdx_909_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zV7s7kKUrwze" title="Shares withheld for tax withholding obligation, shares">17,548 shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_90B_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c20240201__20240229__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjIdOTwfxc53" title="Payroll tax obligations, value">187,000. In February and March 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240201__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFnOdNMCyeVd" title="Number of shares issued"><span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfBQ0BeZSwGe" title="Number of shares issued">27,862 shares of common stock and received proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pid_c20240201__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEQPuDFMBi41" title="Proceeds from issuance of common stock"><span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pid_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaaWpQ0VORkc" title="Proceeds from issuance of common stock">220,000 upon the exercise of options to purchase <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240201__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS0hkrxwwNS7" title="Options to purchase common shares"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq2VFD8DeJre" title="Options to purchase common shares">27,862 shares of common stock with exercise prices between $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_z8nt5xAHsrd2" title="Exercise price per share"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zV6n6QOVWvY5" title="Exercise price per share">6.75 to $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zsrQxwGSsYVc" title="Exercise price per share"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zZaAMWhmeDbi" title="Exercise price per share">8.75 per share.

45000

26520

18480

197000

150000

90164

59836

638000

30000

17384

12616

135000

50000

32452

17548

187000

27862

220000

27862

6.75

8.75

Target Share Price assumes that no dividends or like distributions are made to stockholders of the Company. If such distributions are made, the Target Share Price would decrease accordingly, to the benefit of the employee, to account for the dividend/distribution as a part of the Target Share Price.